UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q


☒			QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~March 31,~~June 30, 2023


☐			TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number 001-38485

Amneal Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)


Delaware			32-0546926
(State or other jurisdiction of incorporation or organization)			(I.R.S. Employer Identification No.)
Amneal Pharmaceuticals, Inc. 400 Crossing Boulevard, Bridgewater, NJ			08807
(Address of principal executive offices)			(Zip Code)

(908) 947-3120

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Class A Common Stock, par value $0.01 per share	AMRX	New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

Large accelerated filer

☐

Accelerated filer

☒

Non-accelerated filer

☐

Smaller reporting company

☐

Emerging growth company

☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of ~~April 30,~~July 31, 2023, there were ~~153,337,273~~154,194,960 shares of Class A common stock outstanding and 152,116,890 shares of Class B common stock outstanding, both with a par value of $0.01.

Amneal Pharmaceuticals, Inc.

Table of Contents


Cautionary Note Regarding Forward-Looking Statements			2

PART I - FINANCIAL INFORMATION
	Item 1.	Financial Statements (Unaudited)	4
		Consolidated Statements of Operations	4
		Consolidated Statements of Comprehensive ~~(Loss)~~ Income ~~Income~~ (Loss)	5
		Consolidated Balance Sheets	6
		Consolidated Statements of Cash Flows	7
		Consolidated Statements of Changes in Stockholders' Equity	9
		Notes to Consolidated Financial Statements	1011
	Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	3738
	Item 3.	Quantitative and Qualitative Disclosures About Market Risk	4551
	Item 4.	Controls and Procedures	4551

PART II - OTHER INFORMATION
	Item 1.	Legal Proceedings	4652
	Item 1A.	Risk Factors	4652
	Item 2.	Unregistered Sales of Equity Securities, ~~and~~ Use of Proceeds, and Issuer Purchase of Equity Securities	4652
	Item 3.	Defaults Upon Senior Securities	4652
	Item 4.	Mine Safety Disclosures	4652
	Item 5.	Other Information	4652
	Item 6.	Exhibits	4754

Signatures			4855

Cautionary Note Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q and Amneal Pharmaceuticals, Inc.’s other publicly available documents contain “forward-looking statements” within the meaning of the safe harbor provisions of the United States (“U.S.”) Private Securities Litigation Reform Act of 1995. Management and representatives of Amneal Pharmaceuticals, Inc. and its subsidiaries (“the Company”, “we”, “us”, or “our”) also may from time to time make forward-looking statements. Forward-looking statements do not relate strictly to historical or current facts and reflect management’s assumptions, views, plans, objectives and projections about the future. Forward-looking statements may be identified by the use of words such as “plans,” “expects,” “will,” “anticipates,” “estimates” and other words of similar meaning in conjunction with, among other things: discussions of future operations; expected operating results and financial performance; impact of planned acquisitions and dispositions; our strategy for growth; product development; regulatory approvals; market position and expenditures.

Because forward-looking statements are based on current beliefs, expectations and assumptions regarding future events, they are subject to uncertainties, risks and changes that are difficult to predict and many of which are outside of our control. Investors should realize that if underlying assumptions prove inaccurate, known or unknown risks or uncertainties materialize, or other factors or circumstances change, our actual results and financial condition could vary materially from expectations and projections expressed or implied in our forward-looking statements. Investors are therefore cautioned not to rely on these forward-looking statements.

Summary of Material Risks

Risks and uncertainties that make an investment in the Company speculative or risky or that could cause our actual results to differ materially from the forward-looking statements contained in this Quarterly Report on Form 10-Q include, but are not limited to:

•our ability to successfully develop, license, acquire and commercialize new products on a timely basis;

•the competition we face in the pharmaceutical industry from brand and generic drug product companies, and the impact of that competition on our ability to set prices;

•our ability to obtain exclusive marketing rights for our products;

•our ability to manage our growth through acquisitions and otherwise;

•our revenues derived from the sales of a limited number of products, a substantial portion of which are through a limited number of customers;

•the continuing trend of consolidation of certain customer groups;

•our dependence on third-party suppliers and distributors for raw materials for our products and certain finished goods;

•our substantial amount of indebtedness and our ability to generate sufficient cash to service our indebtedness in the future, and the impact of interest rate fluctuations on such indebtedness;

•our ability to secure satisfactory terms when negotiating a refinancing or other new indebtedness;

•our dependence on third-party agreements for a portion of our product offerings;

•legal, regulatory and legislative efforts by our brand competitors to deter competition from our generic alternatives;

•risks related to federal regulation of arrangements between manufacturers of branded and generic products;

•our reliance on certain licenses to proprietary technologies from time to time;

•the significant amount of resources we expend on research and development;

•the risk of product liability and other claims against us by consumers and other third parties;

•risks related to changes in the regulatory environment, including U.S. federal and state laws related to healthcare fraud abuse and health information privacy and security and changes in such laws;

•changes to Food and Drug Administration product approval requirements;

•the impact of healthcare reform and changes in coverage and reimbursement levels by governmental authorities and other third-party payers;

•our potential expansion into additional international markets subjecting us to increased regulatory, economic, social and political uncertainties;

•our ability to identify, make and integrate acquisitions or investments in complementary businesses and products on advantageous terms;

•the impact of global economic, political or other catastrophic events, including ~~bank failures;~~recent events affecting the financial services industry;

•our ability to attract, hire and retain highly skilled personnel;

•our obligations under a tax receivable agreement may be significant;

•the high concentration of ownership of our Class A Common Stock and the fact that we are controlled by the Amneal Group; and

•such other factors as may be set forth elsewhere in the Company's Annual Report on Form 10-K for the year ended December 31, 2022, particularly in the section 1A. Risk Factors and our public filings with the SEC.

Investors should carefully read our Annual Report on Form 10-K for the year ended December 31, 2022, including the section 1A. Risk Factors, for a description of certain risks that could, among other things, cause our actual results to differ materially from those expressed in our forward-looking statements. Investors should understand that it is not possible to predict or identify all such factors and should not consider the risks described herein and in our Annual Report to be a complete statement of all potential risks and uncertainties. The Company does not undertake to publicly update any forward-looking statement that may be made from time to time, whether as a result of new information or future events or developments.

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements (Unaudited)

Amneal Pharmaceuticals, Inc.

Consolidated Statements of Operations

(unaudited; in thousands, except per share amounts)


		Three Months Ended March 31,					Three Months Ended June 30,				Six Months Ended June 30,
		2023		2022			2023		2022		2023		2022
Net revenue	Net revenue	$	557,540	$	497,633	Net revenue	$	599,046	$	559,355	$	1,156,586	$	1,056,988
Cost of goods sold	Cost of goods sold	379,354		323,062		Cost of goods sold	379,025		358,836		758,379		681,898
Gross profit	Gross profit	178,186		174,571		Gross profit	220,021		200,519		398,207		375,090
Selling, general and administrative	Selling, general and administrative	102,096		98,665		Selling, general and administrative	105,570		98,806		207,666		197,471
Research and development	Research and development	38,690		52,798		Research and development	37,799		50,748		76,489		103,546
Intellectual property legal development expenses	Intellectual property legal development expenses	1,644		764		Intellectual property legal development expenses	820		821		2,464		1,585
Acquisition, transaction-related and integration expenses	Acquisition, transaction-related and integration expenses	—		434		Acquisition, transaction-related and integration expenses	—		241		—		675
Restructuring and other charges	Restructuring and other charges	510		731		Restructuring and other charges	82		—		592		731
Change in fair value of contingent consideration	Change in fair value of contingent consideration	2,457		200		Change in fair value of contingent consideration	(6,364)		(270)		(3,907)		(70)
Credit related to legal matters, net		(436)		(2,326)
Other operating income		(1,224)		—
Operating income		34,449		23,305
Insurance recoveries for property losses and associated expenses						Insurance recoveries for property losses and associated expenses	—		(1,911)		—		(1,911)
Charges related to legal matters, net						Charges related to legal matters, net	2,017		251,877		1,581		249,551
Other operating expense (income)						Other operating expense (income)	13		(1,175)		(1,211)		(1,175)
Operating income (loss)						Operating income (loss)	80,084		(198,618)		114,533		(175,313)
Other (expense) income:	Other (expense) income:					Other (expense) income:
Interest expense, net	Interest expense, net	(49,315)		(33,335)		Interest expense, net	(50,857)		(35,623)		(100,172)		(68,958)
Foreign exchange gain (loss), net	Foreign exchange gain (loss), net	1,901		(2,013)		Foreign exchange gain (loss), net	421		(5,429)		2,322		(7,442)
Other income, net	Other income, net	3,539		2,122		Other income, net	12		6,939		3,551		9,061
Total other expense, net	Total other expense, net	(43,875)		(33,226)		Total other expense, net	(50,424)		(34,113)		(94,299)		(67,339)
Loss before income taxes		(9,426)		(9,921)
Provision for (benefit from) income taxes		668		(3,461)
Net loss		(10,094)		(6,460)
Less: Net loss attributable to non-controlling interests		3,151		4,742
Net loss attributable to Amneal Pharmaceuticals, Inc. before accretion of redeemable non-controlling interest		(6,943)		(1,718)
Income (loss) before income taxes						Income (loss) before income taxes	29,660		(232,731)		20,234		(242,652)
(Benefit from) provision for income taxes						(Benefit from) provision for income taxes	(23)		7,350		645		3,889
Net income (loss)						Net income (loss)	29,683		(240,081)		19,589		(246,541)
Less: Net (income) loss attributable to non-controlling interests						Less: Net (income) loss attributable to non-controlling interests	(17,766)		119,273		(14,615)		124,015
Net income (loss) attributable to Amneal Pharmaceuticals, Inc. before accretion of redeemable non-controlling interest						Net income (loss) attributable to Amneal Pharmaceuticals, Inc. before accretion of redeemable non-controlling interest	11,917		(120,808)		4,974		(122,526)
Accretion of redeemable non-controlling interest	Accretion of redeemable non-controlling interest	—		(438)		Accretion of redeemable non-controlling interest	—		—		—		(438)
Net loss attributable to Amneal Pharmaceuticals, Inc.		$	(6,943)	$	(2,156)
Net income (loss) attributable to Amneal Pharmaceuticals, Inc.						Net income (loss) attributable to Amneal Pharmaceuticals, Inc.	$	11,917	$	(120,808)	$	4,974	$	(122,964)

Net loss per share attributable to Amneal Pharmaceuticals, Inc.'s class A common stockholders:
Basic and diluted		$	(0.05)	$	(0.01)
Net income (loss) per share attributable to Amneal Pharmaceuticals, Inc.'s class A common stockholders:						Net income (loss) per share attributable to Amneal Pharmaceuticals, Inc.'s class A common stockholders:
Basic						Basic	$	0.08	$	(0.80)	$	0.03	$	(0.82)
Diluted						Diluted	$	0.08	$	(0.80)	$	0.03	$	(0.82)
Weighted-average common shares outstanding:	Weighted-average common shares outstanding:					Weighted-average common shares outstanding:
Basic and diluted		152,109		149,892
Basic						Basic	153,738		150,993		152,928		150,445
Diluted						Diluted	154,887		150,993		154,575		150,445

The accompanying notes are an integral part of these consolidated financial statements.

Amneal Pharmaceuticals, Inc.

Consolidated Statements of Comprehensive Income (Loss) ~~Income~~

(unaudited; in thousands)

Three Months Ended March 31,
2023 2022
Net loss $ (10,094) $ (6,460)
Less: Net loss attributable to non-controlling interests 3,151 4,742
Net loss attributable to Amneal Pharmaceuticals, Inc. before accretion of redeemable non-controlling interest (6,943) (1,718)
Accretion of redeemable non-controlling interest — (438)
Net loss attributable to Amneal Pharmaceuticals, Inc. (6,943) (2,156)
Other comprehensive (loss) income:
Foreign currency translation adjustments arising during the period 1,797 (4,079)
Unrealized (loss) gain on cash flow hedge, net of tax (14,270) 53,624
Less: Other comprehensive loss (income) attributable to non-controlling interests 6,236 (24,955)
Other comprehensive (loss) income attributable to Amneal Pharmaceuticals, Inc. (6,237) 24,590
Comprehensive (loss) income attributable to Amneal Pharmaceuticals, Inc. $ (13,180) $ 22,434


	Three Months Ended June 30,				Six Months Ended June 30,
	2023		2022		2023		2022
Net income (loss)	$	29,683	$	(240,081)	$	19,589	$	(246,541)
Less: Net (income) loss attributable to non-controlling interests	(17,766)		119,273		(14,615)		124,015
Net income (loss) attributable to Amneal Pharmaceuticals, Inc. before accretion of redeemable non-controlling interest	11,917		(120,808)		4,974		(122,526)
Accretion of redeemable non-controlling interest	—		—		—		(438)
Net income (loss) attributable to Amneal Pharmaceuticals, Inc.	11,917		(120,808)		4,974		(122,964)
Other comprehensive income (loss):
Foreign currency translation adjustments arising during the period	260		(11,628)		2,057		(15,707)
Unrealized gain (loss) on cash flow hedge, net of tax	8,312		14,070		(5,958)		67,694
Less: Other comprehensive (income) loss attributable to non-controlling interests	(4,263)		(1,225)		1,973		(26,180)
Other comprehensive income (loss) attributable to Amneal Pharmaceuticals, Inc.	4,309		1,217		(1,928)		25,807
Comprehensive income (loss) attributable to Amneal Pharmaceuticals, Inc.	$	16,226	$	(119,591)	$	3,046	$	(97,157)

The accompanying notes are an integral part of these consolidated financial statements.

Amneal Pharmaceuticals, Inc.

Consolidated Balance Sheets

(unaudited; in thousands, except per share amounts)


		March 31, 2023		December 31, 2022			June 30, 2023		December 31, 2022
Assets	Assets					Assets
Current assets:	Current assets:					Current assets:
Cash and cash equivalents	Cash and cash equivalents	$	144,674	$	25,976	Cash and cash equivalents	$	109,284	$	25,976
Restricted cash	Restricted cash	6,395		9,251		Restricted cash	5,298		9,251
Trade accounts receivable, net	Trade accounts receivable, net	545,760		741,791		Trade accounts receivable, net	674,736		741,791
Inventories	Inventories	529,042		530,735		Inventories	550,558		530,735
Prepaid expenses and other current assets	Prepaid expenses and other current assets	81,424		103,565		Prepaid expenses and other current assets	81,764		103,565
Related party receivables	Related party receivables	30		500		Related party receivables	149		500
Total current assets	Total current assets	1,307,325		1,411,818		Total current assets	1,421,789		1,411,818
Property, plant and equipment, net	Property, plant and equipment, net	462,606		469,815		Property, plant and equipment, net	459,108		469,815
Goodwill	Goodwill	599,156		598,853		Goodwill	599,206		598,853
Intangible assets, net	Intangible assets, net	1,055,319		1,096,093		Intangible assets, net	1,015,376		1,096,093
Operating lease right-of-use assets	Operating lease right-of-use assets	36,127		38,211		Operating lease right-of-use assets	34,031		38,211
Operating lease right-of-use assets - related party	Operating lease right-of-use assets - related party	17,244		17,910		Operating lease right-of-use assets - related party	16,566		17,910
Financing lease right-of-use assets	Financing lease right-of-use assets	62,400		63,424		Financing lease right-of-use assets	61,570		63,424
Other assets	Other assets	86,428		103,217		Other assets	93,240		103,217
Total assets	Total assets	$	3,626,605	$	3,799,341	Total assets	$	3,700,886	$	3,799,341
Liabilities and Stockholders' Equity	Liabilities and Stockholders' Equity					Liabilities and Stockholders' Equity
Current liabilities:	Current liabilities:					Current liabilities:
Accounts payable and accrued expenses	Accounts payable and accrued expenses	$	467,421	$	538,199	Accounts payable and accrued expenses	$	512,719	$	538,199
Current portion of liabilities for legal matters	Current portion of liabilities for legal matters	76,317		107,483		Current portion of liabilities for legal matters	77,011		107,483
Revolving credit facility		100,000		60,000
Revolving credit facilities						Revolving credit facilities	120,000		60,000
Current portion of long-term debt, net	Current portion of long-term debt, net	29,965		29,961		Current portion of long-term debt, net	30,405		29,961
Current portion of operating lease liabilities	Current portion of operating lease liabilities	9,017		8,321		Current portion of operating lease liabilities	9,861		8,321
Current portion of operating lease liabilities - related party	Current portion of operating lease liabilities - related party	2,930		2,869		Current portion of operating lease liabilities - related party	2,992		2,869
Current portion of financing lease liabilities	Current portion of financing lease liabilities	3,309		3,488		Current portion of financing lease liabilities	3,219		3,488
Related party payables - short term	Related party payables - short term	14,750		2,479		Related party payables - short term	21,143		2,479
Total current liabilities	Total current liabilities	703,709		752,800		Total current liabilities	777,350		752,800
Long-term debt, net	Long-term debt, net	2,561,724		2,591,981		Long-term debt, net	2,549,177		2,591,981
Note payable - related party	Note payable - related party	40,128		39,706		Note payable - related party	40,560		39,706
Operating lease liabilities	Operating lease liabilities	30,782		32,126		Operating lease liabilities	28,296		32,126
Operating lease liabilities - related party	Operating lease liabilities - related party	15,163		15,914		Operating lease liabilities - related party	14,388		15,914
Financing lease liabilities	Financing lease liabilities	60,241		60,769		Financing lease liabilities	59,836		60,769
Related party payables - long term	Related party payables - long term	11,207		9,649		Related party payables - long term	9,123		9,649
Other long-term liabilities	Other long-term liabilities	41,456		87,468		Other long-term liabilities	39,282		87,468
Total long-term liabilities	Total long-term liabilities	2,760,701		2,837,613		Total long-term liabilities	2,740,662		2,837,613
Commitments and contingencies (Notes 5 and 19)	Commitments and contingencies (Notes 5 and 19)					Commitments and contingencies (Notes 5 and 19)
Redeemable non-controlling interests	Redeemable non-controlling interests	27,527		24,949		Redeemable non-controlling interests	32,106		24,949
Stockholders' Equity	Stockholders' Equity					Stockholders' Equity
Preferred stock, $0.01 par value, 2,000 shares authorized, none issued at both March 31, 2023 and December 31, 2022		—		—
Class A common stock, $0.01 par value, 900,000 shares authorized at both March 31, 2023 and December 31, 2022; 153,321 and 151,490 shares issued at March 31, 2023 and December 31, 2022, respectively		1,532		1,514
Class B common stock, $0.01 par value, 300,000 shares authorized at both March 31, 2023 and December 31, 2022; 152,117 shares issued at both March 31, 2023 and December 31, 2022		1,522		1,522
Preferred stock, $0.01 par value, 2,000 shares authorized, none issued at both June 30, 2023 and December 31, 2022						Preferred stock, $0.01 par value, 2,000 shares authorized, none issued at both June 30, 2023 and December 31, 2022	—		—
Class A common stock, $0.01 par value, 900,000 shares authorized at both June 30, 2023 and December 31, 2022; 154,050 and 151,490 shares issued at June 30, 2023 and December 31, 2022, respectively						Class A common stock, $0.01 par value, 900,000 shares authorized at both June 30, 2023 and December 31, 2022; 154,050 and 151,490 shares issued at June 30, 2023 and December 31, 2022, respectively	1,540		1,514
Class B common stock, $0.01 par value, 300,000 shares authorized at both June 30, 2023 and December 31, 2022; 152,117 shares issued at both June 30, 2023 and December 31, 2022						Class B common stock, $0.01 par value, 300,000 shares authorized at both June 30, 2023 and December 31, 2022; 152,117 shares issued at both June 30, 2023 and December 31, 2022	1,522		1,522
Additional paid-in capital	Additional paid-in capital	700,722		691,629		Additional paid-in capital	708,233		691,629
Stockholders' accumulated deficit	Stockholders' accumulated deficit	(413,126)		(406,183)		Stockholders' accumulated deficit	(401,209)		(406,183)
Accumulated other comprehensive income	Accumulated other comprehensive income	3,764		9,939		Accumulated other comprehensive income	8,083		9,939
Total Amneal Pharmaceuticals, Inc. stockholders' equity	Total Amneal Pharmaceuticals, Inc. stockholders' equity	294,414		298,421		Total Amneal Pharmaceuticals, Inc. stockholders' equity	318,169		298,421
Non-controlling interests	Non-controlling interests	(159,746)		(114,442)		Non-controlling interests	(167,401)		(114,442)
Total stockholders' equity	Total stockholders' equity	134,668		183,979		Total stockholders' equity	150,768		183,979
Total liabilities and stockholders' equity	Total liabilities and stockholders' equity	$	3,626,605	$	3,799,341	Total liabilities and stockholders' equity	$	3,700,886	$	3,799,341

The accompanying notes are an integral part of these consolidated financial statements.

Amneal Pharmaceuticals, Inc.

Consolidated Statements of Cash Flows

(unaudited; in thousands)
Three Months Ended March 31,
2023 2022
Cash flows from operating activities:
Net loss $ (10,094) $ (6,460)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization 58,150 57,815
Unrealized foreign currency (gain) loss (1,987) 3,140
Amortization of debt issuance costs and discount 2,058 2,195
Change in fair value of contingent consideration 2,457 200
Stock-based compensation 7,596 8,065
Inventory provision 25,204 3,578
Other operating charges and credits, net 2,047 1,155
Changes in assets and liabilities:
Trade accounts receivable, net 195,970 124,268
Inventories (22,508) (25,549)
Prepaid expenses, other current assets and other assets 29,160 (4,423)
Related party receivables 470 4
Accounts payable, accrued expenses and other liabilities (150,483) (48,777)
Related party payables 1,672 5,132
Net cash provided by operating activities 139,712 120,343
Cash flows from investing activities:
Purchases of property, plant and equipment (9,688) (10,793)
Acquisition of business — (84,714)
Acquisition of intangible assets (338) —
Deposits for future acquisition of property, plant, and equipment (1,711) (1,888)
Net cash used in investing activities (11,737) (97,395)
Cash flows from financing activities:
Payments of principal on debt, revolving credit facility, financing leases and other (72,659) (9,796)
Borrowings on revolving credit facility 80,000 —
Proceeds from exercise of stock options — 111
Employee payroll tax withholding on restricted stock unit vesting (2,022) (3,001)
Payments of deferred consideration for acquisitions - related party — (43,998)
Acquisition of redeemable non-controlling interest — (1,722)
Tax distributions to non-controlling interests (18,219) (3,164)
Net cash used in financing activities (12,900) (61,570)
Effect of foreign exchange rate on cash 767 (1,572)
Net increase (decrease) in cash, cash equivalents, and restricted cash 115,842 (40,194)
Cash, cash equivalents, and restricted cash - beginning of period 35,227 256,739
Cash, cash equivalents, and restricted cash - end of period $ 151,069 $ 216,545
Cash and cash equivalents - end of period $ 144,674 $ 210,477
Restricted cash - end of period 6,395 6,068
Cash, cash equivalents, and restricted cash - end of period $ 151,069 $ 216,545


	Six Months Ended June 30,
	2023		2022
Cash flows from operating activities:
Net income (loss)	$	19,589	$	(246,541)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization	115,261		117,511
Unrealized foreign currency (gain) loss	(1,561)		8,014
Amortization of debt issuance costs and discount	4,523		4,388
Loss on refinancing - revolving credit facility	—		291
Intangible asset impairment charges	1,283		5,112
Change in fair value of contingent consideration	(3,907)		(70)
Stock-based compensation	14,157		16,327
Inventory provision	41,806		17,748
Insurance recoveries for property and equipment losses	—		(1,000)
Other operating charges and credits, net	3,364		3,449
Changes in assets and liabilities:
Trade accounts receivable, net	66,976		(26,561)
Inventories	(60,526)		(65,395)
Prepaid expenses, other current assets and other assets	31,898		(119,747)
Related party receivables	351		(159)
Accounts payable, accrued expenses and other liabilities	(107,760)		273,947
Related party payables	2,913		7,508
Net cash provided by (used in) operating activities	128,367		(5,178)
Cash flows from investing activities:
Purchases of property, plant and equipment	(21,691)		(15,842)
Saol Acquisition	—		(84,714)
Acquisition of intangible assets	(1,488)		(10,000)
Deposits for future acquisition of property, plant and equipment	(842)		(3,955)
Proceeds from insurance recoveries for property and equipment losses	—		1,000
Net cash used in investing activities	(24,021)		(113,511)
Cash flows from financing activities:
Payments of deferred financing and refinancing costs	—		(1,622)
Payments of principal on debt, revolving credit facilities, financing leases and other	(87,566)		(63,010)
Borrowings on revolving credit facilities	100,000		85,000
Proceeds from exercise of stock options	—		239
Employee payroll tax withholding on restricted stock unit vesting	(2,033)		(3,291)
Payments of deferred consideration for acquisitions - related party	—		(43,998)
Acquisition of redeemable non-controlling interest	—		(1,722)
Tax distributions to non-controlling interests	(35,557)		(9,917)
Net cash used in financing activities	(25,156)		(38,321)
Effect of foreign exchange rate on cash	165		(1,547)
Net increase (decrease) in cash, cash equivalents, and restricted cash	79,355		(158,557)
Cash, cash equivalents, and restricted cash - beginning of period	35,227		256,739
Cash, cash equivalents, and restricted cash - end of period	$	114,582	$	98,182
Cash and cash equivalents - end of period	$	109,284	$	91,979
Restricted cash - end of period	5,298		6,203
Cash, cash equivalents, and restricted cash - end of period	$	114,582	$	98,182

The accompanying notes are an integral part of these consolidated financial statements.

Amneal Pharmaceuticals, Inc.

Consolidated Statements of Cash Flows (continued)

(unaudited; in thousands)

Three Months Ended March 31,
2023 2022
Supplemental disclosure of cash flow information:
Cash paid for interest $ 41,066 $ 27,289
Cash received (paid), net for income taxes $ 3,421 $ (4,387)
Supplemental disclosure of non-cash investing and financing activity:
Tax distributions to non-controlling interests $ 11,548 $ 3,284
Contingent consideration for acquisition $ — $ 8,796


	Six Months Ended June 30,
	2023		2022
Supplemental disclosure of cash flow information:
Cash paid for interest	$	88,705	$	57,322
Cash received (paid), net for income taxes	$	3,917	$	(6,747)

Supplemental disclosure of non-cash investing and financing activity:
Tax distributions to non-controlling interests	$	18,285	$	—
Contingent consideration for acquisition	$	—	$	8,796
Payable for acquisition of intangible assets	$	1,000	$	31,500

The accompanying notes are an integral part of these consolidated financial statements.

Amneal Pharmaceuticals, Inc.

Consolidated Statements of Changes in Stockholders’ Equity

(unaudited; in thousands)


		Class A Common Stock			Class B Common Stock			Additional Paid-in Capital				Stockholders' Accumulated Deficit		Accumulated Other Comprehensive Income		Non- Controlling Interests			Total Equity				Redeemable Non-Controlling Interests				Class A Common Stock						Class B Common Stock			Additional Paid-in Capital				Stockholders' Accumulated Deficit				Accumulated Other Comprehensive Income				Non- Controlling Interests				Total Equity				Redeemable Non-Controlling Interests
		Shares	Amount		Shares	Amount												Shares								Amount			Shares			Amount
Balance at December 31, 2022		151,490	$	1,514	152,117	$	1,522			$	691,629			$	(406,183)	$	9,939				$	(114,442)			$	183,979		$	24,949
Net (loss) income		—	—		—	—		—				(6,943)		—		(8,688)			(15,631)				5,537
Balance at March 31, 2023																										Balance at March 31, 2023	153,321			$	1,532		152,117	$	1,522			$	700,722			$	(413,126)			$	3,764			$	(159,746)			$	134,668			$	27,527
Net income																										Net income	—			—			—	—		—				11,917				—				10,315				22,232				7,451
Foreign currency translation adjustments	Foreign currency translation adjustments	—	—		—	—		—				—		898		899			1,797				—			Foreign currency translation adjustments	—			—			—	—		—				—				131				129				260				—
Stock-based compensation	Stock-based compensation	—	—		—	—		7,596				—		—		—			7,596				—			Stock-based compensation	—			—			—	—		6,561				—				—				—				6,561				—
Restricted stock unit vesting, net of shares withheld to cover payroll taxes	Restricted stock unit vesting, net of shares withheld to cover payroll taxes	1,831	18		—	—		1,497				—		62		(3,572)			(1,995)				—			Restricted stock unit vesting, net of shares withheld to cover payroll taxes	729			8			—	—		950				—				10				(1,030)				(62)				—
Unrealized loss on cash flow hedge, net of tax		—	—		—	—		—				—		(7,135)		(7,135)			(14,270)				—
Unrealized gain on cash flow hedge, net of tax																										Unrealized gain on cash flow hedge, net of tax	—			—			—	—		—				—				4,178				4,134				8,312				—
Tax distributions	Tax distributions	—	—		—	—		—				—		—		(26,808)			(26,808)				(2,959)			Tax distributions	—			—			—	—		—				—				—				(21,203)				(21,203)				(2,872)
Balance at March 31, 2023		153,321	$	1,532	152,117	$	1,522	$	700,722			$	(413,126)	$	3,764	$	(159,746)		$	134,668			$	27,527
Balance at June 30, 2023																										Balance at June 30, 2023	154,050			$	1,540		152,117	$	1,522	$	708,233			$	(401,209)			$	8,083			$	(167,401)			$	150,768			$	32,106

Class A Common
Stock Class B Common
Stock Additional
Paid-in Capital Stockholders'
Accumulated Deficit Accumulated
Other
Comprehensive Loss Non-
Controlling Interests Total Equity Redeemable Non-Controlling Interests
Shares Amount Shares Amount
Balance at December 31, 2021 149,413 $ 1,492 152,117 $ 1,522 $ 658,350 $ (276,197) $ (24,827) $ 6,633 $ 366,973 $ 16,907
Net (loss) income — — — — — (1,718) — (7,099) (8,817) 2,357
Foreign currency translation adjustments — — — — — — (2,024) (2,055) (4,079) —
Stock-based compensation — — — — 8,065 — — — 8,065 —
Exercise of stock options 7 — — — 65 — — 46 111 —
Restricted stock unit vesting, net of shares withheld to cover payroll taxes 1,355 14 — — 319 — (112) (3,365) (3,144) —
Unrealized gain on cash flow hedge, net of tax — — — — — — 26,614 27,010 53,624 —
Tax distributions, net — — — — — — — (4,443) (4,443) (2,005)
Reclassification of redeemable non-controlling interest — — — — — (438) — (445) (883) 883
Acquisition of redeemable non-controlling interest — — — — — — — — — (1,722)
Balance at March 31, 2022 150,775 $ 1,506 152,117 $ 1,522 $ 666,799 $ (278,353) $ (349) $ 16,282 $ 407,407 $ 16,420


	Class A Common Stock			Class B Common Stock			Additional Paid-in Capital		Stockholders' Accumulated Deficit		Accumulated Other Comprehensive Income		Non- Controlling Interests		Total Equity		Redeemable Non-Controlling Interests
	Shares	Amount		Shares	Amount
Balance at December 31, 2022	151,490	$	1,514	152,117	$	1,522	$	691,629	$	(406,183)	$	9,939	$	(114,442)	$	183,979	$	24,949
Net income	—	—		—	—		—		4,974		—		1,627		6,601		12,988
Foreign currency translation adjustments	—	—		—	—		—		—		1,029		1,028		2,057		—
Stock-based compensation	—	—		—	—		14,157		—		—		—		14,157		—
Restricted stock unit vesting, net of shares withheld to cover payroll taxes	2,560	26		—	—		2,447		—		72		(4,602)		(2,057)		—
Unrealized gain on cash flow hedge, net of tax	—	—		—	—		—		—		(2,957)		(3,001)		(5,958)		—
Tax distributions	—	—		—	—		—		—		—		(48,011)		(48,011)		(5,831)
Balance at June 30, 2023	154,050	$	1,540	152,117	$	1,522	$	708,233	$	(401,209)	$	8,083	$	(167,401)	$	150,768	$	32,106

The accompanying notes are an integral part of these consolidated financial statements.

Amneal Pharmaceuticals, Inc.

Consolidated Statements of Changes in Stockholders’ Equity

(unaudited; in thousands)


	Class A Common Stock			Class B Common Stock			Additional Paid-in Capital		Stockholders' Accumulated Deficit		Accumulated Other Comprehensive (Loss) Income		Non- Controlling Interests		Total Equity		Redeemable Non-Controlling Interests
	Shares	Amount		Shares	Amount
Balance at March 31, 2022	150,775	$	1,506	152,117	$	1,522	$	666,799	$	(278,353)	$	(349)	$	16,282	$	407,407	$	16,420
Net (loss) income	—	—		—	—		—		(120,808)		—		(121,320)		(242,128)		2,047
Foreign currency translation adjustments	—	—		—	—		—		—		(5,792)		(5,836)		(11,628)		—
Stock-based compensation	—	—		—	—		8,262		—		—		—		8,262		—
Exercise of stock options	47	—		—	—		128		—		—		—		128		—
Restricted stock unit vesting, net of shares withheld to cover payroll taxes	374	4		—	—		399		—		—		(636)		(233)		—
Unrealized gain on cash flow hedge, net of tax	—	—		—	—		—		—		7,009		7,061		14,070		—
Tax distributions	—	—		—	—		—		—		—		(2,887)		(2,887)		(582)
Balance at June 30, 2022	151,196	$	1,510	152,117	$	1,522	$	675,588	$	(399,161)	$	868	$	(107,336)	$	172,991	$	17,885


	Class A Common Stock			Class B Common Stock			Additional Paid-in Capital		Stockholders' Accumulated Deficit		Accumulated Other Comprehensive (Loss) Income		Non- Controlling Interests		Total Equity		Redeemable Non-Controlling Interests
	Shares	Amount		Shares	Amount
Balance at December 31, 2021	149,413	$	1,492	152,117	$	1,522	$	658,350	$	(276,197)	$	(24,827)	$	6,633	$	366,973	$	16,907
Net (loss) income	—	—		—	—		—		(122,526)		—		(128,419)		(250,945)		4,404
Foreign currency translation adjustments	—	—		—	—		—		—		(7,816)		(7,891)		(15,707)		—
Stock-based compensation	—	—		—	—		16,327		—		—		—		16,327		—
Exercise of stock options	54	—		—	—		193		—		—		46		239		—
Restricted stock unit vesting, net of shares withheld to cover payroll taxes	1,729	18		—	—		718		—		(112)		(4,001)		(3,377)		—
Unrealized gain on cash flow hedge, net of tax	—	—		—	—		—		—		33,623		34,071		67,694		—
Tax distributions, net	—	—		—	—		—		—		—		(7,330)		(7,330)		(2,587)
Reclassification of redeemable non-controlling interest	—	—		—	—		—		(438)		—		(445)		(883)		883
Acquisition of redeemable non-controlling interest	—	—		—	—		—		—		—		—		—		(1,722)
Balance at June 30, 2022	151,196	$	1,510	152,117	$	1,522	$	675,588	$	(399,161)	$	868	$	(107,336)	$	172,991	$	17,885

The accompanying notes are an integral part of these consolidated financial statements.

Amneal Pharmaceuticals, Inc.

Notes to Consolidated Financial Statements

(unaudited)

1. Nature of Operations

Amneal Pharmaceuticals, Inc. (the “Company”) is a global pharmaceutical company that develops, manufactures, markets, and distributes a diverse portfolio of essential medicines, including complex generics and specialty branded pharmaceuticals. The Company operates principally in the United States (the “U.S.”), India, and Ireland, and sells to wholesalers, distributors, hospitals, chain pharmacies and individual pharmacies, either directly or indirectly. The Company is a holding company, whose principal assets are common units (“Amneal Common Units”) of Amneal Pharmaceuticals, LLC (“Amneal”).

The Company held ~~50.2%~~50.3% of Amneal Common Units and the group, together with their affiliates and certain assignees, who owned Amneal when it was a private company (the “Members” or the “Amneal Group”) held the remaining ~~49.8%~~49.7% as of ~~March 31,~~June 30, 2023.

2. Summary of Significant Accounting Policies

Basis of Presentation

The accompanying unaudited consolidated financial statements, which are prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”), should be read in conjunction with the Company’s annual audited financial statements for the year ended December 31, 2022 included in the Company’s 2022 Annual Report on Form 10-K. Certain information and footnote disclosures normally included in annual financial statements have been omitted from the accompanying unaudited consolidated financial statements. In the opinion of management, the accompanying unaudited consolidated financial statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of the Company’s financial position as of ~~March 31,~~June 30, 2023, cash flows for the ~~three~~six months ended ~~March 31,~~June 30, 2023 and 2022 and the results of its operations, its comprehensive income (loss) ~~income~~ and its changes in stockholders’ equity for the three and six months ended ~~March 31,~~June 30, 2023 and 2022. The consolidated balance sheet data at December 31, 2022 was derived from the Company’s audited annual financial statements, but does not include all disclosures required by U.S. GAAP.

Except for the updates included in this note, the accounting policies of the Company are set forth in Note 2. Summary of Significant Accounting Policies contained in the Company’s 2022 Annual Report on Form 10-K.

Use of Estimates

The preparation of financial statements requires the Company's management to make estimates and assumptions that affect the reported financial position at the date of the financial statements and the reported results of operations during the reporting period. Such estimates and assumptions affect the reported amounts of assets, liabilities, revenues and expenses, and disclosure of contingent assets and liabilities in the consolidated financial statements and accompanying notes. The following are some, but not all, of such estimates: the determination of chargebacks, sales returns, rebates, billbacks, valuation of intangible and other assets acquired in business combinations, allowances for accounts receivable, accrued liabilities, liabilities for legal matters, initial and subsequent valuation of contingent consideration recognized in business combinations, stock-based compensation, valuation of inventory balances, the determination of useful lives for product rights and the assessment of expected cash flows used in evaluating goodwill and other long-lived assets for impairment. Actual results could differ from those estimates.

Recently Adopted Accounting Pronouncements

In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (“ASU 2021-08”), which requires entities to recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606, Revenue from Contracts with Customers (“ASC 606”). The update will generally result in an entity recognizing contract assets and contract liabilities at amounts consistent with those recorded by the acquiree immediately before the acquisition date rather than at fair value. ASU 2021-08 was effective on a prospective basis for fiscal years beginning after December 15, 2022, with early adoption permitted. The Company adopted ASU 2021-08 effective January 1, 2023 and will apply the guidance to subsequent acquisitions. The adoption of ASU 2021-08 did not have an impact on the Company’s consolidated financial statements ~~since~~because the Company did not acquire a business during the three and six months ended ~~March 31,~~June 30, 2023.

1011

~~Recently Issued Accounting Pronouncements~~

In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting (“ASU 2020-04”), which provides elective amendments for entities that have contracts, hedging relationships and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. In January 2021, the FASB issued ASU 2021-01, Reference Rate Reform (Topic 848), to expand and clarify the scope of Topic 848 to include derivative instruments on discounting transactions. In December 2022, the FASB issued ASU 2022-06, Reference Rate reform (Topic 848): Deferral of the Sunset Date of Topic 848, which deferred the sunset date of Topic 848, Reference Rate Reform to December 31, 2024. The Company ~~is currently evaluating~~adopted ASU 2020-04 during the three months ended June 30, 2023 (refer to Note 15. Debt and Note 18. Financial Instruments for additional information). The adoption of ASU 2020-04 did not have a material impact ~~this guidance will have~~ on ~~its~~the Company’s consolidated financial statements.

Reclassifications

The prior period balance related to cost of goods sold impairment charges of $5.1 million, formerly included in a separate income statement caption for both the three and six months ended June 30, 2022, has been reclassified to be included within the income statement caption cost of goods sold to conform with the current period presentation.

The prior period balance related to loss on refinancing of $0.3 million, formerly included in a separate income statement caption for both the three and six months ended June 30, 2022, has been reclassified to be included within the income statement caption other income, net to conform to the current period presentation.

3. ~~Acquisitions~~Acquisition

Saol Baclofen Franchise Acquisition

On December 30, 2021, the Company entered into an asset purchase agreement with certain entities affiliated with Saol International Limited (collectively, “Saol”), a private specialty pharmaceutical company, pursuant to which it agreed to acquire Saol’s baclofen franchise, including Lioresal®, LYVISPAH™, and a pipeline product under development (the “Saol Acquisition”). The Saol Acquisition expanded the Company’s commercial institutional and specialty portfolio in neurology and added commercial infrastructure in advance of its entry into the biosimilar institutional market. The transaction closed on February 9, 2022.

Consideration for the Saol Acquisition included $84.7 million, paid at closing with cash on hand, and contingent royalty payments based on annual net sales for certain acquired assets, beginning in June 2023. ~~Cash paid at closing included $1.1 million for inventory acquired in excess of the normalized level, as defined~~

Refer to Note 3. Acquisitionsin the ~~asset purchase agreement (working capital adjustment).~~

~~For the three months ended March 31,~~Company’s 2022 ~~the Company incurred $0.1 million in transaction costs associated with the Saol Acquisition, which was recorded in acquisition, transaction-related and integration expenses.~~

~~The Saol Acquisition was accounted for under the acquisition method of accounting, with Amneal as the accounting acquirer.~~ ~~The purchase price was calculated as follows (in thousands):~~


~~Cash~~	$	~~84,714~~
~~Contingent consideration (royalties)~~ ~~(1)~~	~~8,796~~
~~Fair value of consideration transferred~~	$	~~93,510~~

~~(1)The estimated fair value of contingent consideration~~Annual Report on ~~the acquisition date was $8.8 million~~ ~~and~~ ~~was based on significant Level 3 inputs that were not observable in the market. Key assumptions included the discount rate, projected year of payments and expected net product sales. Refer to~~ ~~Note 17. Fair Value Measurements~~,Form 10-K for additional ~~information on the methodology and determination of this liability.~~information.

~~The following is a summary of the purchase price allocation for the Saol Acquisition (in thousands):~~


	~~Final Fair Values as of~~ ~~February 9, 2022~~
~~Inventory~~	$	~~2,162~~
~~Prepaid expenses and other current assets~~	98
~~Goodwill~~	~~7,553~~
~~Intangible assets~~	~~83,815~~
~~Total assets acquired~~	~~93,628~~
~~Accounts payable and accrued expenses~~	~~118~~
~~Fair value of consideration transferred~~	$	~~93,510~~

The Company acquired $83.8 million of marketed product rights intangible assets with a weighted average useful life of 11.5 years in the Saol Acquisition. The acquired intangible assets are being amortized over their estimated useful lives.

The estimated fair value of the identifiable intangible assets was determined using the “income approach,” which is a valuation technique that provides an estimate of the fair value of an asset based on market participant expectations of the cash flows an asset would generate over its remaining useful life. The assumptions, including the expected projected cash flows, utilized in the purchase price allocation and in determining the purchase price were based on management's best estimates as of the closing date of the Saol Acquisition on February 9, 2022.

Some of the more significant assumptions inherent in the development of those asset valuations included the estimated net cash flows for each year for each asset (including net revenues, cost of sales, selling and marketing costs and working capital / contributory asset charges), the appropriate discount rate to select in order to measure the risk inherent in each future cash flow stream, the assessment of each asset’s life cycle, the potential regulatory and commercial success risks, competitive trends impacting the asset and each cash flow stream, as well as other factors. The underlying assumptions used to prepare the ~~discounted cash flow analysis may change; accordingly, for these and other reasons, actual results may vary significantly from estimated results.~~

Goodwill is calculated as the excess of the consideration transferred over the net assets recognized. Of the total goodwill acquired in connection with the Saol Acquisition, $5.2 million was allocated to the Company’s Generics segment and $2.4 million was allocated to the Company’s Specialty segment, of which $4.9 million was deductible for tax purposes.

~~From the acquisition date of February 9, 2022 to March 31, 2022, the Saol Acquisition contributed net revenues and an operating loss of $2.9 million and $0.1 million, respectively.~~

4. Revenue Recognition

The Company recognizes revenue in accordance with ASC ~~606,~~ ~~Revenue from Contracts with Customers~~.606. Revenue is recognized when the Company transfers control of its products to the customer, which typically occurs at a point-in-time, either upon shipment or delivery. Substantially all of the Company’s net revenues relate to products which are transferred to the customer at a point-in-time.

License Agreements

Refer to Note 5. Alliance and Collaboration for further information related to revenue recognition associated with a license agreement with multiple performance obligations.

Concentration of Revenue

The following table summarizes revenues from each of the Company’s customers which individually accounted for 10% or more of its total net revenue:

Three Months Ended March 31,
2023 2022
Customer A 22 % 19 %
Customer B 14 % 18 %
Customer C 20 % 23 %
Customer D 9 % 11 %


	Three Months Ended June 30,				Six Months Ended June 30,
	2023		2022		2023		2022
Customer A	24	%	19	%	23	%	19	%
Customer B	16	%	17	%	15	%	17	%
Customer C	20	%	21	%	20	%	22	%
Customer D	11	%	11	%	10	%	11	%

Disaggregated Revenue

The Company’s significant therapeutic classes for its Generics and Specialty segments and sales channels for its AvKARE segment, as determined based on net revenue for the three and six months ended ~~March 31,~~June 30, 2023 and 2022, are set forth below (in thousands):


			Three Months Ended March 31,						Three Months Ended June 30,				Six Months Ended June 30,
			2023		2022				2023		2022		2023		2022
Generics	Generics						Generics
		Anti-Infective	$	5,174	$	6,245		Anti-infective	$	6,092	$	5,566	$	11,266	$	11,811
		Hormonal / Allergy	104,851		96,368			Hormonal / allergy	126,435		118,309		231,286		214,677
		Antiviral	25,474		10,571			Antiviral	3,597		1,296		29,071		11,867
		Central Nervous System	84,582		81,125			Central nervous system	83,604		108,787		168,186		189,912
		Cardiovascular System	32,503		23,453			Cardiovascular system	33,146		32,043		65,649		55,496
		Gastroenterology	14,364		16,620			Gastroenterology	19,905		17,531		34,269		34,151
		Oncology	10,578		17,208			Oncology	28,546		18,424		39,124		35,632
		Metabolic Disease/Endocrine	9,265		11,233			Metabolic disease/ endocrine	14,936		9,988		24,201		21,221
		Respiratory	12,815		5,665			Respiratory	11,136		12,118		23,951		17,783
		Dermatology	18,004		13,477			Dermatology	17,949		17,937		35,953		31,414
		Other therapeutic classes	25,895		35,360			Other therapeutic classes	27,809		22,329		53,704		57,689
		International and other	301		422			International and other	546		567		847		989
		Total Generics net revenue	343,806		317,747			Total Generics net revenue	373,701		364,895		717,507		682,642
Specialty	Specialty						Specialty
		Hormonal / Allergy	24,763		19,419			Hormonal / allergy	29,011		24,320		53,774		43,739
		Central Nervous System	60,139		58,168			Central nervous system	59,563		65,356		119,702		123,524
		Other therapeutic classes	6,776		7,499			Other therapeutic classes	8,420		7,325		15,196		14,824
		Total Specialty net revenue	91,678		85,086			Total Specialty net revenue	96,994		97,001		188,672		182,087
AvKARE	AvKARE						AvKARE
		Distribution	83,230		60,263			Distribution	83,795		64,240		167,025		124,503
		Government Label	24,516		24,459			Government label	29,870		22,280		54,386		46,739
		Institutional	8,862		6,315			Institutional	8,982		6,060		17,844		12,375
		Other	5,448		3,763			Other	5,704		4,879		11,152		8,642
		Total AvKARE net revenue	122,056		94,800			Total AvKARE net revenue	128,351		97,459		250,407		192,259
		Total net revenue	$	557,540	$	497,633		Total net revenue	$	599,046	$	559,355	$	1,156,586	$	1,056,988

A rollforward of the major categories of sales-related deductions for the ~~three~~six months ended ~~March 31,~~June 30, 2023 is as follows (in thousands):

Contract
Charge - Backs
and Sales
Volume
Allowances Cash Discount
Allowances Accrued
Returns
Allowance Accrued
Medicaid and
Commercial
Rebates
Balance at December 31, 2022 $ 573,592 $ 27,454 $ 145,060 $ 86,030
Provision related to sales recorded in the period 760,744 25,462 15,920 49,573
Credits/payments issued during the period (908,454) (28,995) (20,996) (64,149)
Balance at March 31, 2023 $ 425,882 $ 23,921 $ 139,984 $ 71,454


	Contract Charge - Backs and Sales Volume Allowances		Cash Discount Allowances		Accrued Returns Allowance		Accrued Medicaid and Commercial Rebates
Balance at December 31, 2022	$	573,592	$	27,454	$	145,060	$	86,030
Provision related to sales recorded in the period	1,619,720		54,566		34,997		114,905
Credits/payments issued during the period	(1,767,481)		(51,805)		(47,125)		(103,395)
Balance at June 30, 2023	$	425,831	$	30,215	$	132,932	$	97,540

5. Alliance and Collaboration

The Company has entered into several alliance, collaboration, license, distribution and similar agreements with respect to certain of its products and services with third-party pharmaceutical companies. The consolidated statements of operations include revenue recognized under agreements the Company has entered into to develop marketing and/or distribution relationships with its partners to fully leverage the technology platform and revenue recognized under development agreements

which generally obligate the Company to provide research and development (“R&D”) services over multiple periods. The Company’s significant arrangements are discussed below.

License Agreement

On December 28, 2022, Amneal signed a long-term license agreement with Orion Corporation (“Orion”), a globally operating Finnish pharmaceutical company, to commercialize a number of its complex generic products in most parts of Europe, Australia and New Zealand (the “Orion Agreement”). The initial term of the Orion Agreement commences upon commercial launch of the products and will continue for eight years. The Orion Agreement will automatically renew for successive two-year terms unless either party declines such renewal in writing at least one year in advance.

Under the terms of the Orion Agreement, Amneal granted Orion licenses to certain generic products commercially available in the U.S. today and select high-value pipeline products currently under development. In addition, Amneal will be responsible for the performance of all R&D activities to be conducted to obtain regulatory approval for each product. Amneal is entitled to be reimbursed for a percentage of mutually agreed upon R&D expenses from Orion. Orion will be responsible for preparing and filing regulatory documentation, along with paying any application fees seeking regulatory approval for the products.

Upon achieving regulatory approval for products, Amneal will be responsible for manufacturing and supplying products to Orion. Orion will be responsible for all commercialization and marketing activities for the territories described above. Amneal will earn revenue for supplying products to Orion at the greater of: (i) cost plus a stated margin, or (ii) a fixed percentage of the net selling price, as defined in the Orion Agreement.

Upon signing of the Orion Agreement, Amneal was entitled to an upfront, non-refundable payment of €20.0 million, or $21.4 million (based on the exchange rate as of that date), which was collected in January 2023. Amneal is eligible to receive certain one-time sales-based milestones in the aggregate of €45.0 million, or $49.0 million, based on the exchange rate as of ~~March 31,~~June 30, 2023, contingent upon whether Orion achieves certain annual sales targets.

The Orion Agreement is within the scope of ASC Topic 808, Collaborative Arrangements (“ASC 808”). The Company identified performance obligations related to: (1) the grant of a license of functional ~~IP,~~intellectual property (“IP”), (2) the performance of R&D activities, and (3) the supply of products. The Company evaluated that the grant of licenses is in the scope of ASC 606, whereas the performance of R&D activities is in the scope of ASC 730-20, Research and Development Arrangements, because the Company determined that performing R&D activities on behalf of other parties is not part of the ordinary activities of its business. The Company records reimbursement received from Orion for R&D activities as a reduction of R&D expense. The Company concluded each future purchase order from Orion represents a separate contract. Amneal will record revenue related to each purchase order when it transfers control of the products to Orion. At December 31, 2022, Amneal had not performed any reimbursable R&D activities under the Orion Agreement or supplied any products to Orion.

The Company determined that the transaction price under the arrangement was the upfront payment of $21.4 million, which was allocated to the performance obligations based on their relative standalone selling prices. The remaining sales-based milestones payments are variable consideration and were not included in the transaction price because they were fully constrained under ASC 606.

For the year ended December 31, 2022, the Company recognized $8.0 million in license revenue related to the delivery of functional IP, which was recorded in net revenues. The remaining $13.4 million of the transaction price was allocated to the

R&D activities performance obligation and was recorded as deferred income, of which $6.7 million was recorded in accounts payable and accrued expenses and $6.7 million was recorded in other long-term liabilities as of December 31, 2022. During the ~~three~~six months ended ~~March 31,~~June 30, 2023, the Company recognized $0.6 million as a reduction to R&D expense related to services performed under the Orion ~~Agreement.~~Agreement (none during the three months ended June 30, 2023). As of ~~March 31,~~June 30, 2023, deferred income of ~~$6.1~~$8.6 million and ~~$6.7~~$4.2 million, respectively, was recorded in accounts payable and accrued expenses and other long-term liabilities. As of ~~March 31,~~June 30, 2023, no products have been supplied by Amneal under the Orion Agreement.

Biosimilar Licensing and Supply Agreement

On May 7, 2018, the Company entered into a licensing and supply agreement with Mabxience S.L. for its biosimilar candidate for Avastin® (bevacizumab). The supply agreement was subsequently amended on March 2, 2021 and the licensing agreement was amended on March 4, 2021. Pursuant to the agreement, the Company will be the exclusive partner in the U.S. market and will pay development and regulatory milestone payments as well as commercial milestone payments on reaching pre-agreed sales targets in the market to Mabxience, up to $78.3 million.

On April 13, 2022, the Food and Drug Administration (the “FDA”) approved the Company’s biologics license application for bevacizumab-maly, a biosimilar referencing Avastin®. In connection with this regulatory approval and associated activity, the Company paid milestones of $26.5 million in 2022, which were capitalized as product rights intangible assets and are being amortized to cost of sales over their estimated useful lives of 7 years.

Agreements with Kashiv Biosciences, LLC

For details on the Company’s related party agreements with Kashiv, refer to Note 21. Related Party Transactions in this Form 10-Q and Note 24. Related Party Transactions in the Company’s 2022 Annual Report on Form 10-K.

6. Government Grants

In November 2021, Amneal Pharmaceuticals Private Limited, a subsidiary of the Company in India, was selected as one of 55 companies to participate in the India Production Linked Incentive Scheme for the Pharmaceutical Sector (“PLI Scheme”). The government of India established the PLI Scheme to make India’s domestic manufacturing more globally competitive and to create global champions within the pharmaceutical sector by encouraging investment and product diversification with a focus on manufacturing complex and high value goods.

Under the PLI Scheme, the Company is eligible to receive up to 10 billion Indian rupees, or approximately ~~$121.7~~$121.9 million (based on the exchange rate as of ~~March 31,~~June 30, 2023), over a maximum six-year period, starting in 2022. To be eligible to receive the cash incentives, Amneal must achieve (i) minimum cumulative expenditures towards developmental and/or capital investments and (ii) a minimum percentage growth in sales of eligible products.

The Company concluded the PLI Scheme is government assistance in the form of a grant and, in the absence of specific accounting guidance under U.S. GAAP, the Company has analogized to International Accounting Standards 20, Accounting for Government Grants and Disclosure of Government Assistance. The Company evaluated the PLI Scheme to be a grant related to income and will recognize the cash incentives on a systematic basis in other operating income. For the ~~three~~six months ended ~~March 31,~~June 30, 2023, the Company recognized ~~approximately~~ $1.2 million of other operating income ~~(none during~~from the PLI Scheme (immaterial for the three months ended ~~March 31, 2022)~~June 30, 2023). For the three and six months ended June 30, 2022, the Company recognized $1.2 million of other operating income from the PLI Scheme. As of ~~March 31,~~June 30, 2023 and December 31, 2022, the Company recorded a corresponding receivable from the government of India of $5.2 million and $4.0 million, respectively, within prepaid expenses and other current assets.

7. Income Taxes

For the three months ended ~~March 31,~~June 30, 2023, the Company’s ~~provision for (benefit from)~~benefit from income taxes and effective tax ~~rates~~rate were ~~$0.7~~both immaterial, as compared to a provision for income taxes and effective tax rate of $7.4 million and ~~(7.1)~~(3.2)%~~, respectively, compared to $(3.5) million and 34.9%~~, respectively, for the three months ended ~~March 31,~~June 30, 2022. For the six months ended June 30, 2023, the Company’s provision for income taxes and effective tax rate were $0.6 million and 3.2%, respectively, as compared to $3.9 million and (1.6)%, respectively, for the six months ended June 30, 2022. The period-over-period ~~change~~changes in the provision for income taxes was primarily related to a change in the jurisdictional mix of income and a discrete benefit as a result of the completion of an Internal Revenue Service examination and Joint Committee review of the 2012-2018 federal income tax returns, which enabled the Company to recognize previously unrecognized tax benefits during the three and six months ended ~~March 31,~~June 30, 2022.

The Company established a valuation allowance on its deferred tax assets (“DTAs”) based upon all available objective and verifiable evidence both positive and negative, including historical levels of pre-tax income (loss) both on a consolidated basis and tax reporting entity basis, legislative developments, expectations and risks associated with estimates of future pre-tax income, and prudent and feasible tax planning strategies. Since first establishing a valuation allowance, the Company has generated cumulative consolidated three-year pre-tax losses through ~~March 31,~~June 30, 2023. As a result of the losses through ~~March 31,~~June 30, 2023, the Company determined that it is more likely than not that it will not realize the benefits of its gross DTAs and therefore maintained its valuation allowance. As of ~~March 31,~~June 30, 2023 and December 31, 2022, this valuation allowance was $435.4 million and $434.9 million, respectively, and it reduced the carrying value of these gross DTAs to zero.

The Company entered into a tax receivable agreement (“TRA”) for which it is generally required to pay the holders of Amneal Common Units 85% of the applicable tax savings, if any, in U.S. federal and state income tax that it is deemed to realize as a result of certain tax attributes of their Amneal Common Units sold to the Company (or exchanged in a taxable sale) and that are created as a result of (i) the sales of their Amneal Common Units for shares of class A common stock and (ii) tax benefits attributable to payments made under the TRA. In conjunction with the valuation allowance recorded on the DTAs, the Company reversed the accrued TRA liability of $192.8 million during 2019.

The projection of future taxable income involves significant judgment. Actual taxable income may differ from the Company’s estimates, which could significantly impact the timing of the recognition of the contingent liability under the TRA. As noted above, the Company has determined it is more-likely-than-not it will be unable to utilize all of its DTAs subject to the TRA;

therefore, as of ~~March 31,~~June 30, 2023, the Company has not recognized the contingent liability under the TRA related to the tax savings it may realize from common units sold or exchanged. If utilization of these DTAs becomes more likely than not in the future, at such time, Amneal will recognize a liability under the TRA as a result of basis adjustments under Internal Revenue Code Section 754. As of both ~~March 31,~~June 30, 2023 and December 31, 2022, the contingent liability associated with the TRA was approximately $202.7 million, out of which approximately ~~$1.5~~$1.9 million was recorded.

The timing and amount of any payments under the TRA may vary depending upon a number of factors, including the timing and number of Amneal Common Units sold or exchanged for the Company’s class A common stock, the price of the Company’s class A common stock on the date of sale or exchange, the timing and amount of the Company’s taxable income, and the tax rate in effect at the time of realization of the Company’s taxable income (the TRA liability is determined based on a percentage of the corporate tax savings from the use of the TRA’s attributes). Further sales or exchanges occurring subsequent to ~~March 31,~~June 30, 2023 could result in future Amneal tax deductions and obligations to pay 85% of such benefits to the holders of Amneal Common Units. These obligations could be incremental to and substantially larger than the approximate $202.7 million contingent liability as of ~~March 31,~~June 30, 2023 described above. Under certain conditions, such as a change of control or other early termination event, the Company could be obligated to make TRA payments in advance of tax benefits being realized. Payments could also be in excess of the tax savings that the Company may ultimately realize.

Any future recognition of these TRA liabilities will be recorded through charges in the Company’s consolidated statements of operations. However, if the tax attributes are not utilized in future years, it is reasonably possible no amounts would be paid under the TRA in excess of the ~~$1.5~~$1.9 million accrued as of ~~March 31,~~June 30, 2023. Should the Company determine that a DTA with a valuation allowance is realizable in a subsequent period, the related valuation allowance will be reversed and, if a resulting TRA payment is determined to be probable, a corresponding TRA liability will be recorded.

8. ~~Loss~~Earnings (Loss) per Share

Basic ~~loss~~earnings (loss) per share of the Company’s class A common stock is computed by dividing net ~~loss~~income (loss) attributable to Amneal Pharmaceuticals, Inc. by the weighted-average number of shares of class A common stock outstanding during the period. Diluted ~~loss~~earnings (loss) per share of class A common stock is computed by dividing net ~~loss~~income (loss) attributable to

Amneal Pharmaceuticals, Inc. by the weighted-average number of shares of class A common stock outstanding, adjusted to give effect to potentially dilutive securities.

The following table sets forth reconciliations of the numerators and denominators used to compute basic and diluted ~~loss~~earnings (loss) per share of class A common stock (in thousands, except per share amounts):

Three Months Ended
March 31,
2023 2022
Numerator:
Net loss attributable to Amneal Pharmaceuticals, Inc. $ (6,943) $ (2,156)
Denominator:
Weighted-average shares outstanding - basic and diluted 152,109 149,892
Net loss per share attributable to Amneal Pharmaceuticals, Inc.’s class A common stockholders:
Basic and diluted $ (0.05) $ (0.01)


	Three Months Ended June 30,				Six Months Ended June 30,
	2023		2022		2023		2022
Numerator:
Net income (loss) attributable to Amneal Pharmaceuticals, Inc.	$	11,917	$	(120,808)	$	4,974	$	(122,964)
Denominator:
Weighted-average shares outstanding - basic	153,738		150,993		152,928		150,445
Effect of dilutive securities:
Restricted stock units	1,149		—		1,647		—
Weighted-average shares outstanding - diluted	154,887		150,993		154,575		150,445
Net income (loss) per share attributable to Amneal Pharmaceuticals, Inc.’s class A common stockholders:
Basic	$	0.08	$	(0.80)	$	0.03	$	(0.82)
Diluted	$	0.08	$	(0.80)	$	0.03	$	(0.82)

Shares of the Company’s class B common stock do not share in the earnings or losses of the Company and, therefore, are not participating securities. As such, separate presentation of basic and diluted ~~loss~~earnings (loss) per share of class B common stock under the two-class method has not been presented.

The following table presents potentially dilutive securities excluded from the computations of diluted ~~loss~~earnings (loss) per share of class A common stock (in thousands):


		Three Months Ended March 31,					Three Months Ended June 30,				Six Months Ended June 30,
		2023		2022			2023		2022		2023		2022
Stock options	Stock options	2,632	(1)	3,035	(1)	Stock options	2,629	(1)	2,919	(2)	2,629	(1)	2,919	(2)
Restricted stock units	Restricted stock units	11,576	(1)	11,430	(1)	Restricted stock units	—		10,989	(2)	—		10,989	(2)
Performance stock units	Performance stock units	7,018	(1)	7,947	(1)	Performance stock units	7,012	(3)	7,427	(2)	7,012	(3)	7,427	(2)
Shares of class B common stock	Shares of class B common stock	152,117	(2)	152,117	(2)	Shares of class B common stock	152,117	(4)	152,117	(4)	152,117	(4)	152,117	(4)

(1)Excluded from the computation of diluted earnings per share of class A common stock because the exercise price of the stock options exceeded the average market price of class A common stock during the period (out-of-the-money).

(2)Excluded from the computation of diluted loss per share of class A common stock because the effect of their inclusion would have been anti-dilutive since there was a net loss attributable to the Company during the period.

~~(2)~~(3)Excluded from the computation of diluted earnings per share of class A common stock because the performance vesting conditions were not met during the period.

(4)Shares of class B common stock are considered potentially dilutive shares of class A common stock. Shares of class B common stock have been excluded from the computations of diluted loss per share because the effect of their inclusion would have been anti-dilutive under the if-converted method.

9. Trade Accounts Receivable, Net

Trade accounts receivable, net was comprised of the following (in thousands):


		March 31, 2023		December 31, 2022			June 30, 2023		December 31, 2022
Gross accounts receivable	Gross accounts receivable	$	998,134	$	1,344,959	Gross accounts receivable	$	1,133,348	$	1,344,959
Allowance for credit losses	Allowance for credit losses	(2,571)		(2,122)		Allowance for credit losses	(2,566)		(2,122)
Contract charge-backs and sales volume allowances	Contract charge-backs and sales volume allowances	(425,882)		(573,592)		Contract charge-backs and sales volume allowances	(425,831)		(573,592)
Cash discount allowances	Cash discount allowances	(23,921)		(27,454)		Cash discount allowances	(30,215)		(27,454)
Subtotal	Subtotal	(452,374)		(603,168)		Subtotal	(458,612)		(603,168)
Trade accounts receivable, net	Trade accounts receivable, net	$	545,760	$	741,791	Trade accounts receivable, net	$	674,736	$	741,791

Concentration of Receivables

Trade accounts receivable from customers representing 10% or more of the Company’s total trade accounts receivable were as follows:


		March 31, 2023		December 31, 2022			June 30, 2023		December 31, 2022
Customer A	Customer A	36	%	41	%	Customer A	36	%	41	%
Customer B	Customer B	17	%	25	%	Customer B	26	%	25	%
Customer C	Customer C	28	%	21	%	Customer C	22	%	21	%

10. Inventories

Inventories were comprised of the following (in thousands):


		March 31, 2023		December 31, 2022			June 30, 2023		December 31, 2022
Raw materials	Raw materials	$	218,065	$	224,607	Raw materials	$	235,679	$	224,607
Work in process	Work in process	54,169		58,522		Work in process	55,253		58,522
Finished goods	Finished goods	256,808		247,606		Finished goods	259,626		247,606
Total inventories	Total inventories	$	529,042	$	530,735	Total inventories	$	550,558	$	530,735

11. Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets were comprised of the following (in thousands):


		March 31, 2023		December 31, 2022			June 30, 2023		December 31, 2022
Deposits and advances	Deposits and advances	$	3,306	$	1,821	Deposits and advances	$	3,360	$	1,821
Prepaid insurance	Prepaid insurance	4,514		8,090		Prepaid insurance	5,949		8,090
Prepaid regulatory fees	Prepaid regulatory fees	3,540		5,298		Prepaid regulatory fees	1,771		5,298
Income and other tax receivables	Income and other tax receivables	12,943		12,881		Income and other tax receivables	13,394		12,881
Prepaid taxes	Prepaid taxes	13,634		16,593		Prepaid taxes	11,617		16,593
Other current receivables (1)	Other current receivables (1)	14,016		33,133		Other current receivables (1)	14,473		33,133
Chargebacks receivable (2)	Chargebacks receivable (2)	10,964		8,605		Chargebacks receivable (2)	10,987		8,605
Other prepaid assets	Other prepaid assets	18,507		17,144		Other prepaid assets	20,213		17,144
Total prepaid expenses and other current assets	Total prepaid expenses and other current assets	$	81,424	$	103,565	Total prepaid expenses and other current assets	$	81,764	$	103,565

(1)Other current receivables as of December 31, 2022 include a $21.4 million receivable for an upfront payment associated with the Orion Agreement, which was collected in January 2023. Refer to Note 5. Alliance and Collaboration for additional information.

(2)When a sale occurs on a contract item in the Company’s AvKARE segment, the difference between the cost paid to the manufacturer by the Company and the contract cost that the end customer has with the manufacturer is rebated back to the Company by the manufacturer. The Company establishes a chargeback (rebate) receivable and a reduction to cost of goods sold in the same period as the related sale.

12. Goodwill and Other Intangible Assets

The changes in goodwill for the ~~three~~six months ended ~~March 31,~~June 30, 2023 and for the year ended December 31, 2022 were as follows (in thousands):


		March 31, 2023		December 31, 2022			June 30, 2023		December 31, 2022
Balance, beginning of period	Balance, beginning of period	$	598,853	$	593,017	Balance, beginning of period	$	598,853	$	593,017
Goodwill acquired during the period	Goodwill acquired during the period	—		7,553		Goodwill acquired during the period	—		7,553
Adjustment during the period for Puniska Acquisition		—		3,075
Adjustment during the period for the acquisition of Puniska Healthcare Pvt. Ltd.						Adjustment during the period for the acquisition of Puniska Healthcare Pvt. Ltd.	—		3,075
Currency translation	Currency translation	303		(4,792)		Currency translation	353		(4,792)
Balance, end of period	Balance, end of period	$	599,156	$	598,853	Balance, end of period	$	599,206	$	598,853

As of ~~March 31,~~June 30, 2023, $366.3 million, $163.4 million, and $69.5 million of goodwill was allocated to the Specialty, Generics, and AvKARE segments, respectively. As of December 31, 2022, $366.3 million, $163.1 million, and $69.5 million of goodwill was allocated to the Specialty, Generics, and AvKARE segments, respectively. For the year ended December 31, 2022, goodwill acquired during the period was associated with the Saol Acquisition. Refer to Note 3. ~~Acquisitions~~Acquisition for additional information.

Intangible assets ~~at March 31,~~as of June 30, 2023 and December 31, 2022 were comprised of the following (in thousands):


		March 31, 2023							December 31, 2022							June 30, 2023							December 31, 2022
		Weighted-Average Amortization Period (in years)	Cost		Accumulated Amortization		Net		Cost		Accumulated Amortization		Net			Weighted-Average Amortization Period (in years)	Cost		Accumulated Amortization		Net		Cost		Accumulated Amortization		Net
Amortizing intangible assets:	Amortizing intangible assets:														Amortizing intangible assets:
Product rights	Product rights	7.4	$	1,222,612	$	(609,267)	$	613,345	$	1,222,762	$	(573,281)	$	649,481	Product rights	7.2	$	1,221,412	$	(643,771)	$	577,641	$	1,222,762	$	(573,281)	$	649,481
Other intangible assets	Other intangible assets	3.9	133,800		(82,181)		51,619		133,800		(77,943)		55,857		Other intangible assets	3.7	133,800		(86,420)		47,380		133,800		(77,943)		55,857
Subtotal	Subtotal		$	1,356,412	$	(691,448)	$	664,964	$	1,356,562	$	(651,224)	$	705,338	Subtotal		$	1,355,212	$	(730,191)	$	625,021	$	1,356,562	$	(651,224)	$	705,338
In-process research and development	In-process research and development		390,355		—		390,355		390,755		—		390,755		In-process research and development		390,355		—		390,355		390,755		—		390,755
Total intangible assets	Total intangible assets		$	1,746,767	$	(691,448)	$	1,055,319	$	1,747,317	$	(651,224)	$	1,096,093	Total intangible assets		$	1,745,567	$	(730,191)	$	1,015,376	$	1,747,317	$	(651,224)	$	1,096,093

Amortization expense related to intangible assets ~~was $41.1 million and $40.9 million~~ for the three months ended ~~March 31,~~June 30, 2023 and 2022, was $40.8 million and $42.0 million, respectively. Amortization expense related to intangible assets for the six months ended June 30, 2023 and 2022, was $81.9 million and $82.9 million, respectively.

The following table presents future amortization expense for the next five years and thereafter, excluding $390.4 million of in-process research and development (“IPR&D&D”) intangible assets (in thousands):


		Future Amortization			Future Amortization
Remainder of 2023	Remainder of 2023	$	121,942	Remainder of 2023	$	81,134
2024	2024	162,793		2024	163,031
2025	2025	124,439		2025	124,719
2026	2026	73,893		2026	74,102
2027	2027	52,448		2027	52,575
2028	2028	30,753		2028	30,808
Thereafter	Thereafter	98,696		Thereafter	98,652
Total	Total	$	664,964	Total	$	625,021

The Company reviews intangible assets with finite lives for recoverability whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. Indefinite-lived intangible assets, including IPR&D, are tested for impairment if impairment indicators arise and, at a minimum, annually.

Interim Goodwill and In-Process Research and Development Intangible Asset Impairment Tests

On June 30, 2023, the Company received a complete response letter (“CRL”) from the FDA regarding its new drug application for IPX203 for the treatment of Parkinson’s disease. The CRL indicated that although an adequate scientific bridge was established for the safety of one ingredient, levodopa, based on pharmacokinetic studies, it was not adequately established for the other ingredient, carbidopa, and the FDA has requested additional information. The CRL did not identify any issues with respect to the efficacy or manufacturing of IPX203. The Company will work closely with the FDA to address its comments and plans to meet with the agency in the third quarter of 2023 to align on the best path forward.

Based on the Company’s evaluation of the CRL and in connection with the preparation of the Company’s financial statements for the three and six months ended June 30, 2023, the Company updated its estimate of the fair value of the IPX203 IPR&D intangible asset as of June 30, 2023. The Company’s estimate of fair value used a probability-weighted income approach that discounts expected future cash flows to present value using a discount rate of 12.5%. Other valuation inputs included the potential launch date, estimated revenue and operating margin, and the probability of technical and regulatory success. Because the estimated fair value of the IPX203 IPR&D intangible asset exceeded its carrying value by 49% as of June 30, 2023, the Company concluded that the asset was not impaired.

Additionally, in light of the significance of IPX203 to the Specialty reporting unit, the Company performed an interim goodwill impairment test for its Specialty reporting unit, which is the same as the Company’s Specialty reportable segment, as of June 30, 2023. The fair value of the Specialty reporting unit was determined by combining both the income and market approaches. In performing this test, the Company utilized a long-term growth rate of 1% and a discount rate of 11.5% in its estimation of fair value. Other Specialty reporting unit valuation inputs included expected potential launch dates, estimated revenue and operating margin, and the probability of technical and regulatory success of IPR&D assets, the most significant of which is IPX203. The assumptions used in evaluating goodwill for impairment are subject to change and are tracked against historical performance by management. Because the estimated fair value of the Specialty reporting unit exceeded its carrying value by 90% as of June 30, 2023, the Company concluded that its Specialty reporting unit goodwill was not impaired.

While management believes the assumptions used in the interim IPX203 IPR&D intangible asset impairment test were reasonable and commensurate with the views of a market participant, changes in key assumptions, including increasing the discount rate, lowering forecasts for revenue and operating margin, delaying the potential launch date, and lowering the probability of technical and regulatory success, could result in material future impairments of the Company’s IPX203 IPR&D intangible asset.

13. Other Assets

Other assets were comprised of the following (in thousands):


		March 31, 2023		December 31, 2022			June 30, 2023		December 31, 2022
Interest rate swap (1)	Interest rate swap (1)	$	71,316	$	85,586	Interest rate swap (1)	$	79,628	$	85,586
Security deposits	Security deposits	3,566		3,523		Security deposits	3,576		3,523
Long-term prepaid expenses	Long-term prepaid expenses	4,119		3,711		Long-term prepaid expenses	2,034		3,711
Deferred revolving credit facility costs	Deferred revolving credit facility costs	2,068		2,206		Deferred revolving credit facility costs	1,926		2,206
Other long term assets	Other long term assets	5,359		8,191		Other long term assets	6,076		8,191
Total	Total	$	86,428	$	103,217	Total	$	93,240	$	103,217

(1)Refer to Note 17. Fair Value Measurements and Note 18. Financial Instruments for information about the Company’s interest rate swap.

1920

14. Accounts Payable and Accrued Expenses

Accounts payable and accrued expenses were comprised of the following (in thousands):


		March 31, 2023		December 31, 2022			June 30, 2023		December 31, 2022
Accounts payable	Accounts payable	$	136,922	$	165,980	Accounts payable	$	139,527	$	165,980
Accrued returns allowance (1)	Accrued returns allowance (1)	139,984		145,060		Accrued returns allowance (1)	132,932		145,060
Accrued compensation	Accrued compensation	32,115		54,038		Accrued compensation	45,650		54,038
Accrued Medicaid and commercial rebates (1)	Accrued Medicaid and commercial rebates (1)	71,454		86,030		Accrued Medicaid and commercial rebates (1)	97,540		86,030
Accrued royalties	Accrued royalties	17,370		19,309		Accrued royalties	27,172		19,309
Commercial chargebacks and rebates	Commercial chargebacks and rebates	10,226		10,226		Commercial chargebacks and rebates	10,226		10,226
Accrued professional fees	Accrued professional fees	13,826		11,386		Accrued professional fees	15,201		11,386
Taxes payable		1,069		359
Accrued other	Accrued other	44,455		45,811		Accrued other	44,471		46,170
Total accounts payable and accrued expenses	Total accounts payable and accrued expenses	$	467,421	$	538,199	Total accounts payable and accrued expenses	$	512,719	$	538,199

(1)Refer to Note 4. Revenue Recognition for a rollforward of the balance from December 31, 2022 to ~~March 31,~~June 30, 2023.

15. Debt

The following is a summary of the Company’s ~~total~~ indebtedness under its term loans (in thousands):


		March 31, 2023		December 31, 2022			June 30, 2023		December 31, 2022
Term Loan due May 2025	Term Loan due May 2025	$	2,557,126	$	2,563,876	Term Loan due May 2025	$	2,550,376	$	2,563,876
Rondo Term Loan due January 2025	Rondo Term Loan due January 2025	47,000		72,000		Rondo Term Loan due January 2025	39,750		72,000
Total debt	Total debt	2,604,126		2,635,876		Total debt	2,590,126		2,635,876
Less: debt issuance costs	Less: debt issuance costs	(12,437)		(13,934)		Less: debt issuance costs	(10,544)		(13,934)
Total debt, net of debt issuance costs	Total debt, net of debt issuance costs	2,591,689		2,621,942		Total debt, net of debt issuance costs	2,579,582		2,621,942
Less: current portion of long-term debt	Less: current portion of long-term debt	(29,965)		(29,961)		Less: current portion of long-term debt	(30,405)		(29,961)
Total long-term debt, net	Total long-term debt, net	$	2,561,724	$	2,591,981	Total long-term debt, net	$	2,549,177	$	2,591,981

There have been no material changes in the Company’s long-term debt since December 31, 2022, except as disclosed below. Refer to Note 16. Debt in the Company’s 2022 Annual Report on Form 10-K for additional information and definitions of terms used in this note.

In January 2023, the Company borrowed $80.0 million under the New Revolving Credit Facility to fund an $83.9 million payment related to the Opana ER® antitrust litigation settlement agreements (refer to Note 19. Commitments and Contingencies). In March 2023, the Company repaid $40.0 million of its borrowings on the New Revolving Credit Facility from cash on hand. As of ~~March 31,~~June 30, 2023, the Company had $100.0 million in borrowings and $245.9 million of available capacity under the New Revolving Credit Facility.

During the three and six months ended ~~March 31,~~June 30, 2023, the Company repaid ~~$25.0~~$7.3 million and $32.3 million, respectively, of principal outstanding on the Rondo Term Loan, of which ~~$22.8~~$27.8 million was ~~prepaid.~~prepaid as of June 30, 2023. Additionally, the Company borrowed $20.0 million under the Rondo Revolving Credit Facility during the second quarter of 2023 for working capital purposes. As of June 30, 2023, $20.0 million was outstanding under the Rondo Revolving Credit Facility and there was $10.0 million of available capacity.

Reference Rate Reform

On May 31, 2023, the Company executed an amendment to the Term Loan (the “Amended Term Loan”), which changed the variable reference rate from the London interbank offered rate (“LIBOR”) to the one-month adjusted term secured overnight financing rate (“SOFR”), subject to a floor of (0.11448%) plus 3.5%.

The Company also executed an amendment to the related interest rate swap (the “Amended Swap ”) that: (i) set a new fixed rate equal to 1.366%, (ii) changed the referenced floating rate from LIBOR to the one-month SOFR and (iii) established a floating

2021

rate floor of (0.11448%). After adopting ASC 848, Reference Rate Reform and electing certain applicable practical expedients, the Company determined that the amendments do not modify its existing accounting conclusions. As a result, the Company determined that the hedging relationship between the Amended Swap and the Amended Term Loan remained highly effective.

On April 20, 2023, the Company executed an amendment to the Rondo Revolving Credit Facility, which changed the variable reference rate in the Rondo Term Loan from LIBOR to the one-month adjusted term SOFR, subject to a floor of 0.1% plus 2.25%.

The amendments to the term loans and swap agreement did not have a material impact on the Company’s consolidated financial statements as of June 30, 2023 or for the three and six months then ended.

16. Other Long-Term Liabilities

Other long-term liabilities were comprised of the following (in thousands):


		March 31, 2023		December 31, 2022			June 30, 2023		December 31, 2022
Uncertain tax positions	Uncertain tax positions	$	572	$	563	Uncertain tax positions	$	473	$	563
Long-term portion of liabilities for legal matters (1)	Long-term portion of liabilities for legal matters (1)	—		49,442		Long-term portion of liabilities for legal matters (1)	752		49,442
Long-term compensation	Long-term compensation	18,207		16,737		Long-term compensation	21,175		16,737
Contingent consideration (2)	Contingent consideration (2)	13,384		11,997		Contingent consideration (2)	10,110		11,997
Other long-term liabilities	Other long-term liabilities	9,293		8,729		Other long-term liabilities	6,772		8,729
Total other long-term liabilities	Total other long-term liabilities	$	41,456	$	87,468	Total other long-term liabilities	$	39,282	$	87,468

(1) Refer to Note 19. Commitments and Contingencies for additional information.

(2) Refer to Note 17. Fair Value Measurements for additional information.

17. Fair Value Measurements

Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement that should be determined using assumptions that market participants would use in pricing an asset or liability. Valuation techniques used to measure fair value should maximize the use of observable inputs and minimize the use of unobservable inputs. To measure fair value, the Company uses the following fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable:

Level 1 – Quoted prices in active markets for identical assets or liabilities.

Level 2 – Inputs other than Level 1 that are observable for the asset or liability, either directly or indirectly, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data by correlation or other means.

Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Value is determined using pricing models, discounted cash flow methodologies, or similar techniques and also includes instruments for which the determination of fair value requires significant judgment or estimation.

Assets and Liabilities Measured at Fair Value on a Recurring Basis

The Company evaluates its financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level of classification for each reporting period. The following table sets forth the Company’s financial assets and liabilities that were measured at fair value on a recurring basis as of ~~March 31,~~June 30, 2023 and December 31, 2022 (in thousands):


				Fair Value Measurement Based on									Fair Value Measurement Based on
March 31, 2023		Total		Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
June 30, 2023										June 30, 2023	Total		Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets	Assets									Assets
Interest rate swap (1)	Interest rate swap (1)	$	71,316	$	—	$	71,316	$	—	Interest rate swap (1)	$	79,628	$	—	$	79,628	$	—
Liabilities	Liabilities									Liabilities
Deferred compensation plan liabilities (2)	Deferred compensation plan liabilities (2)	$	9,832	$	—	$	9,832	$	—	Deferred compensation plan liabilities (2)	$	9,940	$	—	$	9,940	$	—
Contingent consideration liabilities (3)	Contingent consideration liabilities (3)	$	17,884	$	—	$	—	$	17,884	Contingent consideration liabilities (3)	$	11,520	$	—	$	—	$	11,520

December 31, 2022	December 31, 2022									December 31, 2022
Assets	Assets									Assets
Interest rate swap (1)	Interest rate swap (1)	$	85,586	$	—	$	85,586	$	—	Interest rate swap (1)	$	85,586	$	—	$	85,586	$	—
Liabilities	Liabilities									Liabilities
Deferred compensation plan liabilities (2)	Deferred compensation plan liabilities (2)	$	9,674	$	—	$	9,674	$	—	Deferred compensation plan liabilities (2)	$	9,674	$	—	$	9,674	$	—
Contingent consideration liability (3)	Contingent consideration liability (3)	$	15,427	$	—	$	—	$	15,427	Contingent consideration liability (3)	$	15,427	$	—	$	—	$	15,427

(1)The fair value measurement of the Company’s interest rate swap classified within Level 2 of the fair value hierarchy is a model-derived valuation as of a given date in which all significant inputs are observable in active markets including certain financial information and certain assumptions regarding past, present, and future market conditions. Refer to Note 18. Financial Instruments for information on the Company's interest rate swap.

(2)These liabilities are recorded at the value of the amount owed to the plan participants, with changes in value recognized as compensation expense. The calculation of the deferred compensation plan obligation is derived from observable market data by reference to hypothetical investments selected by the participants.

(3)The fair value measurement of contingent consideration liabilities has been classified as Level 3 recurring liabilities as the valuations require judgment and estimation of factors that are not currently observable in the market. If different assumptions were used for various inputs, the estimated fair values could be higher or lower than what the Company determined. As of ~~March 31,~~June 30, 2023 and December 31, 2022, the contingent consideration liability associated with the Saol Acquisition included ~~$0.6~~$0.5 million and $0.1 million, respectively, recorded in accounts payable and accrued expenses and ~~$13.4~~$10.1 million and $12.0 million, respectively, recorded in other-longer term liabilities. As of ~~March 31,~~June 30, 2023 and December 31, 2022, the contingent consideration liability associated with the acquisition of Kashiv Specialty Pharmaceuticals, LLC (“KSP”) was valued at approximately ~~$3.9~~$0.9 million and $3.3 million, respectively, and recorded within related party payables - long term.

There were no transfers between levels in the fair value hierarchy during the ~~three~~six months ended ~~March 31,~~June 30, 2023.

Contingent consideration

On April 2, 2021, the Company completed the acquisition of KSP, which provides for contingent milestone payments of up to an aggregate of $8.0 million (undiscounted) upon the achievement of certain regulatory milestones, as well as contingent royalty payments that are tiered depending on the aggregate annual net sales for certain future pharmaceutical products.

On February 9, 2022, the Company completed the Saol Acquisition, which provides for contingent royalty payments that are tiered depending on the aggregate annual net sales for certain pharmaceutical products, beginning in 2023.

There were no contingent royalty payments for the ~~three~~six months ended ~~March 31,~~June 30, 2023.

The following table provides a reconciliation of the contingent consideration liability measured at fair value on a recurring basis using significant unobservable inputs (Level 3) (in thousands):

~~Three~~Six Months Ended
~~March 31,~~June 30, 2023

Balance, beginning of period

15,427

Change in fair value during the period

~~2,457~~ (3,907)

Balance, end of period

~~17,884~~11,520

The fair value measurement of the contingent consideration liabilities were determined based on significant unobservable inputs, including the discount rate, the cost of debt, estimated probabilities of success, timing of achieving specified regulatory milestones and the estimated amount of future sales of the acquired products. The contingent consideration liabilities were estimated by applying a probability-weighted expected payment model for contingent milestone payments and Monte Carlo simulation models for contingent royalty payments, which were then discounted to present value. Changes to the fair values of the contingent consideration liabilities can result from changes to one or a number of the aforementioned inputs. If different assumptions were used for various inputs, the estimated fair value could be higher or lower than what the Company determined.

The following table summarizes the significant unobservable inputs used in the fair value measurement of the Company’s material contingent consideration liabilities as of ~~March 31,~~June 30, 2023:


Contingent Consideration Liability	Contingent Consideration Liability	Fair Value as of March 31, 2023 (in thousands)		Unobservable input		Range				Weighted Average(1)	Contingent Consideration Liability		Fair Value as of June 30, 2023 (in thousands)			Unobservable input		Range				Weighted Average(1)
Regulatory Milestones (KSP acquisition)		$400		Discount rate		6.5%	-	7.4%		6.6%
				Probability of payment		1.8%	-	20.0%		18.6%
				Projected year of payment		2024	-	2026		2024
Royalties (KSP acquisition)		$3,500		Discount rate		12.5%	-	12.5%		12.5%
			Probability of payment		1.8%	-	20.0%		18.6%
			Projected year of payment		2024	-	2033		2028
Royalties (Saol Acquisition)	Royalties (Saol Acquisition)		td3,984		Discount rate		17.5%	-	17.5%		17.5%	Royalties (Saol Acquisition)			td0,600		Discount rate		17.4%	-	17.4%		17.4%
				Projected year of payment		2023	-	2033		2027				Projected year of payment			2023	-	2033		2027

(1) Unobservable inputs were weighted by the relative fair value of each product candidate acquired.

Assets and Liabilities Not Measured at Fair Value on a Recurring Basis

The carrying amounts of cash, accounts receivable and accounts payable approximate their fair values due to the short-term maturity of these instruments.

The Term Loan, as defined in Note 16. Debt in the Company’s 2022 Annual Report on Form 10-K, is in the Level 2 category within the fair value level hierarchy. The fair value was determined using market data for valuation. The fair value of the Term Loan at ~~March 31,~~June 30, 2023 was approximately ~~$2.4~~$2.5 billion as compared to approximately $2.3 billion at December 31, 2022.

The Rondo Term Loan, as defined in Note 16. Debt in the Company’s 2022 Annual Report on Form 10-K, is in the Level 2 category within the fair value level hierarchy. The fair value of the Rondo Term Loan at ~~March 31,~~June 30, 2023 and December 31, 2022 was ~~$46.5~~$39.6 million and $70.9 million, respectively.

The Sellers Notes, as defined in Note 16. Debt in the Company’s 2022 Annual Report on Form 10-K, are in the Level 2 category within the fair value level hierarchy. The fair value of the Sellers Notes at ~~March 31,~~June 30, 2023 and December 31, 2022 was ~~$39.7~~$40.4 million and $39.1 million, respectively.

Refer to Note 16. Debt in the Company’s 2022 Annual Report on Form 10-K for detailed information about its indebtedness, including definitions of terms.

Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis

There were no non-recurring fair value measurements during the ~~three~~six months ended ~~March 31,~~June 30, 2023 and 2022.

18. Financial Instruments

The Company uses an interest rate swap to manage its exposure to market risks for changes in interest rates.

Interest Rate Risk

Interest income earned on cash and cash equivalents may fluctuate as interest rates change; however, due to their relatively short maturities, the Company does not hedge these assets or their investment cash flows because the impact of interest rate risk is not material. The Company is exposed to interest rate risk on its debt obligations. The Company’s debt obligations consist of variable-rate and fixed-rate debt instruments. The Company’s primary objective is to achieve the lowest overall cost of funding while managing the variability in cash outflows within an acceptable range. To achieve this objective, the Company has entered into an interest rate swap on the Term Loan.

Interest Rate Derivative – Cash Flow Hedge

The interest rate swap involves the periodic exchange of payments without the exchange of underlying principal or notional amounts. In October 2019, the Company entered into an interest rate lock agreement for a total notional amount of $1.3 billion to hedge part of the Company's interest rate exposure associated with the variability in future cash flows from changes in the one-month LIBOR associated with the Term Loan. On May 31, 2023 the Company executed the Amended Swap Agreement that, among other things, changed the variable reference rate from LIBOR to the one-month SOFR (refer to Note 15. Debt).

As of ~~March 31,~~June 30, 2023, the total gain, net of income taxes, related to the Company’s cash flow hedge was ~~$71.3~~$79.6 million, of which ~~$35.4~~$39.7 million was recognized in accumulated other comprehensive income and ~~$35.9~~$39.9 million was recognized in non-controlling interests.

A summary of the fair values of derivative instruments in the consolidated balance sheets was as follows (in thousands):

March 31, 2023

December 31, 2022

June 30, 2023

December 31, 2022

Derivatives Designated as Hedging Instruments

Balance Sheet
Classification

Fair Value

Balance Sheet
Classification

Fair Value

Derivatives Designated as Hedging Instruments

Balance Sheet
Classification

Fair Value

Balance Sheet
Classification

Fair Value

Variable-to-fixed interest rate swap

Other assets

71,316

Other assets

85,586

Variable-to-fixed interest rate swap

Other assets

79,628

Other assets

85,586

19. Commitments and Contingencies

Commitments

Commercial Manufacturing, Collaboration, License, and Distribution Agreements

The Company continues to seek to enhance its product line and develop a balanced portfolio of differentiated products through product acquisitions and in-licensing. Accordingly, the Company, in certain instances, may be contractually obligated to make potential future development, regulatory, and commercial milestone, royalty and/or profit-sharing payments in conjunction with collaborative agreements or acquisitions that the Company has entered ~~into~~ with third parties. The Company has also licensed certain technologies or intellectual property from various third parties. The Company is generally required to make upfront payments as well as other payments upon successful completion of regulatory or sales milestones. The agreements generally permit the Company to terminate the agreement with no significant continuing obligation. The Company could be required to make significant payments pursuant to these arrangements. These payments are contingent upon the occurrence of certain future events and, given the nature of these events, it is unclear when, if ever, the Company may be required to pay such amounts. Further, the timing of any future payment is not reasonably estimable. Refer to Note 5. Alliance and Collaboration for additional information. Certain of these arrangements are with related parties. Refer to Note 21. Related Party Transactions for additional information.

Contingencies

Legal Proceedings

The Company's legal proceedings are complex, constantly evolving, and subject to uncertainty. As such, the Company cannot predict the outcome or impact of its significant legal proceedings which are set forth below. Additionally, the Company manufactures and derives a portion of its revenue from the sale of pharmaceutical products in the opioid class of drugs and may therefore face claims arising from the regulation and/or consumption of such products. While the Company believes it has

meritorious claims and/or defenses to the matters described below (and intends to vigorously prosecute and defend them), the nature and cost of litigation is unpredictable, and an unfavorable outcome of such proceedings could include damages, fines, penalties and injunctive or administrative remedies. For any proceedings where losses are probable and reasonably capable of estimation, the Company accrues a potential loss. When the Company has a probable loss for which a reasonable estimate of the liability is a range of losses and no amount within that range is a better estimate than any other amount, the Company records the loss at the low end of the range. While these accruals have been deemed reasonable by the Company’s management, the assessment process relies heavily on estimates and assumptions that may ultimately prove inaccurate or incomplete. Additionally, unforeseen circumstances or events may lead the Company to subsequently change its estimates and assumptions. Unless otherwise indicated below, the Company is unable at this time to estimate the possible loss or the range of loss, if any, associated with such legal proceedings and claims. Any such claims, proceedings, investigations or litigation, regardless of the merits, might result in substantial costs to defend or settle, borrowings under the Company’s debt agreements, restrictions on product use or sales, or otherwise harm the Company’s business. The ultimate resolution of any or all claims, legal proceedings or investigations are inherently uncertain and difficult to predict, could differ materially from the Company’s estimates and could have a material adverse effect on its results of operations and/or cash flows in any given accounting period, or on ~~the~~ its overall financial condition. The Company currently intends to vigorously prosecute and/or defend these proceedings as appropriate. From time to time, however, the Company may settle or otherwise resolve these matters on terms and conditions that it believes to be in its best ~~interest~~. interest. An insurance recovery, if any, is recorded in the period in which it is probable the recovery will be realized. For the three and six months ended ~~March 31,~~June 30, 2023, ~~and 2022, credit~~charges related to legal matters, net ~~was $0.4~~were $2.0 million and ~~$2.3~~$1.6 million, respectively. For the three and six months ended June 30, 2022, charges related to legal matters, net were $251.9 million and $249.6 million, respectively, and primarily consisted of a charge for the settlement of the Opana ER® antitrust litigation of $262.8 million, net of insurance recoveries associated with a securities class action settled during 2022.

Liabilities for legal matters were comprised of the following (in thousands):


Matter	Matter	March 31, 2023		December 31, 2022		Matter	June 30, 2023		December 31, 2022
Opana ER® antitrust litigation	Opana ER® antitrust litigation	$	50,000	$	83,944	Opana ER® antitrust litigation	$	50,000	$	83,944
Opana ER® antitrust litigation-accrued interest	Opana ER® antitrust litigation-accrued interest	1,216		1,423		Opana ER® antitrust litigation-accrued interest	1,590		1,423
Opana ER® antitrust litigation-imputed interest	Opana ER® antitrust litigation-imputed interest	(1,070)		—		Opana ER® antitrust litigation-imputed interest	(736)		—
Civil prescription opioid litigation	Civil prescription opioid litigation	20,048		17,993		Civil prescription opioid litigation	21,222		17,993

Galeas v. Amneal		1,200		1,200
Other	Other	4,923		2,923		Other	4,935		4,123
Current portion of liabilities for legal matters	Current portion of liabilities for legal matters	$	76,317	$	107,483	Current portion of liabilities for legal matters	$	77,011	$	107,483

Opana ER® antitrust litigation	Opana ER® antitrust litigation	$	—	$	50,000	Opana ER® antitrust litigation	$	—	$	50,000
Opana ER ® antitrust litigation-accrued interest	Opana ER ® antitrust litigation-accrued interest	—		847		Opana ER ® antitrust litigation-accrued interest	—		847
Opana ER ® antitrust litigation-imputed interest	Opana ER ® antitrust litigation-imputed interest	—		(1,405)		Opana ER ® antitrust litigation-imputed interest	—		(1,405)
Prescription Opioid Litigation						Prescription Opioid Litigation	752		—
Long-term portion of liabilities for legal matters (included in other long-term liabilities)	Long-term portion of liabilities for legal matters (included in other long-term liabilities)	$	—	$	49,442	Long-term portion of liabilities for legal matters (included in other long-term liabilities)	$	752	$	49,442

Refer to the respective discussions below for additional information on the significant matters in the tables above.

Refer to Note 21. Commitments and Contingencies in our Annual Report on Form 10-K for a general discussion of Medicaid Reimbursement and Price Reporting Matters

The Company is required to provide pricing information to state agencies, including agencies that administer federal Medicaid programs. Certain state agencies have alleged that manufacturers have reported improper pricing information, which allegedly caused them to overpay reimbursement costs. Other agencies have alleged that manufacturers have failed to timely file required reports concerning pricing information. Liabilities are periodically established by the Company for any potential claims or settlements of overpayment. The Company intends to vigorously defend against any such claims. The ultimate settlement of any potential liability for such claims may be higher or lower than estimated.

~~Federal~~ and ~~State Healthcare Programs~~

~~In the United Sta~~tes, many of our products are eligible for reimbursement under federal and state health care programs such as Medicaid, Medicare, TRICARE, and/or state pharmaceutical assistance programs, and as a result, certain federal and state healthcare laws and regulations pertaining to reimbursement are applicable to our business. We could be subject to claims from federal and state healthcare programs for non-compliance with these laws and regulations.

Patent Litigation.

2526

~~Patent Litigation~~

There is substantial litigation in the pharmaceutical, biological, and biotechnology industries with respect to the manufacture, use, and sale of new products which are the subject of conflicting patent and intellectual property claims. One or more patents often cover the brand name products for which the Company is developing generic versions and the Company typically has patent rights covering the Company’s branded products.

Under federal law, when a drug developer files an Abbreviated New Drug Application (“ANDA”) for a generic drug seeking approval before expiration of a patent which has been listed with the FDA as covering the brand name product, the developer must certify its product will not infringe the listed patent(s) and/or the listed patent is invalid or unenforceable (commonly referred to as a “Paragraph IV” certification). Notices of such certification must be provided to the patent holder, who may file a suit for patent infringement within 45 days of the patent holder’s receipt of such notice. If the patent holder files suit within the 45-day period, the FDA can review and tentatively approve the ANDA, but generally is prevented from granting final marketing approval of the product until a final judgment in the action has been rendered in favor of the generic drug developer, or 30 months from the date the notice was received, whichever is sooner. The Company’s Generics segment is typically subject to patent infringement litigation brought by branded pharmaceutical manufacturers in connection with the Company’s Paragraph IV certifications seeking an order delaying the approval of the Company’s ANDA until expiration of the patent(s) at issue in the litigation.

The uncertainties inherent in patent litigation make the outcome of such litigation difficult to predict. For the Company’s Generics segment, the potential consequences in the event of an unfavorable outcome in such litigation include delaying the launch of its generic products until patent expiration. If the Company were to launch its generic product prior to successful resolution of a patent litigation, the Company could be liable for potential damages measured by the profits lost by the branded product manufacturer rather than the profits earned by the Company if it is found to infringe a valid, enforceable patent, or enhanced treble damages in cases of willful infringement. For the Company’s Specialty segment, an unfavorable outcome may significantly accelerate generic competition ahead of expiration of the patents covering the Company’s branded products. All such litigation typically involves significant expense.

The Company is generally responsible for all of the patent litigation fees and costs associated with current and future products not covered by its alliance and collaboration agreements. The Company has agreed to share legal expenses with respect to third-party and Company products under the terms of certain of the alliance and collaboration agreements. The Company records the costs of patent litigation as expense in the period when incurred for products it has developed, as well as for products which are the subject of an alliance or collaboration agreement with a third-party.

Other Litigation Related to the Company’s Business

Opana ER® FTC Matters

On February 25, 2014, Impax Laboratories, Inc. (“Impax”) received a Civil Investigative Demands (“CID”) from the Federal Trade Commission (“FTC”) concerning its investigation into the drug Opana® ER and its generic equivalents. On March 30, 2016, the FTC filed a complaint against Impax, Endo Pharmaceuticals Inc. (“Endo”), and others in the United States District Court for the Eastern District of Pennsylvania, alleging that Impax and Endo violated antitrust laws when they entered into a June 2010 settlement agreement that resolved patent litigation in connection with the submission of Impax’s ANDA for generic original Opana® ER. In October 2016, the Court granted Impax’s motion to sever, formally terminating the suit against Impax. In January 2017, the FTC filed a Part 3 Administrative Complaint against Impax with similar allegations regarding the 2010 settlement. Following trial, in May 2018, the Administrative Law Judge ruled in favor of Impax and dismissed the Complaint in its entirety. FTC Complaint Counsel appealed the decision to the full Commission, and in March 2019, the FTC issued an Opinion & Order reversing the Administrative Law Judge’s decision. The Opinion & Order did not provide for any monetary damages but enjoined Impax from entering into future agreements containing certain terms. Impax filed a Petition for Review of the FTC’s Opinion & Order with the United States Court of Appeals for the Fifth Circuit, and on April 13, 2021, the Fifth Circuit issued a decision denying Impax’s Petition for Review, effectively affirming the FTC’s Opinion & Order. On September 10, 2021, Impax filed a petition for writ of certiorari in the Supreme Court, which was denied in December 2021.

On July 12, 2019, the Company received a ~~CID~~Civil Investigative Demand (“CID”) from the ~~FTC~~Federal Trade Commission (the “FTC”) concerning an August 2017 settlement agreement between Impax Laboratories, Inc. (“Impax”) and Endo Pharmaceuticals Inc. (“Endo”), which resolved a subsequent patent infringement and breach of contract dispute between the parties regarding the ~~above-referenced~~ June 2010 settlement agreement related to Opana® ER. The Company cooperated with the FTC regarding the CID. On January 25, 2021, the FTC filed a complaint against Endo, Impax and Amneal in the ~~United States~~U.S. District Court for the District of Columbia, alleging that the 2017 settlement violated antitrust laws. In April 2021, the Company filed a motion to dismiss the FTC’s complaint, which the District Court granted on March 24, 2022. The FTC appealed the District Court’s

decision in May 2022, which appeal remains pending. The Company believes it has strong defenses to the FTC’s allegations and intends to vigorously defend the action, however, no assurance can be given as to the timing or outcome of the litigation.

Opana ER® Antitrust Litigation

From June 2014 to April 2015, a number of complaints styled as class actions on behalf of direct purchasers and indirect purchasers (or end-payors) and several separate individual complaints on behalf of certain direct purchasers (the “opt-out plaintiffs”) of Opana ER® were filed against Endo and ~~Impax.~~

~~In June 2022,~~ Impax ~~entered~~and consolidated into ~~a preliminary settlement agreement with the class of direct purchasers that, if all conditions are satisfied, would result~~multi-district litigation (“MDL”) in the ~~resolution~~U.S. District Court for the Northern District of substantially all the direct purchasers’ and individual complainants’ underlying claims and lawsuits in the MDL. At the same time, Impax entered into a settlement agreement with individual complainants that resolved all of their claims and lawsuits in the MDL. Subsequently, Impax entered into a separate preliminary settlement agreement with the class of indirect purchasers that, if all conditions are satisfied, would result in the resolution of substantially all the indirect purchasers’ underlying claims and lawsuits in the MDL. The direct purchaser plaintiffs, indirect purchaser plaintiffs, and individual complainants are referred to herein collectively as “the Plaintiffs.” On November 3, 2022, the N.D. Ill. approved the direct purchasers’ settlement. On December 15, 2022, the N.D. Ill. approved the indirect purchasers’ settlement.Illinois.

Impax subsequently entered into settlement agreements with all of the Plaintiffs that were subsequently approved by the court. Pursuant to the settlement agreements, the Company agreed to pay a total of $265.0 million between 2022 and mid-January 2024 to resolve substantially all of the ~~Plaintiffs’~~plaintiffs’ claims. The cumulative amount of payments made by the Company pursuant to the settlement agreements was $215.0 million as of ~~March 31,~~June 30, 2023, of which $83.9 million was paid during January 2023, primarily using borrowings under the New Revolving Credit Facility (refer to Note 15. Debt). As of ~~March 31,~~June 30, 2023, the liability for the remaining settlement payment of $50.0 million and 3% stated interest thereon was included in the current portion of liabilities for legal matters. The remaining imputed interest of ~~$1.1~~$0.7 million as of ~~March 31,~~June 30, 2023 will be recognized to interest expense during the final payment period. The settlement agreements are not an admission of liability or fault by Impax, the Company or its subsidiaries. Upon court approval of the final settlement agreements as discussed above, substantially all the claims and lawsuits in the litigation were resolved.

~~Sergeants Benevolent Association Health & Welfare Fund v. Actavis, PLC, et. al.~~

In August 2015, a complaint styled as a class action was filed against Forest Laboratories (a subsidiary of Actavis plc) and numerous generic drug manufacturers, including Amneal, in the United States District Court for the Southern District of New York involving patent litigation settlement agreements between Forest Laboratories and the generic drug manufacturers concerning generic versions of Forest’s Namenda® IR product. The complaint (as amended on February 12, 2016) asserts federal and state antitrust claims on behalf of indirect purchasers, who allege in relevant part that during the class period they indirectly purchased Namenda® IR or its generic equivalents in various states at higher prices than they would have absent the defendants’ allegedly unlawful anticompetitive conduct. Plaintiff sought, among other things, unspecified monetary damages, and equitable relief, including disgorgement and restitution. In June 2019, the Company reached a settlement with the plaintiff, subject to Court approval. On September 10, 2019, the Court entered an order preliminarily approving the settlement and indefinitely staying the case as to the settling defendants (including the Company), until the disposition of the claims against the non-settling defendants. The remaining defendants subsequently also settled with the plaintiff. The plaintiff filed proposed materials seeking final approval of all settlements, including with the Company, and to finally resolve the case. The Court held a fairness hearing on the proposed settlements on March 23, 2023. All settlements were approved, including as to the Company, and no further action is required. The amount of the settlement was not material to the Company’s consolidated financial statements.

United States Department of Justice Investigations

On November 6, 2014, Impax disclosed that one of its sales representatives received a grand jury subpoena from the Antitrust Division of the United States Department of Justice (the “DOJ”). On March 13, 2015, Impax received a grand jury subpoena from the DOJ requesting the production of information and documents regarding the sales, marketing, and pricing of four generic prescription medications. Impax ~~has~~ cooperated in the investigation and produced documents and information in response to the subpoenas from 2014 to 2016. However, no assurance can be given as to the timing or outcome of the investigation.

On April 30, 2018, Impax received a CID from the Civil Division of the DOJ (the “Civil Division”). The CID requests the production of information and documents regarding the pricing and sale of Impax’s pharmaceuticals and interactions with other generic pharmaceutical manufacturers regarding whether generic pharmaceutical manufacturers engaged in market allocation and price-fixing agreements, paid illegal remuneration, and caused false claims to be submitted to the ~~Federal~~federal government. Impax has cooperated with the Civil Division’s investigation. However, no assurance can be given as to the timing or outcome of the investigation.

~~Impax~~On May 15, 2023, Amneal received a CID from the Civil Division requesting information and documents related to the manufacturing and shipping of diclofenac sodium 1% gel labeled as “prescription only.” The Company has cooperated with the Civil Division’s investigation. However, no assurance can be given as to the timing or outcome of the investigation.

In Re Generic Pharmaceuticals Pricing Antitrust Litigation

Since March 2016, multiple putative antitrust class action complaints have been filed on behalf of direct purchasers, indirect purchasers (or end-payors), and indirect resellers, as well as individual complaints on behalf of certain direct and indirect purchasers, and municipalities (the “opt-out plaintiffs”) against manufacturers of generic drugs, including Impax and the Company. The complaints allege a conspiracy to fix, maintain, stabilize, and/or raise prices, rig bids, and allocate markets or customers for various generic drugs in violation of federal and state antitrust and consumer protection laws. Plaintiffs seek unspecified monetary damages and equitable relief, including disgorgement and restitution. The lawsuits have been

consolidated in an MDL in the United States District Court for the Eastern District of Pennsylvania (In re Generic Pharmaceuticals Pricing Antitrust Litigation, No. 2724, (E.D. Pa.)).

On May 10, 2019, Attorneys General of 43 States and the Commonwealth of Puerto Rico filed a complaint in the United States District Court for the District of Connecticut against various manufacturers and individuals, including the Company, alleging a conspiracy to fix, maintain, stabilize, and/or raise prices, rig bids, and allocate markets or customers for multiple generic drugs. On November 1, 2019, the State Attorneys General filed an Amended Complaint on behalf of nine additional states and territories. On June 10, 2020, Attorneys General of 46 States, the Commonwealth of Puerto Rico, the Commonwealth of the Northern Mariana Islands, the Territory of Guam, the U.S. Virgin Islands, and the District of Columbia filed a new complaint against various manufacturers and individuals, including the Company, alleging a conspiracy to fix prices, rig bids, and allocate markets or customers for additional generic drugs. Plaintiff ~~States~~states seek unspecified monetary damages and penalties and equitable relief, including disgorgement and restitution. On September 9, 2021, the State Attorneys General filed an Amended Complaint on behalf of California in addition to the original ~~Plaintiff States.~~plaintiff states.

Both the May 10, 2019 and June 10, 2020 lawsuits have been incorporated into MDL No. 2724, and the June 10, 2020 lawsuit has been selected for bellwether status. ~~On March 30, 2022, the~~The State of Alabama and the Territory of Guam have both voluntarily dismissed all ~~its~~of their claims in the two actions against all defendants, including the Company, without ~~prejudice. On February 21, 2023, the Territory of Guam voluntarily dismissed all its claims in the two actions against all defendants, including the Company, with~~ prejudice. On February 27, 2023, the Court addressed defendants’ motions to dismiss the June 10, 2020 bellwether action, holding that the states may not pursue certain federal remedies, and otherwise denying Amneal’s joint and individual motion to dismiss. The court did not analyze the substance of the states’ state law claims, reserving those issues for a separate ruling. On March 24, 2023, certain Defendants including the Company filed a motion requesting that the Court certify for appeal its February 27, 2023 order denying Defendants’ motion to dismiss, arguing that the Order involved two controlling questions of law as to which immediate appellate review is warranted (1) whether the complaint adequately alleges an “overarching conspiracy,” and (2) whether the Court properly deferred adjudication of Defendants’ claim-splitting defense.

Fact and document discovery in MDL No. 2724 are proceeding. The court has entered a Pretrial Order setting a schedule for the bellwether cases, which includes a June 1, 2023 deadline for bellwether fact discovery and a March 13, 2024 deadline for the filing of summary judgment motions. No trial date has been set.

On July 1, 2023, 152 hospital systems, health care centers, and retail pharmacies filed a complaint in the United States District Court for the Northern District of California against manufacturers of generic drugs, including Impax and the Company. Like the complaints that were previously consolidated in MDL No. 2724, the complaint claims that defendants engaged in an unlawful conspiracy to fix, maintain and/or stabilize the prices, rig bids, and allocate markets or customers for various generic drugs in violation of federal and state antitrust and consumer protection laws, and seeks unspecified monetary damages and equitable relief, including disgorgement and restitution. Plaintiffs also filed a notice that they are asserting claims based on the same alleged conspiracy as plaintiffs in MDL No. 2724, and that they believe transfer and coordination of their case with the MDL may be appropriate.

On June 3, 2020, the Company and Impax were also named in a putative class action complaint filed in the Federal Court of Canada in Toronto, Ontario against numerous generic pharmaceutical manufacturers, on behalf of a putative class of individuals who purchased generic drugs in the private sector from 2012 to the present (Kathryn Eaton v. Teva Canada Limited, et. al., No. T-607-20). The complaint alleges price fixing, among other claims. On August 23, 2022, the plaintiff filed a second amended complaint. On May 30, 2023, the plaintiff served materials for their motion to certify the action as a class proceeding, define the class and certify the common questions to be decided, among other things. The ~~case~~Court has ~~otherwise~~ not ~~progressed to date.~~set a date for the return of the plaintiff’s motion.

Civil Prescription Opioid Litigation

The Company and certain of its affiliates have been named as defendants in ~~various matters~~over 900 cases filed in state and federal courts relating to the sale of prescription opioid pain relievers. Plaintiffs in these actions include state Attorneys General, county and municipal governments, hospitals, Native American tribes, pension funds, third-party payors, and individuals. Plaintiffs seek unspecified monetary damages and other forms of relief based on various causes of action, including negligence, public nuisance, unjust enrichment, and civil conspiracy, as well as alleged violations of the Racketeer Influenced and Corrupt Organizations Act (“RICO”), state and federal controlled substances laws and other statutes. All cases involving the Company also name other manufacturers, distributors, and retail pharmacies as defendants, and there are numerous other cases involving allegations relating to prescription opioid pain relievers against other manufacturers, distributors, and retail pharmacies in which the Company and its affiliates are not named.

Nearly all cases pending in federal district courts have been consolidated for pre-trial proceedings in an MDL in the United States District Court for the Northern District of Ohio (In re: National Prescription Opiate Litigation, Case No. 17-mdl-2804). There are approximately 922 cases in the MDL in which the Company or its affiliates have been named as defendants. Three third-party payor cases were dismissed from the MDL on April 18, 2023. Since December 31, 2022, three additional opioid cases have been filed against the Company or come to the Company’s attention as result of service of a complaint upon the Company. The three cases are: (1) Cuyahoga County, OH et al. v. Mylan Pharmaceuticals, Inc. et al., Civil Action No. 1:23-op-45003-DAP, which was directly filed in the MDL pending in the United States District Court for the Northern District of Ohio; (2) The City of Atlanta, GA et al. v. Mylan Pharmaceuticals, Inc. et al., Case 1:23-cv-01193-TWT (N.D. Ga.), which is a federal case that will not be consolidated into the MDL; and (3) Palm Beach County, FL et al. v. Mylan Pharmaceuticals, Inc. et al., Case 9:23-cv-80431-RLR (S.D. Fla.), another federal case that will not be consolidated into the MDL. The Company is also named in ~~approximately 77~~various state court cases pending in ~~ten~~nine states. ~~The Company has filed motions to dismiss in many of these cases.~~ No firm trial dates have been set except in ~~Alabama (July 24, 2023) and~~ Texas (May 20, 2024 (Dallas County) and September 30, 2024 (Bexar County)).

The Company ~~was not involved in the September 2022 trial in New Mexico previously reported because of the~~reached a settlement ~~the Company reached~~agreement with the New Mexico Attorney General to resolve ~~the New Mexico Attorney General’s~~its claims against the Company, which was finalized on April 24, 2023. ~~The Company anticipates entry of a~~A Consent Judgment dismissing the ~~New Mexico Attorney General’s lawsuit in~~case was entered on May 15, 2023.

~~On August 3, 2022, the~~

The Company ~~and certain of its affiliates were named as defendants in~~reached a Complaint filed in Tennessee state court, along with numerous other manufacturers, distributors, retailers, and healthcare providers, in which it is alleged the defendants are liable in civil damages to six minors who allegedly were born with neonatal abstinence syndrome (“NAS”) allegedly as a result of their biological mothers’ alleged use of diverted prescription opioid medications. The plaintiffs’ claim against each defendant in that case requires plaintiffs to prove by clear and convincing evidence that the defendant intentionally participated in Tennessee in that state’s illegal drug market as defined in the Tennessee Drug Dealer Liability Act. The case is currently stayed, but the Company intends to file a motion to dismiss the complaint when the case resumes. On November 1, 2022, the Company entered into a preliminary settlement agreement to resolve all pending litigation brought by West Virginia political ~~subdivisions.~~subdivisions, which was signed on May 25, 2023. The ~~Company also was named in~~ two ~~NAS~~neonatal abstinence syndrome cases in West Virginia state court ~~which have been consolidated with other West Virginia state court NAS cases before the West Virginia Mass Litigation Panel.~~ were dismissed on May 31, 2023.

The Company ~~filed~~reached a ~~motion~~preliminary settlement with a group of private hospitals in Alabama (the “Alabama Hospitals”) in June 2023 to ~~dismiss~~resolve the ~~complaints on February 3, 2023, which~~hospitals’ claims against the ~~court granted on April 17, 2023.~~Company. The Company anticipates ~~entry~~a final determination approving the settlement in 2023.

On January 13, 2023, Amneal Pharmaceuticals, Inc., Amneal, and Amneal Pharmaceuticals of ~~an order dismissing~~New York, LLC (“Amneal New York”), received a subpoena from the ~~NAS cases in May 2023.~~New York Attorney General, seeking information regarding its business concerning opioid-containing products. The Company is cooperating with the request and providing responsive information.

Based on the ~~preliminary~~ settlement ~~agreement and preliminary settlement agreement~~agreements with the states of New Mexico and West Virginia ~~respectively,~~ and an assessment of the information available, the Company recorded an $18.0 million charge for the year ended December 31, 2022, related to the majority of the MDL and state court cases. Based on an increase in the number of political subdivision cases and the preliminary settlement with the Alabama Hospitals, the Company recorded ~~a $2.1~~charges of $2.0 million ~~charge~~and $4.0 million for the three and six months ended ~~March 31, 2023.~~June 30, 2023, respectively. For the remaining cases, primarily brought by other hospitals, pension funds, third-party payors and individuals, the Company has not recorded a liability as of ~~March 31,~~June 30, 2023 and December 31, 2022, because it concluded that a loss was not probable and estimable.

~~Securities Class Action~~

On December 18, 2019, Cambridge Retirement System filed a putative class action complaint in the Superior Court of New Jersey, Somerset County against the Company and certain current or former officers alleging violations of Sections 11, 12(a)(2) and 15 of the Securities Act of 1933 (Cambridge Retirement System v. Amneal Pharmaceuticals, Inc., et al., No. SOM-L-1701-19). Plaintiffs alleged that the May 7, 2018, amended registration statement and prospectus issued in connection with the Amneal/Impax business combination was materially false and/or misleading because it failed to disclose that Amneal allegedly engaged in anticompetitive conduct to fix generic drug prices. On March 28, 2022, the parties executed a settlement agreement for $25.0 million. On April 29, 2022, the court preliminarily approved the settlement. On August 16, 2022, the court gave final approval to the settlement. For the year ended December 31, 2021, the Company recorded a $25.0 million charge associated with this case. For the three months ended March 31, 2022, the Company recorded an insurance recovery of $4.0 million.

United States Department of Justice / Drug Enforcement Administration Subpoenas ~~/ New York Subpoenas~~

On July 7, 2017, Amneal ~~Pharmaceuticals of~~ New York ~~LLC~~ received an administrative subpoena issued by the Long Island, NY District Office of the Drug Enforcement Administration (the “DEA”) requesting information related to compliance with certain recordkeeping and reporting requirements. On or about April 12, 2019 and May 28, 2019, the Company received grand jury subpoenas from the U.S. Attorney’s Office for the Eastern District of New York (the “USAO”) relating to similar topics concerning the Company’s suspicious order monitoring program and its compliance with the Controlled Substances Act. The Company is cooperating with the USAO in responding to the subpoenas and has entered civil and criminal tolling agreements

with the USAO through approximately November 15, 2023. It is not possible to determine the exact outcome of these investigations.

On March 14, 2019, Amneal received a subpoena from an Assistant U.S. Attorney (“AUSA”) for the Southern District of Florida. The subpoena requested information and documents generally related to the marketing, sale, and distribution of oxymorphone. The Company intends to cooperate with the AUSA regarding the subpoena. However, no assurance can be given as to the timing or outcome of its underlying investigation.

On October 7, 2019, Amneal received a subpoena from the New York State Department of Financial Services seeking documents and information related to sales of opioid products in the state of New York. The Company is cooperating with the request and providing responsive information. It is not possible to determine the exact outcome of this investigation.

On January 13, 2023, Amneal Pharmaceuticals, Inc., Amneal, and Amneal Pharmaceuticals of New York, LLC, received a subpoena from the New York Attorney General, seeking information regarding its business concerning opioid-containing products. The Company is cooperating with the request and providing responsive information. It is not possible to determine the exact timing or outcome of the investigation.

Ranitidine Litigation

The Company and its affiliates have been named as defendants, along with numerous other brand and generic pharmaceutical manufacturers, wholesale distributors, retail pharmacy chains, and repackagers of ranitidine-containing products, in In re Zantac/Ranitidine NDMA Litigation (MDL No. 2924), pending in the Southern District of Florida. Plaintiffs allege that defendants failed to disclose and/or concealed the alleged inherent presence of N-Nitrosodimethylamine (or “NDMA”) in brand-name Zantac® or generic ranitidine and the alleged associated risk of cancer. Consolidated groups of (a) personal injury plaintiffs, (b) economic loss/medical monitoring class action plaintiffs, and (c) third-party payor plaintiffs have each filed master complaints. The Company or its affiliates have been named in these three master complaints and approximately 313 personal injury short form complaints. On July 8, 2021, the MDL court dismissed all claims by all plaintiffs against the generic drug manufacturers, including the Company and its affiliates, without leave to file further amended complaints. Plaintiffs ~~have~~ appealed the MDL court’s ~~dismissal~~dismissals to the 11th Circuit Court of ~~Appeals, which has consolidated~~Appeals. On November 7, 2022, the ~~appeals~~11th Circuit affirmed the MDL court’s dismissal of ~~the personal injury cases.~~cases brought by third-party payors. The 11th Circuit ~~Court of Appeals~~ has not established a briefing schedule yet in the ~~appeals.~~appeals of the other cases.

On June 18, 2020, Amneal was named in a lawsuit filed in New Mexico brought by the New Mexico Attorney General alleging claims of public nuisance, negligence, and violations of consumer protection laws against various brand and generic manufacturers and store-brand distributors of Zantac®/Ranitidine. Plaintiff seeks unspecified compensatory and punitive damages, as well as abatement, medical monitoring, restitution, and injunctive relief. The Company ~~filed a motion to dismiss based on lack of personal jurisdiction on January 26, 2022, that remains pending.~~

~~On October 1, 2021, Amneal~~ and Amneal Pharmaceuticals of New York, LLC were named as defendants in two Pennsylvania state court complaints, along with twenty-five other defendants, including brand-name manufacturers, generic manufacturers, and one Pennsylvania-based pharmacy. The complaint track cases are coordinated in the Philadelphia County Court of Common Pleas with other Pennsylvania ranitidine cases in which the Company is not a party under what is known as a Mass Tort Program (MTP). Companyits affiliates have been named in three additional cases filed on September 27, 2022, each of which is part of the MTP. Company affiliates were named in two additional cases filed on December 31, 2022, which were removed to federal court on January 4, 2023.

In a lawsuit filed on February 8, 2022 by Gary Ross in Illinois state court, Amneal and Amneal Pharmaceuticals of New York, LLC were named as defendants, along with twenty other defendants, including brand-name manufacturers, generic manufacturers, and retailers in which plaintiff claimed personal injury from use of ranitidine. The generic drug manufacturers filed a motion to dismiss on March 28, 2022, which remains pending. On March 1, 2022, plaintiff Barbara Martin filed a lawsuit in Illinois state court naming Amneal, Amneal Pharmaceuticals of New York, LLC, and Amneal Pharmaceuticals, Inc., along with seven other defendants, including brand-name manufacturers, generic manufacturers, and retailers. Plaintiff has attempted to serve only Amneal Pharmaceuticals of New York, LLC. The Company filed a motion to dismiss on May 6, 2022. In addition, the Company and/or its affiliates, as well as multiple other defendants including other generic drug manufacturers, havealso been named as defendants in ~~six multi-plaintiff cases filed in three different Illinois counties~~various state lawsuits in which plaintiffs allege injuries in the form of various cancers from the use of ranitidine. The cases have been consolidated in a statewide consolidated proceeding in Cook County, Illinois. At the appropriate time, the Company ~~intends~~has already filed motions to dismiss or plans to file motions to ~~dismiss.~~

The Company and/or its affiliates, as well as multiple other defendants including other generic drug manufacturers, have been named in 94 single-plaintiff cases filed in California since August 2022, in which plaintiffs allege injuriesdismiss in the ~~form~~future. Three of ~~various~~

~~cancers from the use of ranitidine. The~~those cases ~~were transferred to Judicial Council Coordination Proceedings~~brought by individuals and pending in ~~Alameda~~Cook County, ~~California. At~~Illinois have trial dates: Gross (June 5, 2024), Snider (October 23, 2024), and Tucker (January 16, 2025). Another case in New Mexico has a September 15, 2025, trial date. There are no trial dates in any of the ~~appropriate time, the Company intends to file motions to dismiss.~~

On September 26, 2022, Amneal Pharmaceuticals of New York, LLC was named as one of multiple defendants in a single-plaintiff case filed in Suffolk County, New York, alleging injuries in the form of bladder cancer from the use of ranitidine. At the appropriate time, the Company intends to file a motion to dismiss.other cases.

Metformin Litigation

Amneal and AvKARE, Inc. were named as defendants, along with numerous other manufacturers, retail pharmacies, and wholesalers, in several putative class action lawsuits pending in the United States District Court for the District of New Jersey

(“D.N.J.”), consolidated as In Re Metformin Marketing and Sales Practices Litigation (No. 2:20-cv-02324-MCA-MAH). The lawsuits ~~all~~either 1) allege ~~that defendants made and sold to putative class members generic metformin products that were “adulterated” or “contaminated” with NDMA.~~

~~On July 6, 2020, a consolidated~~ economic loss ~~complaint filed on behalf of consumers and third-party payors who purchased or paid or made reimbursements for metformin alleges that plaintiffs suffered economic losses~~ in connection with their ~~purchases~~purchase or reimbursements due to the ~~purported contamination. On January 31, 2023, the Court granted in part and denied in part Defendants’ third motion to dismiss. As part~~alleged contamination of its ruling, the Court granted AvKare’s motion to dismiss for lack of standing. On March 16, 2023, Amneal Pharmaceuticals, Inc. and Amneal filed separate answers to Plaintiffs’ consolidated economic loss complaint.

~~Additionally, the consolidated matters include two~~generic metformin products with NDMA or 2) are seeking medical monitoring ~~class action complaints filed in October 2020, on behalf of consumers who consumed allegedly contaminated metformin, alleging~~or evaluation due to alleged “cellular damage, genetic harm, and/or are at an increased risk of developing cancer” ~~and seek medical monitoring, including evaluation and treatment. Amneal Pharmaceuticals, Inc. and AvKare~~from consuming allegedly contaminated metformin. The parties are ~~named as defendants~~currently engaged in one action, and Amneal Pharmaceuticals, Inc. and a retail pharmacy are named as defendants in the other action. Amneal Pharmaceuticals, Inc.’s and AvKare’s time to answer, move or otherwise respond to the Complaints is stayed until after plaintiffs file an amended or consolidated complaint in each action.

discovery.

On February 2, 2023, the Court ordered discovery to proceed, and further written fact discovery has now commenced. On March 24, 2023, the parties filed a joint submission setting forth the parties’ positions related to a discovery scheduling order proposal, which remains pending.

On March 29, 2021, a plaintiff filed a complaint in the United States District Court for the Middle District of Alabama asserting claims against manufacturers of Valsartan, Losartan, and Metformin based on the alleged presence of nitrosamines in those products. The only allegations against the Company concern Metformin (Davis v. Camber Pharmaceuticals, Inc., et al., C.A. No. 2:21-00254 (M.D. Ala.) (the “Davis Action”)). On May 5, 2021, the United States Judicial Panel on Multidistrict Litigation (the “JPML”) transferred the Davis Action into the In re: Valsartan, Losartan, and Irbesartan Products Liability Litigation multi-district litigation for pretrial proceedings.

Xyrem® (Sodium Oxybate) Antitrust Litigation

Amneal has been named as a defendant, along with Jazz Pharmaceuticals, Inc. (“Jazz”) and numerous other manufacturers of generic versions of Jazz’s Xyrem® (sodium oxybate), in several ~~putative~~ class action lawsuits filed in the United States District Court for the Northern District of California and the United States District Court for the Southern District of New York, alleging that the generic manufacturers entered into anticompetitive agreements with Jazz in connection with the settlement of patent litigation related to Xyrem®. ~~Plaintiffs seek unspecified monetary damages and penalties as well as equitable relief, including disgorgement and restitution. On December 16, 2020, the JPML transferred the~~The actions tohave been consolidated in the United States District Court for the Northern District of California for ~~consolidated~~ pretrial proceedings (In re Xyrem (Sodium Oxybate) Antitrust Litigation, No. 5:20-md-02966-LHK (N.D. Cal.)). ~~Plaintiffs filed a consolidated amended class complaint in March 2021, which Defendants moved to dismiss.~~

On August 13, 2021, the District Court granted in part and denied in part Defendants’ motion, dismissing the federal damages claims and a number of state-law claims, while permitting the remaining claims to proceed. On January 9, 2023, Amneal reached a settlement in principle with the ~~putative~~ class plaintiffs and executed a settlement agreement on February 28, 2023. The remaining opt-out plaintiffs in the federal case are United Healthcare Services, Inc., Humana Inc., Molina Healthcare Inc., and Health Care Services Corporation.

~~Discovery closed on January 30, 2023, and briefing related to class certification is scheduled to culminate with a hearing that took place on April 19, 2023.~~

In a separate action in California state court filed by Aetna Inc., another opt-out plaintiff, the court held that it lacks jurisdiction over several defendants, including Amneal, on December 27, 2022, and later issued an order dismissing Amneal without prejudice. On January 27, 2023, Aetna filed an amended complaint identifying several parties, including Amneal, as alleged non-party co-conspirators.

Value Drug Company v. Takeda Pharmaceuticals U.S.A., Inc.

On August 5, 2021, Value Drug Company filed a purported class action lawsuit in the United States District Court for the Eastern District of Pennsylvania against Takeda Pharmaceuticals U.S.A., Inc. (“Takeda”) and numerous other manufacturers of generic versions of Takeda’s Colcrys® (colchicine), including Amneal, alleging that the generic manufacturers conspired with Takeda to restrict output of generic Colcrys® in order to maintain higher prices, in violation of the antitrust laws. The Company, along with the other defendants, moved to dismiss for failure to state a claim, and on December 28, 2021, the Court granted the motion in full, with leave to amend. On January 18, 2022, Plaintiff filed its amended complaint, making substantively the same antitrust allegations, but alleging that the violations were effectuated by either a single overarching conspiracy or a series of bilateral conspiracies. The Company moved to dismiss the amended complaint for failure to state a claim. On March 30, 2022, the Court granted in part and denied in party defendants’ motion, dismissing the newly pled bilateral conspiracy claims but allowing the revised overarching conspiracy claim to proceed against all defendants. On November 23, 2022, the Court denied plaintiff’s motion for class certification without prejudice. Plaintiff filed its renewed motion for class certification on December 22, 2022. Following opposition and reply briefing, the Court held a hearing on the renewed motion for class certification on February 7, 2023. The Court also granted defendants the opportunity to submit a supplemental brief in opposition to the renewed motion for class certification, which was filed on February 14, 2023. Defendants filed two motions for summary judgment on January 13, 2023, one filed by Takeda, and another filed jointly by Amneal, Watson, and Teva. Defendants also filed motions to exclude the opinions of five of plaintiff’s six experts. Plaintiff filed a motion for partial summary judgment on January 13, 2023. Plaintiff did not file any motions to exclude any of defendants’ experts. Briefing on the motions for summary judgment and motions to exclude expert testimony was completed on February 6, 2023. On January 18, 2023, the Court issued an order vacating all trial-related deadlines and requiring Defendants to file a joint notice as to potential revised trial dates within ten days of the Court’s decision on Plaintiff’s renewed motion for class certification. On February 28, 2023, the Court granted in part defendants’ motion to exclude the testimony of Plaintiff’s patent litigation expert. On March 1, 2023, the Court denied plaintiff’s renewed motion for class certification. On March 13, 2023, the Court denied the remainder of defendants’ motions to exclude plaintiff’s experts. On March 14, 2023, the Court entered a scheduling order setting out discrete schedules depending on whether additional plaintiffs seek to join plaintiff’s complaint. On April 10, 2023, plaintiff filed a motion for leave to amend its complaint to add 18 former absent class members as plaintiffs, which the Court subsequently granted. Plaintiffs’ second amended complaint did not add any new legal theories or allegations. On April 14, 2023, the Court entered a scheduling order requiring the new plaintiffs to provide discovery on their claims by May 1, 2023, and setting a 22-day jury trial to begin on September 5, 2023.

~~Galeas v. Amneal Pharmaceuticals, Inc.~~

On July 27, 2021, Cesy Galeas filed a purported class action lawsuit in the U.S. District Court for the Eastern District of New York against Amneal Pharmaceuticals, Inc., alleging that the payment schedule for certain workers violated New York Labor Law. Specifically, the purported class, which presently consists of one named plaintiff contends that the Company paid the employees all owed wages, but did so bi-weekly, instead of weekly. In March 2022, the parties reached an agreement to settle the claims for $1.2 million, subject to, among other things, court approval of the contemplated settlement agreement. The parties dismissed the federal litigation and re-filed the litigation in New York Supreme Court, Nassau County, for purposes of settlement approval, and filed a motion to approve the settlement agreement on July 13, 2022 and the Court granted the same on September 28, 2022. A third-party administrator completed administering the notification process for class members with instructions on how to submit claims. The Court held a fairness hearing on February 28, 2023, during which no potential claimants raised objections. The Court approved the settlement on March 1, 2023. The third party administrator will distribute the settlement funds in accordance with the agreement. The Company recorded a $1.2 million charge associated with this matter during the year ended December 31, 2022.

Russell Thiele, et al. v. Kashiv Biosciences, LLC, et.al.

On March 22, 2022, two purported Amneal Pharmaceuticals, Inc. stockholders filed a stockholder derivative lawsuit in the Court of Chancery of the State of Delaware against Kashiv and certain members of the Company’s Board of Directors. The Company is named as a nominal defendant. For additional details of the claim, refer to Note 21. Commitments and Contingencies of our 2022 Annual Report on Form 10-K. On May 2, 2023, the parties entered into a final settlement agreement that, if approved by the court, would fully resolve this matter. Pursuant to the settlement, the Company has agreed to amend the January 11, 2021 Membership Interest Purchase Agreement with Kashiv to reduce certain royalties on future sales payable by Kashiv, adopt certain governance changes, and pay to plaintiffs’ counsel a court-ordered ~~attorneys~~attorneys’ fees and expense award in an amount ~~not to exceed $2~~of $1.9 million. The ~~parties have submitted the proposed settlement to the~~ Court of Chancery ~~and requested that~~approved the ~~Court of Chancery schedule a hearing to review the fairness of the proposed settlement.~~ final settlement agreement on July 27, 2023.

Indian Tax Authority Matters

Amneal Pharmaceuticals Pvt. Ltd. (“Amneal Pvt.”), RAKS Pharmaceuticals Pvt. Ltd., and Puniska Healthcare Pvt. Ltd. (“Puniska”), which are subsidiaries of the Company, are currently involved in litigations with Indian tax authorities concerning Central Excise Tax, Service Tax, Goods & Services Tax, and Value Added Tax for various periods of time between 2014 and 2017. These subsidiaries have contested certain of these assessments, which are at various stages of the administrative process. The Company strongly believes its Indian subsidiaries have meritorious defenses in the matter.

20. Stockholders’ Equity and Redeemable Non-Controlling Interests

On May 9, 2023, the stockholders of the Company approved an amendment and restatement of the Amneal Pharmaceuticals, Inc. 2018 Incentive Award Plan (the “Stock Plan”), which authorizes an additional 20 million shares of class A common stock available for issuance under the Stock Plan, resulting in a total shares reserved under the Stock Plan of 57 million shares, and extends the term of the Stock Plan until May 9, 2033.

Non-Controlling Interests

The Company consolidates the financial statements of Amneal and its subsidiaries and records non-controlling interests for the portion of Amneal’s economic interests that is not held by the Company. Non-controlling interests are adjusted for capital transactions that impact the non-publicly held economic interests in Amneal.

Under the terms of Amneal’s limited liability company agreement, as amended, Amneal is obligated to make tax distributions to its members. During the three and six months ended ~~March 31,~~June 30, 2023, the Company recorded net tax distributions of $21.20 million and $48.01 million, respectively, as a reduction of non-controlling interests. During the three and six months ended June 30, 2022, the Company recorded net tax distributions of ~~$26.81~~$2.89 million and ~~$4.44~~$7.33 million, respectively, as a reduction of non-controlling ~~interests, respectively.~~interests.

The Company acquired a 98% interest in KSP on April 2, 2021. The sellers of KSP, a related party, hold the remaining interests. The Company attributes 2% of the net income or loss of KSP to the non-controlling interests.

Redeemable Non-Controlling Interests

The Company acquired a 65.1% controlling interest in both AvKARE Inc., a Tennessee corporation, now a limited liability company (“AvKARE, LLC”), and Dixon-Shane, LLC d/b/a R&S Northeast LLC, a Kentucky limited liability company (“R&S”), in 2020. The sellers of AvKARE, LLC and R&S hold the remaining 34.9% interest (“Rondo Class B Units”) in the holding company that directly owns the acquired companies (“Rondo”). Beginning on January 1, 2026, the holders of the Rondo Class B Units have the right (“Put Right”) to require the Company to acquire the Rondo Class B Units for a purchase price that is based on a multiple of Rondo’s earnings before income taxes, depreciation, and amortization (EBITDA) if certain financial targets and other conditions are met. Additionally, beginning on January 31, 2020, the Company has the right to acquire the Rondo Class B Units based on the same value and conditions as the Put Right. The Rondo Class B Units are also redeemable by the holders upon a change in control. ~~Since~~Because the redemption of the Rondo Class B Units is outside of the Company’s control, the units have been presented outside of stockholders’ equity as redeemable non-controlling interests.

The Company attributes 34.9% of the net income or loss associated with Rondo to redeemable non-controlling interests. The Company will also accrete the redeemable non-controlling interests to redemption value upon an event that makes redemption probable. For the three and six months ended ~~March 31,~~June 30, 2023, the Company recorded tax distributions of $2.87 million and $5.83 million as a reduction of redeemable non-controlling interests, respectively. For the three and six months ended June 30, 2022, the Company recorded tax distributions of ~~$2.96~~$0.58 million and ~~$2.01~~$2.59 million as a reduction of redeemable non-controlling interests, respectively.

Redeemable Non-Controlling Interests - Puniska ~~Healthcare Pvt. Ltd.~~

The Company acquired 74% of the equity interests in Puniska~~Healthcare Pvt. Ltd. (“Puniska”)~~ on November 2, 2021. Amneal was required pursuant to the purchase agreement to acquire the remaining 26% of Puniska upon approval of the transaction by the government of India.~~Since~~ Because approval of the government of India was outside of the Company’s control, upon closing of the acquisition of Puniska, the equity interests of Puniska that the Company did not own were presented outside of stockholders’ equity as redeemable non-controlling interests. The Company attributed 26% of the net losses of Puniska to the redeemable non-controlling interests.

Upon approval of the transaction by the government of India in March 2022, the Company paid the $1.7 million redemption value for the remaining 26% of the equity interests of Puniska. For the ~~three~~six months ended ~~March 31,~~June 30, 2022, thethe Company recorded accretion of $0.9 million to increase the redeemable non-controlling interests to redemption value.

3331

Changes in Accumulated Other Comprehensive (Loss) Income by Component (in thousands):


		Foreign currency translation adjustments		Unrealized (loss) gain on cash flow hedge, net of tax		Accumulated other comprehensive (loss) income			Foreign currency translation adjustments		Unrealized (loss) gain on cash flow hedge, net of tax		Accumulated other comprehensive (loss) income
Balance December 31, 2021	Balance December 31, 2021	$	(18,845)	$	(5,982)	$	(24,827)	Balance December 31, 2021	$	(18,845)	$	(5,982)	$	(24,827)
Other comprehensive loss before reclassification	Other comprehensive loss before reclassification	(13,394)		48,270		34,876		Other comprehensive loss before reclassification	(13,394)		48,270		34,876
Reallocation of ownership interests	Reallocation of ownership interests	(143)		33		(110)		Reallocation of ownership interests	(143)		33		(110)
Balance December 31, 2022	Balance December 31, 2022	(32,382)		42,321		9,939		Balance December 31, 2022	(32,382)		42,321		9,939
Other comprehensive loss before reclassification	Other comprehensive loss before reclassification	898		(7,135)		(6,237)		Other comprehensive loss before reclassification	1,029		(2,957)		(1,928)
Reallocation of ownership interests	Reallocation of ownership interests	(195)		257		62		Reallocation of ownership interests	(270)		342		72
Balance March 31, 2023		$	(31,679)	$	35,443	$	3,764
Balance June 30, 2023								Balance June 30, 2023	$	(31,623)	$	39,706	$	8,083

Refer to Note 22. Stockholders’ Equity in the Company’s 2022 Annual Report on Form 10-K for additional information.

21. Related Party Transactions

The Company has various business agreements with certain parties in which there is some common ownership. However, the Company does not directly own or manage any of such related parties. Except as disclosed below, as of and for the three and six months ended ~~March 31,~~June 30, 2023, there were no material changes to our related party agreements or relationships as described in Note 24. Related Party Transactions and Note 22. Stockholders’ Equity in our 2022 Annual Report on Form 10-K.

The following table summarizes the Company’s related party transactions (in thousands):


			Three Months Ended March 31,						Three months ended June 30,				Six months ended June 30,
Related Party and Nature of Transaction	Related Party and Nature of Transaction	Caption in Balance Sheet and Statement of Operations	2023		2022		Related Party and Nature of Transaction	Caption in Balance Sheet and Statement of Operations	2023		2022		2023		2022
Kashiv Biosciences LLC	Kashiv Biosciences LLC						Kashiv Biosciences LLC
Parking space lease	Parking space lease	Research and development	$	17	$	25	Parking space lease	Research and development	$	33	$	25	$	50	$	50
License and commercialization agreement - Filgrastim and Pegfilgrastim - regulatory approval milestone for Filgrastim	License and commercialization agreement - Filgrastim and Pegfilgrastim - regulatory approval milestone for Filgrastim	Selling, general and administrative	—		5,000		License and commercialization agreement - Filgrastim and Pegfilgrastim - regulatory approval milestone for Filgrastim	Selling, general and administrative	—		—		—		5,000
Development and commercialization agreement - Ganirelix Acetate and Cetrorelix Acetate	Development and commercialization agreement - Ganirelix Acetate and Cetrorelix Acetate	Research and development	50		17		Development and commercialization agreement - Ganirelix Acetate and Cetrorelix Acetate	Research and development	—		1,706		50		1,723
License and commercialization agreement - Filgrastim and Pegfilgrastim - regulatory approval milestone for Pegfilgrastim							License and commercialization agreement - Filgrastim and Pegfilgrastim - regulatory approval milestone for Pegfilgrastim	Intangible asset	—		15,000		—		15,000
Development and commercialization agreement - Filgrastim and Pegfilgrastim - Royalty expense (Releuko)	Development and commercialization agreement - Filgrastim and Pegfilgrastim - Royalty expense (Releuko)	Cost of goods sold	144		—		Development and commercialization agreement - Filgrastim and Pegfilgrastim - Royalty expense (Releuko)	Cost of goods sold	—		—		144		—
Storage agreement	Storage agreement	Research and development	(48)		—		Storage agreement	Research and development	(34)		—		(82)		—
Inventory purchases under development and commercialization agreement - Filgrastim and Pegfilgrastim (Releuko)							Inventory purchases under development and commercialization agreement - Filgrastim and Pegfilgrastim (Releuko)	Inventory and cost of goods sold	499		—		499		—
Total	Total		$	163	$	5,042	Total		$	498	$	16,731	$	661	$	21,773

Other Related Parties	Other Related Parties						Other Related Parties
Kanan, LLC - operating lease	Kanan, LLC - operating lease	Inventory and cost of goods sold	$	566	$	526	Kanan, LLC - operating lease	Inventory and cost of goods sold	$	592	$	526	$	1,158	$	1,052
Sutaria Family Realty, LLC - operating lease	Sutaria Family Realty, LLC - operating lease	Inventory and cost of goods sold	$	305	$	296	Sutaria Family Realty, LLC - operating lease	Inventory and cost of goods sold	$	314	$	305	$	619	$	601
PharmaSophia, LLC - research and development services income	PharmaSophia, LLC - research and development services income	Research and development	$	—	$	(15)	PharmaSophia, LLC - research and development services income	Research and development	$	—	$	(15)	$	—	$	(30)
Apace KY, LLC d/b/a Apace Packaging LLC - packaging agreement	Apace KY, LLC d/b/a Apace Packaging LLC - packaging agreement	Inventory and cost of goods sold	$	1,836	$	458	Apace KY, LLC d/b/a Apace Packaging LLC - packaging agreement	Inventory and cost of goods sold	$	3,731	$	964	$	5,567	$	1,422
Tracy Properties LLC - operating lease	Tracy Properties LLC - operating lease	Selling, general and administrative	$	169	$	135	Tracy Properties LLC - operating lease	Selling, general and administrative	$	94	$	136	$	263	$	271
AzaTech Pharma LLC - supply agreement	AzaTech Pharma LLC - supply agreement	Inventory and cost of goods sold	$	575	$	1,221	AzaTech Pharma LLC - supply agreement	Inventory and cost of goods sold	$	1,969	$	1,431	$	2,544	$	2,652
AvPROP, LLC - operating lease	AvPROP, LLC - operating lease	Selling, general and administrative	$	47	$	40	AvPROP, LLC - operating lease	Selling, general and administrative	$	43	$	50	$	90	$	90
Avtar Investments, LLC - consulting services	Avtar Investments, LLC - consulting services	Research and development	$	188	$	84	Avtar Investments, LLC - consulting services	Research and development	$	9	$	85	$	197	$	169
TPG Operations, LLC - consulting services	TPG Operations, LLC - consulting services	Selling, general and administrative	$	—	$	19	TPG Operations, LLC - consulting services	Selling, general and administrative	$	—	$	—	$	—	$	19
Alkermes	Alkermes	Inventory and cost of goods sold	$	2	$	—	Alkermes	Inventory and cost of goods sold	$	88	$	77	$	90	$	107
R&S Solutions - logistics services	R&S Solutions - logistics services	Selling, general and administrative	$	20	$	—	R&S Solutions - logistics services	Selling, general and administrative	$	20	$	20	$	40	$	39
Members - tax receivable agreement (TRA liability)	Members - tax receivable agreement (TRA liability)	Other expense	$	826	$	—	Members - tax receivable agreement (TRA liability)	Other expense	$	405	$	—	$	1,231	$	—

3433

The following table summarizes the amounts due to or from the Company for related party transactions (in thousands):


		March 31, 2023		December 31, 2022			June 30, 2023		December 31, 2022
Sellers of AvKARE LLC and R&S - state tax indemnification	Sellers of AvKARE LLC and R&S - state tax indemnification	$	—	$	486	Sellers of AvKARE LLC and R&S - state tax indemnification	$	—	$	486
Kashiv - various agreements	Kashiv - various agreements	28		12		Kashiv - various agreements	28		12
Asana BioSciences, LLC	Asana BioSciences, LLC	2		2		Asana BioSciences, LLC	2		2
Apace KY, LLC d/b/a Apace Packaging LLC - packaging agreement						Apace KY, LLC d/b/a Apace Packaging LLC - packaging agreement	119		—
Related party receivables - short term	Related party receivables - short term	$	30	$	500	Related party receivables - short term	$	149	$	500

Kashiv - various agreements	Kashiv - various agreements	$	75	$	110	Kashiv - various agreements	$	100	$	110
Apace Packaging, LLC - packaging agreement	Apace Packaging, LLC - packaging agreement	1,061		756		Apace Packaging, LLC - packaging agreement	1,070		756
AzaTech Pharma LLC - supply agreement	AzaTech Pharma LLC - supply agreement	855		863		AzaTech Pharma LLC - supply agreement	1,113		863
Avtar Investments LLC - consulting services	Avtar Investments LLC - consulting services	85		72		Avtar Investments LLC - consulting services	89		72
Sellers of AvKARE LLC and R&S - accrued interest on Sellers Notes	Sellers of AvKARE LLC and R&S - accrued interest on Sellers Notes	442		442		Sellers of AvKARE LLC and R&S - accrued interest on Sellers Notes	442		442
Members - tax receivable agreement	Members - tax receivable agreement	631		201		Members - tax receivable agreement	631		201
R&S Solutions LLC - logistics services	R&S Solutions LLC - logistics services	13		7		R&S Solutions LLC - logistics services	7		7
Alkermes Plc	Alkermes Plc	—		28		Alkermes Plc	36		28
Kanan LLC - operating lease		41		—
Members - tax distributions	Members - tax distributions	8,767		—		Members - tax distributions	17,655		—
Rondo Class B unit holders - tax distributions		2,780		—
Related party payables - short term	Related party payables - short term	$	14,750	$	2,479	Related party payables - short term	$	21,143	$	2,479

Kashiv - contingent consideration (1)	Kashiv - contingent consideration (1)	$	3,900	$	3,290	Kashiv - contingent consideration (1)	$	860	$	3,290
Sellers of AvKARE LLC and R&S - accrued interest on Sellers Notes	Sellers of AvKARE LLC and R&S - accrued interest on Sellers Notes	6,481		5,929		Sellers of AvKARE LLC and R&S - accrued interest on Sellers Notes	7,034		5,929
Members - tax receivable agreement	Members - tax receivable agreement	826		430		Members - tax receivable agreement	1,229		430
Related party payables - long term	Related party payables - long term	$	11,207	$	9,649	Related party payables - long term	$	9,123	$	9,649

(1) The contingent consideration liability was associated with the acquisition of KSP. Refer to Note 17. Fair Value Measurements for additional information.

TPG is a significant stockholder of the Company. A Managing Director of TPG is an observer of the Company’s Board. TPG Capital BD, LLC (“TPG Capital”) has been providing the Company with advice and assistance with respect to the planned refinancing or replacement of certain indebtedness of the Company and will receive a customary fee, in an amount to be negotiated, contingent on the closing of a transaction. For the three and six months ended ~~March 31,~~June 30, 2023, the Company did not incur any costs related to services provided by TPG Capital.

22. Segment Information

The Company has three reportable segments: Generics, Specialty, and AvKARE.

Generics

The Company’s Generics segment includes a retail and institutional portfolio of approximately 260 product families covering an extensive range of dosage forms and delivery systems, including both immediate and extended release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches and topicals.

Specialty

The Company’s Specialty segment is engaged in the development, promotion, sale and distribution of proprietary branded pharmaceutical products, with a focus on products addressing central nervous system disorders, including Parkinson’s disease, and endocrine disorders.

AvKARE

The Company’s AvKARE segment provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, primarily focused on serving the Department of Defense and the Department of Veterans Affairs.

AvKARE is also a wholesale distributor of bottle and unit dose pharmaceuticals under the registered names of AvKARE and AvPAK, and medical and surgical products. AvKARE is also a packager and wholesale distributor of pharmaceuticals and vitamins to its retail and institutional customers who are located throughout the U.S. focused primarily on offering 340b-qualified entities products to provide consistency in care and pricing.

Chief Operating Decision Makers

The Company’s chief operating decision makers evaluate the financial performance of the Company’s segments based upon segment operating income (loss). Items below operating income (loss) are not reported by segment, ~~since~~because they are excluded from the measure of segment profitability reviewed by the Company’s chief operating decision maker. Additionally, general and administrative expenses, certain selling expenses, certain litigation settlements, and non-operating income and expenses are included in “Corporate and Other.” The Company does not report balance sheet information by segment ~~since~~because it is not reviewed by the Company’s chief operating decision makers.

The tables below present segment information reconciled to total Company financial results, with segment operating income or loss, including gross profit less direct selling expenses, R&D expenses, and other operating expenses to the extent specifically identified by segment (in thousands):


Three Months Ended March 31, 2023		Generics (1)		Specialty		AvKARE (1)		Corporate and Other		Total Company
Three Months Ended June 30, 2023												Three Months Ended June 30, 2023	Generics (1)		Specialty		AvKARE (1)		Corporate and Other		Total Company
Net revenue	Net revenue	$	343,806	$	91,678	$	122,056	$	—	$	557,540	Net revenue	$	373,701	$	96,994	$	128,351	$	—	$	599,046
Cost of goods sold	Cost of goods sold	230,551		43,191		105,612		—		379,354		Cost of goods sold	225,189		46,512		107,324		—		379,025
Gross profit	Gross profit	113,255		48,487		16,444		—		178,186		Gross profit	148,512		50,482		21,027		—		220,021
Selling, general and administrative	Selling, general and administrative	27,600		22,379		12,940		39,177		102,096		Selling, general and administrative	28,040		22,759		14,015		40,756		105,570
Research and development	Research and development	32,359		6,331		—		—		38,690		Research and development	31,108		6,691		—		—		37,799
Intellectual property legal development expenses	Intellectual property legal development expenses	1,624		20		—		—		1,644		Intellectual property legal development expenses	801		19		—		—		820
Restructuring and other charges	Restructuring and other charges	99		—		—		411		510		Restructuring and other charges	—		82		—		—		82
Change in fair value of contingent consideration	Change in fair value of contingent consideration	—		2,457		—		—		2,457		Change in fair value of contingent consideration	—		(6,364)		—		—		(6,364)
(Credit) charges related to legal matters, net		(2,444)		—		—		2,008		(436)
Other operating income		(1,224)		—		—		—		(1,224)
Charges related to legal matters, net												Charges related to legal matters, net	2,017		—		—		—		2,017
Other operating expense												Other operating expense	13		—		—		—		13
Operating income (loss)	Operating income (loss)	$	55,241	$	17,300	$	3,504	$	(41,596)	$	34,449	Operating income (loss)	$	86,533	$	27,295	$	7,012	$	(40,756)	$	80,084


Three Months Ended March 31, 2022		Generics (1)		Specialty		AvKARE (1)		Corporate and Other		Total Company
Six Months Ended June 30, 2023												Six Months Ended June 30, 2023	Generics (1)		Specialty		AvKARE (1)		Corporate and Other		Total Company
Net revenue	Net revenue	$	317,747	$	85,086	$	94,800	$	—	$	497,633	Net revenue	$	717,507	$	188,672	$	250,407	$	—	$	1,156,586
Cost of goods sold	Cost of goods sold	199,030		43,853		80,179		—		323,062		Cost of goods sold	455,740		89,703		212,936		—		758,379
Gross profit	Gross profit	118,717		41,233		14,621		—		174,571		Gross profit	261,767		98,969		37,471		—		398,207
Selling, general and administrative	Selling, general and administrative	27,593		24,400		13,410		33,262		98,665		Selling, general and administrative	55,640		45,138		26,955		79,933		207,666
Research and development	Research and development	43,221		9,577		—		—		52,798		Research and development	63,467		13,022		—		—		76,489
Intellectual property legal development expenses (credit)		772		(8)		—		—		764
Acquisition, transaction-related and integration expenses		—		—		—		434		434
Intellectual property legal development expenses												Intellectual property legal development expenses	2,425		39		—		—		2,464
Restructuring and other charges	Restructuring and other charges	206		—		—		525		731		Restructuring and other charges	99		82		—		411		592
Change in fair value of contingent consideration	Change in fair value of contingent consideration	—		200		—		—		200		Change in fair value of contingent consideration	—		(3,907)		—		—		(3,907)
Charges (credit) related to legal matters, net		1,674		—		—		(4,000)		(2,326)
(Credit) charges related to legal matters, net												(Credit) charges related to legal matters, net	(427)		—		—		2,008		1,581
Other operating income												Other operating income	(1,211)		—		—		—		(1,211)
Operating income (loss)	Operating income (loss)	$	45,251	$	7,064	$	1,211	$	(30,221)	$	23,305	Operating income (loss)	$	141,774	$	44,595	$	10,516	$	(82,352)	$	114,533


Three Months Ended June 30, 2022	Generics (1)		Specialty		AvKARE (1)		Corporate and Other		Total Company
Net revenue	$	364,895	$	97,001	$	97,459	$	—	$	559,355
Cost of goods sold	228,535		42,791		87,510		—		358,836
Gross profit	136,360		54,210		9,949		—		200,519
Selling, general and administrative	26,558		23,171		12,735		36,342		98,806
Research and development	44,174		6,574		—		—		50,748
Intellectual property legal development expenses	778		43		—		—		821
Acquisition, transaction-related and integration expenses	8		32		—		201		241
Change in fair value of contingent consideration	—		(270)		—		—		(270)
Insurance recoveries for property losses and associated expenses	(1,911)		—		—		—		(1,911)
Charges related to legal matters, net	483		—		—		251,394		251,877
Other operating income	(1,175)		—		—		—		(1,175)
Operating income (loss)	$	67,445	$	24,660	$	(2,786)	$	(287,937)	$	(198,618)


Six Months Ended June 30, 2022	Generics (1)		Specialty		AvKARE (1)		Corporate and Other		Total Company
Net revenue	$	682,642	$	182,087	$	192,259	$	—	$	1,056,988
Cost of goods sold	427,565		86,644		167,689		—		681,898
Gross profit	255,077		95,443		24,570		—		375,090
Selling, general and administrative	54,151		47,571		26,145		69,604		197,471
Research and development	87,395		16,151		—		—		103,546
Intellectual property legal development expenses	1,550		35		—		—		1,585
Acquisition, transaction-related and integration expenses	8		32		—		635		675
Restructuring and other charges	206		—		—		525		731
Change in fair value of contingent consideration	—		(70)		—		—		(70)
Insurance recoveries for property losses and associated expenses	(1,911)		—		—		—		(1,911)
Charges related to legal matters, net	2,157		—		—		247,394		249,551
Other operating income	(1,175)		—		—		—		(1,175)
Operating income (loss)	$	112,696	$	31,724	$	(1,575)	$	(318,158)	$	(175,313)

(1)Operating results for the sale of Amneal products by AvKARE are included in Generics.

23. Insurance Recoveries for Property Losses and Associated Expenses

On September 1, 2021, Tropical Storm Ida brought extreme rainfall and flash flooding to New Jersey that caused damage to two of the Company’s facilities. Operations at these facilities were closed for the majority of September 2021 in order to assess the damage, make repairs and restore operations.

The Company concluded that all inventory on-hand at the time of the flooding was damaged and unsellable and that a majority of the equipment was damaged beyond repair. In addition, the Company incurred significant costs to repair both facilities. The Company has insurance policies for property damage, inventory losses and business interruption. Insurance recoveries are recorded in the periods when it is probable they will be realized. During each of the three and six months ended June 30, 2022, insurance recoveries of $1.9 million associated with property damage and inventory losses were received and recorded in insurance recoveries for property losses and associated expenses.

24. Subsequent Events

During July 2023, the Company repaid $30.0 million of borrowings on the New Revolving Credit Facility from cash on hand and borrowed an additional $10.0 million under the Rondo Revolving Credit Facility for working capital purposes.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Amneal Pharmaceuticals, Inc. (the “Company”, “we,” “us,” or “our”) is a global pharmaceutical company that develops, manufactures, markets, and distributes a diverse portfolio of essential medicines, including complex generics and specialty branded pharmaceuticals. We operate principally in the United States (the “U.S.”), India, and Ireland, and sell to wholesalers, distributors, hospitals, chain pharmacies and individual pharmacies, either directly or indirectly. We are a holding company, whose principal assets are common units (“Amneal Common Units”) of Amneal Pharmaceuticals, LLC (“Amneal”).

The Company held ~~50.2%~~50.3% of Amneal Common Units and the group, together with their affiliates and certain assignees, who owned Amneal when it was a private company, held the remaining ~~49.8%~~49.7% as of ~~March 31,~~June 30, 2023. The Company is Amneal’s sole managing member, having the sole voting power to make all of Amneal’s business decisions and control its management. Therefore, the Company consolidates the financial statements of Amneal and its subsidiaries. The Company records non-controlling interests for the portion of Amneal’s economic interests that it does not hold.

The following discussion and analysis contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including those set forth under Item 1A. Risk Factors in our 2022 Annual Report on Form 10-K and under the heading Cautionary Note Regarding Forward-Looking Statements included elsewhere in this Quarterly Report on Form 10-Q.

The following discussion and analysis for the three and six months ended ~~March 31,~~June 30, 2023 should also be read in conjunction with the consolidated financial statements and related notes thereto included elsewhere in this Quarterly Report on Form 10-Q and with our audited consolidated financial statements for the year ended December 31, 2022 included in our 2022 Annual Report on Form 10-K.

Overview

We have three reportable segments: Generics, Specialty, and AvKARE.

Generics

Our Generics segment includes approximately 260 product families covering an extensive range of dosage forms and delivery systems, including both immediate and extended release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, ophthalmics, films, transdermal patches and topicals. We focus on developing products with substantial barriers-to-entry resulting from complex drug formulations or manufacturing, or legal or regulatory challenges. Generic products, particularly in the U.S., generally contribute most significantly to revenues and gross margins at the time of their launch, and even more so in periods of market exclusivity, or in periods of limited generic competition. As such, the timing of new product introductions can have a significant impact on the Company’s financial results. The entrance into the market of additional competition generally has a negative impact on the volume and/or pricing of the affected products. Additionally, pricing is determined by market place dynamics and is often affected by factors outside of the Company’s control.

Specialty

Our Specialty segment is engaged in the development, promotion, sale and distribution of proprietary branded pharmaceutical products, with a focus on products addressing CNS disorders, including Parkinson’s disease, and endocrine disorders. Our portfolio of products includes Rytary®, an extended release oral capsule formulation of carbidopa-levodopa for the treatment of Parkinson’s disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication. In addition to Rytary®, our promoted Specialty portfolio also includes Unithroid® (levothyroxine sodium), for the treatment of hypothyroidism, which is sold under a license and distribution agreement with Jerome Stevens Pharmaceuticals, Inc., and Lyvispah® (baclofen), a unique dissolvable granule formulation used to treat muscle stiffness, spasms and pain from multiple sclerosis.

Our Specialty products are marketed through skilled specialty sales and marketing teams, who call on neurologists, movement disorder specialists, endocrinologists and primary care physicians in key markets throughout the U.S. Our Specialty segment also has a number of product candidates that are in varying stages of development.

For Specialty products, the majority of the product’s commercial value is usually realized during the period in which the product has market exclusivity. In the U.S., when market exclusivity expires and generic versions of a product are approved and marketed, there can often be very substantial and rapid declines in the branded product’s sales.

On June 30, 2023, we received a complete response letter (“CRL”) from the Food and Drug Administration regarding our new drug application for IPX203 for the treatment of Parkinson’s disease. Refer to Note 12. Goodwill and Other Intangible Assets for further information on the CRL and our interim goodwill and in-process research and development intangible asset impairment tests. Refer to the information under the heading “If we are unable to successfully develop or commercialize new products, our operating results will suffer.” in the Operational and Competitive Risks section of Item 1A. Risk Factors in our 2022 Annual Report on Form 10-K for additional information associated with the risk related to FDA approval of IPX203.

AvKARE

Our AvKARE segment provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies. AvKARE is a re-packager of bottle and unit dose pharmaceuticals under the registered names of AvKARE and AvPAK, which service the Department of Defense and Department of Veteran Affairs as well as institutional customers. AvKARE is also a wholesale distributor of pharmaceuticals, over the counter products and medical supplies to institutional customers which are located throughout the U.S. focused primarily on offering 340b-qualified entities products to provide consistency in care and pricing.

The Pharmaceutical Industry

The pharmaceutical industry is highly competitive and highly regulated. As a result, we face a number of industry-specific factors and challenges, which can significantly impact our results. For a more detailed explanation of our business and its risks, refer to our 2022 Annual Report on Form 10-K, as supplemented by Part II, Item 1A “Risk Factors” of our subsequent Quarterly Reports on Form 10-Q.

Inflation

While it is difficult to accurately measure the impact of inflation, we estimate our business will experience an increase in costs due to inflation of approximately ~~$15.0~~$20.0 million for the year ending December 31, 2023, excluding the impact of rising interest rates. However, rising inflationary pressures due to higher input costs, including higher material, transportation, labor and other costs, could exceed our expectations, which would further adversely impact our operating results in future periods.

Uncertainties in Financial Markets

In March 2023, certain U.S. and international government banking regulators took steps to intervene in the operations of certain financial institutions due to liquidity concerns, which caused general heightened uncertainties in financial markets. While these events have not had a material direct impact on our operations, if further liquidity and financial stability concerns arise with respect to banks and financial institutions, either nationally or in specific regions, our ability to access cash or enter into new financing arrangements on favorable terms, or at all, may be threatened, which could have a material adverse effect on our business, financial condition and results of operations.

Results of Operations

Comparison of Three Months Ended June 30, 2023 to Three Months Ended June 30, 2022

Consolidated Results

The following table sets forth our summarized, consolidated results of operations for the three months ended ~~March 31,~~June 30, 2023 and 2022 (in thousands):


		Three Months Ended March 31,				Increase (Decrease)					Three Months Ended June 30,				Increase (Decrease)
		2023		2022		$		%			2023		2022		$		%
Net revenue	Net revenue	$	557,540	$	497,633	$	59,907	12.0	%	Net revenue	$	599,046	$	559,355	$	39,691	7.1	%
Cost of goods sold	Cost of goods sold	379,354		323,062		56,292		17.4	%	Cost of goods sold	379,025		358,836		20,189		5.6	%
Gross profit	Gross profit	178,186		174,571		3,615		2.1	%	Gross profit	220,021		200,519		19,502		9.7	%
Selling, general and administrative	Selling, general and administrative	102,096		98,665		3,431		3.5	%	Selling, general and administrative	105,570		98,806		6,764		6.8	%
Research and development	Research and development	38,690		52,798		(14,108)		(26.7)	%	Research and development	37,799		50,748		(12,949)		(25.5)	%
Intellectual property legal development expenses	Intellectual property legal development expenses	1,644		764		880		115.2	%	Intellectual property legal development expenses	820		821		(1)		(0.1)	%
Acquisition, transaction-related and integration expenses	Acquisition, transaction-related and integration expenses	—		434		(434)		nm		Acquisition, transaction-related and integration expenses	—		241		(241)		(100.0)	%
Restructuring and other charges	Restructuring and other charges	510		731		(221)		(30.2)	%	Restructuring and other charges	82		—		82		nm
Change in fair value of contingent consideration	Change in fair value of contingent consideration	2,457		200		2,257		nm		Change in fair value of contingent consideration	(6,364)		(270)		(6,094)		nm
Credit related to legal matters, net		(436)		(2,326)		1,890		(81.3)	%
Other operating income		(1,224)		—		(1,224)		nm
Operating income		34,449		23,305		11,144		47.8	%
Insurance recoveries for property losses and associated expenses										Insurance recoveries for property losses and associated expenses	—		(1,911)		1,911		(100.0)	%
Charges related to legal matters, net										Charges related to legal matters, net	2,017		251,877		(249,860)		(99.2)	%
Other operating expense (income)										Other operating expense (income)	13		(1,175)		1,188		nm
Operating income (loss)										Operating income (loss)	80,084		(198,618)		278,702		(140.3)	%
Total other expense, net	Total other expense, net	(43,875)		(33,226)		(10,649)		32.1	%	Total other expense, net	(50,424)		(34,113)		(16,311)		47.8	%
Loss before income taxes		(9,426)		(9,921)		495		(5.0)	%
Provision for (benefit from) income taxes		668		(3,461)		4,129		(119.3)	%
Net loss		$	(10,094)	$	(6,460)	$	(3,634)	56.3	%
Income (loss) before income taxes										Income (loss) before income taxes	29,660		(232,731)		262,391		(112.7)	%
(Benefit from) provision for income taxes										(Benefit from) provision for income taxes	(23)		7,350		(7,373)		(100.3)	%
Net income (loss)										Net income (loss)	$	29,683	$	(240,081)	$	269,764	(112.4)	%

nm - not meaningful

Net Revenue

Net revenue for the three months ended ~~March 31,~~June 30, 2023 increased ~~12.0%~~7.1% from the prior year period primarily due to:

•Growth in our Generics segment of ~~$26.1~~$8.8 million, primarily due to ~~favorable timing of~~ new generics products launched in 2023 and 2022 that contributed ~~net~~ revenue growth of ~~$30.5~~$11.2 million, the launch of biosimilars and strong volume growth, partially offset by continued price erosion. ~~Net revenue for the three months ended March 31, 2023 included a non-recurring customer order of $21.0 million related to 2022 new product launches.~~

•~~An increase~~Growth in our AvKARE segment of $30.9 million, due to growth in our distribution and government label channels driven by new product introductions.

Specialty segment net revenue of ~~$6.6~~$97.0 million ~~primarily driven~~was flat compared to the prior year period as growth in Unithroid® of 23.6% was offset by ~~increases~~a 4.2% decline in ~~net revenue~~Rytary® due to timing of ~~38.5%~~shipments as we continue to experience strong total prescription growth and ~~14.1%~~a decline in our ~~promoted products Unithroid® and Rytary®, respectively, resulting from continued strong prescription growth.~~

•~~An increase in our AvKARE segment net revenue of $27.3 million primarily driven by growth in our distribution channel.~~non-promoted products.

Cost of Goods Sold and Gross Profit

Cost of goods sold increased~~17.4%~~ 5.6% for the three months ended ~~March 31,~~June 30, 2023 as compared to the prior year period. The increase in cost of goods sold was primarily due to increased volume across our Generics and AvKARE segments and product mix.

Gross profit as a percentage of net revenue increased to 36.7% for the three months ended June 30, 2023 from 35.8% in the prior year period primarily as a result of the factors noted above.

Selling, General, and Administrative

Selling, general, and administrative (“SG&A”) expenses for the three months ended June 30, 2023 increased 6.8% from the prior year period primarily due to increases in employee compensation and higher freight charges driven by increased sales volume.

Research and Development

Research and development (“R&D”) expenses for the three months ended June 30, 2023 decreased 25.5% compared to the prior year period primarily due to lower project spend of $8.8 million partially resulting from timing of regulatory filing fees and operating efficiencies in our infrastructure.

Change in Fair Value of Contingent Consideration

Refer to Note 17. Fair Value Measurements for information about the estimation of our contingent consideration liabilities. The $6.1 million decrease in the change in fair value of contingent consideration for the three months ended June 30, 2023 as compared to the prior year period was primarily driven by a decrease in the associated forecasted revenues.

Insurance Recoveries for Property Losses and Associated Expenses

During the three months ended June 30, 2022, insurance recoveries of $1.9 million associated with property damage and inventory losses were received and recorded in insurance recoveries for property losses and associated expenses.

Charges Related to Legal Matters, Net

For the three months ended June 30, 2023, we recorded a charge of $2.0 million for civil prescription opioid litigation. For the three months ended June 30, 2022, we recorded a net charge of $251.9 million primarily consisting of a charge for the settlement of Opana® ER antitrust litigation of $262.8 million, net of insurance recoveries associated with a securities class action settled during 2022.

Total Other Expense, Net

Total other expense, net for the three months ended June 30, 2023 increased 47.8% compared to the prior year period. This increase was primarily driven by a $15.2 million increase in interest expense as a result of higher rates on our variable rate debt and increased amounts outstanding on our revolving credit facilities.

(Benefit From) Provision For Income Taxes

For the three months ended June 30, 2023, the Company’s benefit from income taxes and effective tax rate were both immaterial, as compared to a provision for income taxes and effective tax rate of $7.4 million and (3.2)%, respectively, for the three months ended June 30, 2022. The period-over-period change in the provision for income taxes was primarily related to a change in the jurisdictional mix of income and a discrete benefit as a result of the completion of an Internal Revenue Service examination and Joint Committee review of the 2012-2018 federal income tax returns, which enabled the Company to recognize previously unrecognized tax benefits during the three months ended June 30, 2022.

Generics

The following table sets forth results of operations for our Generics segment for the three months ended June 30, 2023 and 2022 (in thousands):


	Three Months Ended June 30,				Increase (Decrease)
	2023		2022		$		%
Net revenue	$	373,701	$	364,895	$	8,806	2.4	%
Cost of goods sold	225,189		228,535		(3,346)		(1.5)	%
Gross profit	148,512		136,360		12,152		8.9	%
Selling, general and administrative	28,040		26,558		1,482		5.6	%
Research and development	31,108		44,174		(13,066)		(29.6)	%
Intellectual property legal development expenses	801		778		23		3.0	%
Acquisition, transaction-related and integration expenses	—		8		(8)		nm
Insurance recoveries for property losses and associated expenses	—		(1,911)		1,911		(100.0)	%
Charges related to legal matters, net	2,017		483		1,534		317.6	%
Other operating expense (income)	13		(1,175)		1,188		nm
Operating income	$	86,533	$	67,445	$	19,088	28.3	%

nm - not meaningful

Net Revenue

Generics net revenue for the three months ended June 30, 2023 increased 2.4% compared to the prior year period primarily due to new generics products launched in 2023 and 2022 that contributed revenue growth of $11.2 million, the launch of biosimilars and strong volume growth, partially offset by continued price erosion.

Cost of Goods Sold and Gross Profit

Generics cost of goods sold for the three months ended June 30, 2023 decreased 1.5% compared to the prior year period primarily due to lower intangible asset impairment charges and favorable product mix, partially offset by the costs associated with increased sales volume and an increased inventory provision.

Generics gross profit as a percentage of net revenue increased to 39.7% for the three months ended June 30, 2023 from 37.4% in the prior year period primarily as a result of the factors noted above.

Selling, General, and Administrative

Generics SG&A expense for the three months ended June 30, 2023 increased 5.6% compared to the prior year period primarily due to an increase in employee compensation and higher freight charges due to increased sales volume, partially offset by lower legal fees.

Research and Development

Generics R&D expenses for the three months ended June 30, 2023 decreased 29.6% compared to the prior year period primarily due to a decrease in project spend of $7.9 million partially due to timing of regulatory filing fees and operating efficiencies in our infrastructure.

Insurance Recoveries for Property Losses and Associated Expenses

Charges Related to Legal Matters, Net

For the three months ended June 30, 2023, we recorded a charge of $2.0 million for civil prescription opioid litigation. Charges related to legal matters, net for the three months ended June 30, 2022 were immaterial.

Specialty

The following table sets forth results of operations for our Specialty segment for the three months ended June 30, 2023 and 2022 (in thousands):


	Three Months Ended June 30,				Increase (Decrease)
	2023		2022		$		%
Net revenue	$	96,994	$	97,001	$	(7)	nm
Cost of goods sold	46,512		42,791		3,721		8.7	%
Gross profit	50,482		54,210		(3,728)		(6.9)	%
Selling, general and administrative	22,759		23,171		(412)		(1.8)	%
Research and development	6,691		6,574		117		1.8	%
Intellectual property legal development expenses	19		43		(24)		(55.8)	%
Acquisition, transaction-related and integration expenses	—		32		(32)		(100.0)	%
Restructuring and other charges	82		—		82		nm
Change in fair value of contingent consideration	(6,364)		(270)		(6,094)		nm
Operating income	$	27,295	$	24,660	$	2,635	10.7	%

nm - not meaningful

Net Revenue

Specialty net revenue for the three months ended June 30, 2023 was flat compared to the prior year period as growth in Unithroid® of 23.6% was partially offset by a 4.2% decline in Rytary® due to timing of shipments as we continue to experience strong total prescription growth and a decline in our non-promoted products.

Cost of Goods Sold and Gross Profit

Specialty cost of goods sold for the three months ended June 30, 2023 increased 8.7% compared to the prior year period. Specialty gross profit as a percentage of net revenue decreased to 52.0% for the three months ended June 30, 2023 from 55.9% in the prior year period, primarily due to unfavorable product mix.

Selling, General, and Administrative

Specialty SG&A expense for the three months ended June 30, 2023 decreased 1.8% compared to the prior year period primarily due to a decrease in third party marketing spend for our promoted products, partially offset by increased compensation costs.

Research and Development

Specialty R&D expenses for the three months ended June 30, 2023 increased 1.8% compared to the prior year period primarily due to higher employee compensation and overhead costs, partially offset by reduced project spend.

Change in Fair Value of Contingent Consideration

Refer to Note 17. Fair Value Measurements for information about the estimation of our contingent consideration liabilities. The $6.1 million increase in the change in fair value of contingent consideration for the three months ended June 30, 2023 as compared to the prior year period was primarily driven by a decrease in the related liability as a result of a decrease in the associated forecasted revenues.

AvKARE

The following table sets forth results of operations for our AvKARE segment for the three months ended June 30, 2023 and 2022 (in thousands):


	Three Months Ended June 30,				Increase (Decrease)
	2023		2022		$		%
Net revenue	$	128,351	$	97,459	$	30,892	31.7	%
Cost of goods sold	107,324		87,510		19,814		22.6	%
Gross profit	21,027		9,949		11,078		111.3	%
Selling, general and administrative	14,015		12,735		1,280		10.1	%
Operating income (loss)	$	7,012	$	(2,786)	$	9,798	(351.7)	%

Net Revenue

AvKARE net revenue for the three months ended June 30, 2023 increased 31.7% as compared to the prior year period primarily due to growth in our distribution and government channels driven by new product introductions.

Cost of Goods Sold and Gross Profit

AvKARE cost of goods sold for the three months ended June 30, 2023 increased 22.6% as compared to the prior year period, and gross profit as a percentage of net revenue increased to 16.4% for the three months ended June 30, 2023 from 10.2% in the prior year period primarily due to the increase in sales through our higher margin government channel and a lower inventory provision.

Selling, General and Administrative

AvKARE SG&A expense for the three months ended June 30, 2023 increased 10.1% as compared to the prior year period primarily due to higher employee compensation.

Comparison of Six Months Ended June 30, 2023 to Six Months Ended June 30, 2022

Consolidated Results

The following table sets forth our summarized, consolidated results of operations for the six months ended June 30, 2023 and 2022 (in thousands):


	Six Months Ended June 30,				Increase (Decrease)
	2023		2022		$		%
Net revenue	$	1,156,586	$	1,056,988	$	99,598	9.4	%
Cost of goods sold	758,379		681,898		76,481		11.2	%
Gross profit	398,207		375,090		23,117		6.2	%
Selling, general and administrative	207,666		197,471		10,195		5.2	%
Research and development	76,489		103,546		(27,057)		(26.1)	%
Intellectual property legal development expenses	2,464		1,585		879		55.5	%
Acquisition, transaction-related and integration expenses	—		675		(675)		(100.0)	%
Restructuring and other charges	592		731		(139)		(19.0)	%
Change in fair value of contingent consideration	(3,907)		(70)		(3,837)		nm
Insurance recoveries for property losses and associated expenses	—		(1,911)		1,911		(100.0)	%
Charges related to legal matters, net	1,581		249,551		(247,970)		(99.4)	%
Other operating income	(1,211)		(1,175)		(36)		3.1	%
Operating income (loss)	114,533		(175,313)		289,846		(165.3)	%
Total other expense, net	(94,299)		(67,339)		(26,960)		40.0	%
Income (loss) before income taxes	20,234		(242,652)		262,886		(108.3)	%
Provision for income taxes	645		3,889		(3,244)		(83.4)	%
Net income (loss)	$	19,589	$	(246,541)	$	266,130	(107.9)	%

nm - not meaningful

Net Revenue

Net revenue for the six months ended June 30, 2023 increased 9.4% from the prior year period primarily due to:

•Growth in our Generics segment of $34.9 million primarily due to new generics products launched in 2023 and 2022 that contributed net revenue growth of $20.7 million, the launch of biosimilars and volume growth, partially offset by continued price erosion. Net revenue for the six months ended June 30, 2023 included a non-recurring customer order of $21.0 million.

•Growth in Specialty segment net revenue of $6.6 million primarily driven by increases in net revenue of 30.0% and 4.2% in our promoted products Unithroid® and Rytary®, respectively, resulting from continued strong prescription growth and favorable pricing.

•Growth in our AvKARE segment net revenue of $58.1 million primarily driven by growth in our distribution, government label and institutional channels driven by growth in new product introductions.

Cost of Goods Sold and Gross Profit

Cost of goods sold increased 11.2%for the six months ended June 30, 2023 as compared to the prior year period. The increase in cost of goods sold was primarily due to increased AvKARE volume and an increase in the inventory provision. Cost of goods sold for the ~~three~~six months ended ~~March 31,~~June 30, 2023 included $11.0 million associated with the non-recurring customer order in our Generics segment discussed above.

Gross profit as a percentage of net revenue decreased to ~~32.0%~~34.4% for the ~~three~~six months ended ~~March 31,~~June 30, 2023 from ~~35.1%~~35.5% in the prior year period primarily as a result of the factors noted above.

3945

Selling, General, and Administrative

~~Selling, general, and administrative (“~~SG~~&A”)~~&A expenses for the ~~three~~six months ended ~~March 31,~~June 30, 2023 increased ~~3.5%~~5.2% from the prior year period primarily due to increases in employee compensation, higher freight charges driven by increased sales volume and higher costs associated with our biosimilar launches, partially offset by a decrease of $5.0 million associated with a regulatory approval in the prior year period.

Research and Development

~~Research and development (“~~R~~&D”)~~&D expenses for the ~~three~~six months ended ~~March 31,~~June 30, 2023 decreased ~~26.7%~~26.1% compared to the prior year period primarily due to reduced project spend of $12.5 million, a decrease in in-licensing and upfront milestone payments of ~~$5.2 million, reduced project spend of $3.7~~$5.6 million, and operating efficiencies in our infrastructure.

Intellectual Property Legal Development Expense

Intellectual property legal development expenses include, but are not limited to, costs associated with formulation assessments, patent challenge opinions and strategy, and litigation expenses to defend our intellectual property. Intellectual property legal development expenses for the ~~three~~six months ended ~~March 31,~~June 30, 2023 and 2022 were ~~$1.6~~$2.5 million and ~~$0.8~~$1.6 million, respectively. Expenses may vary based on the number of individual cases and corresponding litigation outstanding in a particular period.

Change in Fair Value of Contingent Consideration

Refer to Note 17. Fair Value Measurements for information about the estimation of our contingent consideration liabilities. The ~~$2.3~~$3.8 million ~~increase~~ decrease in the change in fair value of contingent consideration (income) for the ~~three~~six months ended ~~March 31,~~June 30, 2023 as compared to the prior year period was primarily driven by a decrease in ~~our cost~~the related liability as a result of ~~debt~~a decrease in the associated forecasted revenues.

Insurance Recoveries for Property Losses and Associated Expenses

During the ~~passage~~six months ended June 30, 2022, insurance recoveries of ~~time.~~$1.9 million associated with property damage and inventory losses were received and recorded in insurance recoveries for property losses and associated expenses.

~~Credits~~Charges Related to Legal Matters, Net

For the ~~three~~six months ended ~~March 31,~~June 30, 2023, ~~we recorded a~~charges related to legal matters, net ~~credit~~was $1.6 million, primarily comprised of ~~$0.4~~$4.1 million ~~for~~in charges associated with prescription opioid litigation, offset by a litigation settlement ~~gain, partially offset by charges for legal proceedings.~~gain. For the ~~three~~six months ended ~~March 31,~~June 30, 2022, we recorded a net ~~credit~~charge of ~~$2.3~~$249.6 million ~~for an~~primarily comprised of charges associated with Opana® ER antitrust litigation, net of insurance ~~recovery of $4.0 million, partially offset by charges for legal proceedings.~~recoveries associated with a securities class action.

Other Operating Income

Other operating income for the ~~three~~six months ended ~~March 31,~~June 30, 2023 and 2022 was comprised of income earned from the India Production Linked Incentive Scheme for the Pharmaceutical Sector. Refer to Note 6. Government Grants for additional information.

Total Other Expense, Net

Total other expense, net for the ~~three~~six months ended ~~March 31,~~June 30, 2023 increased ~~32.1%~~40.0% as compared to the prior year period. ~~This~~The increase was primarily driven by a ~~$16.0~~$31.2 million increase in interest expense as a result of higher rates on our variable rate debt and increased amounts outstanding on our revolving credit ~~facility, partially offset by $3.9 million in period over period foreign exchange gains related to the Indian rupee and the Euro.~~facilities.

Provision For Income Taxes

For the ~~three~~six months ended ~~March 31,~~June 30, 2023 and 2022, our provision for ~~(benefit from)~~ income taxes and effective tax rates were ~~$0.7~~$0.6 million and ~~(7.1)%~~3.2% and ~~$(3.5)~~$3.9 million and ~~34.9%~~(1.6)%, respectively. The period-over-period change was primarily related to a change in the jurisdictional mix of income and a discrete benefit resulting from of the completion of an Internal Revenue Service examination and Joint Committee review of the 2012-2018 federal income tax returns, which enabled the Company to recognize previously unrecognized tax benefits in the ~~three~~six months ended ~~March 31,~~June 30, 2022.

4046

Generics

The following table sets forth results of operations for our Generics segment for the ~~three~~six months ended ~~March 31,~~June 30, 2023 and 2022 (in thousands):


		Three Months Ended March 31,				Increase (Decrease)					Six Months Ended June 30,				Increase (Decrease)
		2023		2022		$		%			2023		2022		$		%
Net revenue	Net revenue	$	343,806	$	317,747	$	26,059	8.2	%	Net revenue	$	717,507	$	682,642	$	34,865	5.1	%
Cost of goods sold	Cost of goods sold	230,551		199,030		31,521		15.8	%	Cost of goods sold	455,740		427,565		28,175		6.6	%
Gross profit	Gross profit	113,255		118,717		(5,462)		(4.6)	%	Gross profit	261,767		255,077		6,690		2.6	%
Selling, general and administrative	Selling, general and administrative	27,600		27,593		7		nm		Selling, general and administrative	55,640		54,151		1,489		2.7	%
Research and development	Research and development	32,359		43,221		(10,862)		(25.1)	%	Research and development	63,467		87,395		(23,928)		(27.4)	%
Intellectual property legal development expenses	Intellectual property legal development expenses	1,624		772		852		110.4	%	Intellectual property legal development expenses	2,425		1,550		875		56.5	%
Acquisition, transaction-related and integration expenses										Acquisition, transaction-related and integration expenses	—		8		(8)		(100.0)	%
Restructuring and other charges	Restructuring and other charges	99		206		(107)		(51.9)	%	Restructuring and other charges	99		206		(107)		nm
Insurance recoveries for property losses and associated expenses										Insurance recoveries for property losses and associated expenses	—		(1,911)		1,911		(100.0)	%
(Credit) charges related to legal matters, net	(Credit) charges related to legal matters, net	(2,444)		1,674		(4,118)		(246.0)	%	(Credit) charges related to legal matters, net	(427)		2,157		(2,584)		(119.8)	%
Other operating income	Other operating income	(1,224)		—		(1,224)		nm		Other operating income	(1,211)		(1,175)		(36)		3.1	%
Operating income	Operating income	$	55,241	$	45,251	$	9,990	22.1	%	Operating income	$	141,774	$	112,696	$	29,078	25.8	%

nm - not meaningful

Net Revenue

Generics net revenue for the ~~three~~six months ended ~~March 31,~~June 30, 2023 increased ~~8.2%~~5.1% compared to the prior year period primarily due to favorable timing of new generics products launched in 2023 and 2022 that contributed net revenue growth of ~~$30.5~~$20.7 million, the launch of biosimilars and volume growth, partially offset by continued price erosion. Net revenue for the ~~three~~six months ended ~~March 31,~~June 30, 2023 included a non-recurring customer order of $21.0 ~~million related to 2022 new product launches.~~million.

Cost of Goods Sold and Gross Profit

Generics cost of goods sold for the ~~three~~six months ended ~~March 31,~~June 30, 2023 increased ~~15.8%~~6.6% as compared to the prior year period primarily due to the costs associated with increased sales volume and an increased inventory provision. Cost of goods sold for the ~~three~~six months ended ~~March 31,~~June 30, 2023 included $11.0 million associated with the non-recurring customer order discussed above.

Generics gross profit as a percentage of net revenue decreased to ~~32.9%~~36.5% for the ~~three~~six months ended ~~March 31,~~June 30, 2023 from 37.4% in the prior year period primarily as a result of the factors noted above.

Selling, General, and Administrative

Generics SG&A expense for the ~~three~~six months ended ~~March 31,~~June 30, 2023 ~~was flat~~increased 2.7% compared to the prior year period ~~as increases~~primarily due to an increase in employee compensation, higher freight charges driven by increased sales volume and costs associated with our biosimilar launches, ~~were~~partially offset by a decrease of $5.0 million associated with a biosimilar regulatory approval in the prior year period.

Research and Development

Generics R&D expenses for the ~~three~~six months ended ~~March 31,~~June 30, 2023 decreased ~~25.1%~~27.4% compared to the prior year period primarily due to ~~a decrease in~~reduced project spend of $10.3 million, decreased in-licensing and upfront milestone payments of ~~$2.7 million, reduced project spend of $2.4~~$3.1 million and operating efficiencies in our ~~infrastructure.~~infrastructure, including reduced employee compensation costs.

Intellectual Property Legal Development Expenses

Intellectual property legal development expenses include, but are not limited to, costs associated with formulation assessments, patent challenge opinions and strategy, and litigation expenses to defend our intellectual property. Intellectual property legal development expenses for the ~~three~~six months ended ~~March 31,~~June 30, 2023 and 2022 were ~~$1.6~~$2.4 million and ~~$0.8~~$1.6 million, respectively. Expenses may vary based on the number of individual cases and corresponding litigation outstanding in a particular period.

4147

Insurance Recoveries for Property Losses and Associated Expenses

During the six months ended June 30, 2022, insurance recoveries of $1.9 million associated with property damage and inventory losses were received and recorded in insurance recoveries for property losses and associated expenses.

(Credit) Charges Related to Legal Matters, Net

For the ~~three~~six months ended ~~March 31,~~June 30, 2023, a litigation settlement gain was partially offset by $4.1 million of charges ~~for legal proceedings.~~associated with prescription opioid litigation. For the ~~three~~six months ended ~~March 31,~~June 30, 2022, we recorded charges of ~~$1.7~~$2.2 million for employment and other legal proceedings.

Other Operating Income

Other operating income for the ~~three~~six months periods ended ~~March 31,~~June 30, 2023 and 2022 was comprised of income earned from the India Production Linked Incentive Scheme for the Pharmaceutical Sector. Refer to Note 6. Government Grants for additional information.

Specialty

The following table sets forth results of operations for our Specialty segment for the ~~three~~six months ended ~~March 31,~~June 30, 2023 and 2022 (in thousands):


		Three Months Ended March 31,				Increase (Decrease)					Six Months Ended June 30,				Increase (Decrease)
		2023		2022		$		%			2023		2022		$		%
Net revenue	Net revenue	$	91,678	$	85,086	$	6,592	7.7	%	Net revenue	$	188,672	$	182,087	$	6,585	3.6	%
Cost of goods sold	Cost of goods sold	43,191		43,853		(662)		(1.5)	%	Cost of goods sold	89,703		86,644		3,059		3.5	%
Gross profit	Gross profit	48,487		41,233		7,254		17.6	%	Gross profit	98,969		95,443		3,526		3.7	%
Selling, general and administrative	Selling, general and administrative	22,379		24,400		(2,021)		(8.3)	%	Selling, general and administrative	45,138		47,571		(2,433)		(5.1)	%
Research and development	Research and development	6,331		9,577		(3,246)		(33.9)	%	Research and development	13,022		16,151		(3,129)		(19.4)	%
Intellectual property legal development expenses (credit)		20		(8)		28		nm
Intellectual property legal development expenses										Intellectual property legal development expenses	39		35		4		11.4	%
Acquisition, transaction-related and integration expenses										Acquisition, transaction-related and integration expenses	—		32		(32)		(100.0)	%
Restructuring and other charges										Restructuring and other charges	82		—		82		nm
Change in fair value of contingent consideration	Change in fair value of contingent consideration	2,457		200		2,257		nm		Change in fair value of contingent consideration	(3,907)		(70)		(3,837)		nm
Operating income	Operating income	$	17,300	$	7,064	$	10,236	144.9	%	Operating income	$	44,595	$	31,724	$	12,871	40.6	%

nm - not meaningful

Net Revenue

Specialty net revenue for the ~~three~~six months ended ~~March 31,~~June 30, 2023 increased ~~7.7%~~3.6% compared to the prior year period, primarily driven by increases in net revenue of ~~38.5%~~30.0% and ~~14.1%~~4.2% in our promoted products Unithroid® and Rytary®, respectively, resulting from continued strong prescription ~~growth.~~growth and favorable pricing.

Cost of Goods Sold and Gross Profit

Specialty cost of goods sold for the ~~three~~six months ended ~~March 31,~~June 30, 2023 ~~decreased 1.5%~~increased 3.5% as compared to the prior year ~~period.~~period, primarily due to an increase in net revenue. Specialty gross profit as a percentage of net revenue ~~increased to 52.9%~~was flat at 52.5% for the ~~three~~six months ended ~~March 31,~~June 30, 2023 ~~from 48.5%~~as compared to 52.4% in the prior year ~~period, primarily due to the increase in net revenues and favorable product mix.~~period.

Selling, General, and Administrative

Specialty SG&A expense for the ~~three~~six months ended ~~March 31,~~June 30, 2023 decreased ~~8.3%~~5.1% as compared to the prior year period primarily due to a decrease in third party marketing spend for our promoted products.

Research and Development

Specialty R&D expenses for the ~~three~~six months ended ~~March 31,~~June 30, 2023 decreased ~~33.9%~~19.4% as compared to the prior year period primarily due to a decrease in in-licensing and upfront milestone payments of $2.5 million.

Change in Fair Value of Contingent Consideration

Refer to Note 17. Fair Value Measurements for information about the estimation of our contingent consideration liabilities. The ~~$2.3~~$3.8 million ~~increase~~decrease in the change in fair value of contingent consideration (income) for the ~~three~~six months ended ~~March 31,~~June 30, 2023 as compared to the prior year period was primarily driven by a decrease in ~~our cost~~the related liability as a result of ~~debt and~~a decrease in the ~~passage of time.~~corresponding forecasted revenues.

AvKARE

The following table sets forth results of operations for our AvKARE segment for the ~~three~~six months ended ~~March 31,~~June 30, 2023 and 2022 (in thousands):


		Three Months Ended March 31,				Increase (Decrease)					Six Months Ended June 30,				Increase (Decrease)
		2023		2022		$		%			2023		2022		$		%
Net revenue	Net revenue	$	122,056	$	94,800	$	27,256	28.8	%	Net revenue	$	250,407	$	192,259	$	58,148	30.2	%
Cost of goods sold	Cost of goods sold	105,612		80,179		25,433		31.7	%	Cost of goods sold	212,936		167,689		45,247		27.0	%
Gross profit	Gross profit	16,444		14,621		1,823		12.5	%	Gross profit	37,471		24,570		12,901		52.5	%
Selling, general and administrative	Selling, general and administrative	12,940		13,410		(470)		(3.5)	%	Selling, general and administrative	26,955		26,145		810		3.1	%
Operating income		$	3,504	$	1,211	$	2,293	189.3	%
Operating income (loss)										Operating income (loss)	$	10,516	$	(1,575)	$	12,091	nm

nm - not meaningful

Net Revenue

AvKARE net revenue for the ~~three~~six months ended ~~March 31,~~June 30, 2023 increased ~~28.8%~~30.2% as compared to the prior year period, primarily driven by growth in our distribution, ~~channel~~.government label and institutional channels resulting from growth in new product introductions.

Cost of Goods Sold and Gross Profit

AvKARE cost of goods sold for the ~~three~~six months ended ~~March 31,~~June 30, 2023 increased ~~31.7%~~27.0% as compared to the prior year period, and gross profit as a percentage of net revenue ~~decreased~~increased to ~~13.5%~~15.0% for the ~~three~~six months ended ~~March 31,~~June 30, 2023 from ~~15.4%~~12.8% in the prior year period, primarily due to the increase in sales through our ~~lower~~higher margin ~~distribution~~government channel.

Selling, General and Administrative

AvKARE SG&A expense for the six months ended June 30, 2023 increased 3.1% compared to the prior year period primarily due to higher employee compensation.

Liquidity and Capital Resources

Our primary source of liquidity is cash generated from operations, available cash on hand, and borrowings under debt financing arrangements, including $245.9 million of available capacity, as of June 30, 2023, on our New Revolving Credit Facility, as defined in Note 16. Debt in our 2022 Annual Report on Form ~~10-K, as of March 31, 2023.~~10-K. Refer to Note 16. Debt in our 2022 Annual Report on Form 10-K for additional information on our debt.As of June 30, 2023, there was $10.0 million of available capacity under the Rondo Revolving Credit Facility. We believe these sources are sufficient to fund our planned operations, meet our interest and contractual obligations, including acquisitions, and provide sufficient liquidity over the next 12 months from the date of filing of this Form 10-Q. However, our ability to satisfy our working capital requirements and debt obligations will depend upon economic conditions, our ability to negotiate and maintain satisfactory terms under our borrowing and debt facilities in the future, and demand for our products, which are factors that may be out of our control.

We estimate that we will invest approximately $50.0 million to $60.0 million during 2023 for capital expenditures to support and grow our existing operations, primarily related to investments in manufacturing equipment, information technology and facilities.

During the ~~three~~six months ended ~~March 31,~~June 30, 2023, we prepaid ~~$22.8~~$27.8 million of principal outstanding on the Rondo Term Loan. Over the next 12 months, we expect to make substantial payments, including a $50.0 million payment associated with the Opana ER® antitrust litigation settlement agreements, monthly interest and quarterly principal amounts due for our debt instruments, including our Term Loan and Rondo Term Loan, as well as contractual payments for leased premises. Refer to Note 16. Debt

and Note 18. Leases in our 2022 Annual Report on Form 10-K and Note 15. Debt in this Form 10-Q for additional information on our indebtedness and leases, respectively.

We are party to a tax receivable agreement (“TRA”) that requires us to make cash payments to the Members other than the Company, in respect of certain tax benefits that we may realize or may be deemed to realize as a result of sales or exchanges of Amneal Common Units by the Members. The timing and amount of any payments under the TRA will also vary, depending upon a number of factors including the timing and number of Amneal Common Units sold or exchanged for our class A common stock, the price of our class A common stock on the date of sale or exchange, the timing and amount of our taxable income, and the tax rate in effect at the time of realization of our taxable income. The ~~tax receivable agreement~~TRA also requires that we make an accelerated payment to the Members equal to the present value of all future payments due under the agreement upon certain change of control and similar transactions. Further sales or exchanges occurring subsequent to ~~March 31,~~June 30, 2023 could result in future Amneal tax deductions and obligations to pay 85% of such benefits to the holders of Amneal Common Units. These obligations could be incremental to and substantially larger than the approximate $202.7 million contingent liability as of ~~March 31,~~June 30, 2023 (refer to Note 7. Income Taxes). As a result of the foregoing, our obligations under the ~~tax~~

~~receivable agreement~~TRA could have a substantial negative impact on our liquidity. For further details, refer to Item 1A. Risk Factors in our 2022 Annual Report on Form 10-K.

In addition, pursuant to the limited liability operating agreement of Amneal, as amended, in connection with any tax period, we will be required to make distributions to ~~Amneal’s~~Amneal's members, on a pro rata basis in proportion to the number of Amneal Common Units held by each member, of cash until each member (other than Amneal) has received an amount at least equal to its assumed tax liability and Amneal has received an amount sufficient to enable it to timely satisfy all of its U.S. federal, state and local and non-U.S. tax liabilities, and meet its obligations pursuant to the TRA. During the ~~three~~six months ended ~~March 31,~~June 30, 2023 and 2022, we made cash tax distributions of ~~$18.04~~$29.73 million and ~~$2.53~~$7.33 million (net), respectively, to the Members. During ~~April~~July 2023, we made cash tax distributions of ~~$8.77 million to the Members.~~$17.7 million.

In 2020, we acquired a 65.1% controlling interest in both AvKARE Inc., a Tennessee corporation, now a limited liability company (“AvKARE, LLC”), and Dixon-Shane, LLC d/b/a R&S Northeast LLC, a Kentucky limited liability company (“R&S”). The sellers of AvKARE, LLC and R&S (the “AvKARE Sellers”) hold the remaining 34.9% interest in the holding company that directly owns the acquired companies (“Rondo”). We attribute 34.9% of the net income or loss associated with Rondo to redeemable non-controlling interests. During the ~~three~~six months ended ~~March 31,~~June 30, 2023 and 2022, we made cash tax distributions of ~~$0.18~~$5.83 million and ~~$0.63~~$2.59 million, respectively, ~~to the AvKARE Sellers. During April 2023, we made cash tax distributions of $2.78 million~~ to the AvKARE Sellers.

As of ~~March 31,~~June 30, 2023, our cash and cash equivalents consist of cash on deposit and highly liquid investments. A portion of our cash flows are derived outside the U.S. As a result, we are subject to market risk associated with changes in foreign exchange rates. We maintain cash balances at both U.S. based and foreign country based commercial banks. At various times during the year, our cash balances held in the U.S. may exceed amounts that are insured by the Federal Deposit Insurance Corporation (FDIC). We make our investments in accordance with our investment policy. The primary objectives of our investment policy are liquidity and safety of principal.

Cash Flows

The following table sets forth our summarized, consolidated cash flows for the ~~three~~six months ended ~~March 31,~~June 30, 2023 and 2022 (in thousands):


		Three Months Ended March 31,				Increase (Decrease)					Six Months Ended June 30,				Increase (Decrease)
		2023		2022		$		%			2023		2022		$		%
Cash provided by (used in):	Cash provided by (used in):									Cash provided by (used in):
Operating activities	Operating activities	$	139,712	$	120,343	$	19,369	16.1	%	Operating activities	$	128,367	$	(5,178)	$	133,545	nm
Investing activities	Investing activities	(11,737)		(97,395)		85,658		(87.9)	%	Investing activities	(24,021)		(113,511)		89,490		(78.8)	%
Financing activities	Financing activities	(12,900)		(61,570)		48,670		(79.0)	%	Financing activities	(25,156)		(38,321)		13,165		(34.4)	%
Effect of exchange rate changes on cash	Effect of exchange rate changes on cash	767		(1,572)		2,339		(148.8)	%	Effect of exchange rate changes on cash	165		(1,547)		1,712		(110.7)	%
Net increase (decrease) in cash, cash equivalents, and restricted cash	Net increase (decrease) in cash, cash equivalents, and restricted cash	$	115,842	$	(40,194)	$	156,036	(388.2)	%	Net increase (decrease) in cash, cash equivalents, and restricted cash	$	79,355	$	(158,557)	$	237,912	(150.0)	%

nm - not meaningful

Cash Flows from Operating Activities

Net cash provided by operating activities was ~~$139.7~~$128.4 million for the ~~three~~six months ended ~~March 31,~~June 30, 2023 as compared to ~~$120.3~~$5.2 million used in operating activities for the prior year period. The increase in operating cash flows from the prior year period was primarily driven by increased ~~period-over-period~~profitability adjusted for non-cash items, favorable collections of outstanding accounts receivable due to timing of sales in the quarter ended December 31, 2022 ~~receipt of a $21.4 million upfront payment associated with the Orion Agreement~~ and a ~~lower net loss adjusted for non-cash items, partially offset by an $83.9~~$14.5 million ~~payment~~decrease in cash payments related to the Opana ER® antitrust litigation settlement ~~agreements in January 2023.~~agreements.

Cash Flows from Investing Activities

Net cash used in investing activities for the ~~three~~six months ended ~~March 31,~~June 30, 2023 was ~~$11.7~~$24.0 million as compared to ~~$97.4~~$113.5 million for the prior year period. The decrease in net cash used in investing activities from the prior year period was primarily due to $84.7 million of cash paid to acquire ~~certain assets~~the baclofen franchise ~~comprising a business~~ from entities affiliated with Saol International Limited during the prior year period.

Cash Flows from Financing Activities

Net cash used in financing activities was ~~$12.9~~$25.2 million for the ~~three~~six months ended ~~March 31,~~June 30, 2023 as compared to ~~$61.6~~$38.3 million for the prior year period. The decrease in net cash used in financing activities from the prior year period was primarily due to a $44.0 million payment for deferred consideration associated with the ~~acquisition~~acquisitions of Kashiv Specialty Pharmaceuticals, LLC and Puniska Healthcare Pvt. Ltd. in the prior year period, ~~and net borrowings under the New Revolving Credit Facility of $40.0 million, partially offset by a~~ ~~$22.8 million~~ ~~prepayment of principal~~lower prepayments on the Rondo Term Loan, and an increase in net borrowings under our revolving credit facilities, partially offset by a ~~$15.1~~$25.6 million increase in tax distributions to non-controlling interests. Refer to Note 15. Debt in this Form 10-Q and Note 16. Debt in our 2022 Annual Report on Form 10-K for details of our debt, including defined terms.

Commitments and Contractual Obligations

The contractual obligations of the Company are set forth in Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations contained in the Company’s 2022 Annual Report on Form 10-K. As of ~~March 31,~~June 30, 2023, there have been no material changes to the disclosure presented in our 2022 Annual Report on Form 10-K.

Off-Balance Sheet Arrangements

We did not have any off-balance sheet arrangements as of ~~March 31,~~June 30, 2023.

Critical Accounting Policies and Estimates

For a discussion of the Company’s critical accounting policies and estimates, see Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations in our 2022 Annual Report on Form 10-K. There have been no material changes to the disclosures presented in our 2022 Annual Report on Form 10-K.

Recently Issued Accounting Standards

Recently issued accounting standards are discussed in Note 2. Summary of Significant Accounting Policies.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

There has not been any material change in our assessment of market risk as set forth in Item 7A. Quantitative and Qualitative Disclosures About Market Risk, in our 2022 Annual Report on Form 10-K.

Item 4. Controls and Procedures

Disclosure Controls and Procedures

We maintain disclosure controls and procedures (as defined in Rule 13a-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) that are designed to ensure information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our Co-Chief Executive Officers and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

Our management, with the participation of our Co-Chief Executive Officers and Chief Financial Officer, evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q. Based upon that evaluation, our Co-Chief Executive Officers and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of ~~March 31,~~June 30, 2023.

Changes in Internal Control over Financial Reporting

During the quarter ended ~~March 31,~~June 30, 2023, there were no changes in our internal control over financial reporting which materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Limitations on the Effectiveness of Controls

Management, including our Co-Chief Executive Officers and Chief Financial Officer, does not expect that our disclosure controls and procedures or our system of internal control over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well designed or operated, can provide only reasonable, but not absolute, assurance that the objectives of the system of internal control are met. The design of our control system reflects the fact that there are resource constraints, and that the benefits of such control system must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control failures and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the intentional acts of individuals, by collusion of two or more people, or by management override of the controls. The design of any system of controls is also based in part on certain assumptions about the likelihood of future events, and there can be no assurance that the design of any particular control will always succeed in achieving its objective under all potential future conditions.

Part II – OTHER INFORMATION

Item 1. Legal Proceedings

Information pertaining to legal proceedings can be found in Note 19. Commitments and Contingencies and is incorporated by reference herein.

Item 1A. Risk Factors

There have been no material changes to the disclosures presented in our 2022 Annual Report on Form 10-K under Item 1A. Risk Factors.

Item 2. Unregistered Sales of Equity Securities, ~~and~~ Use of Proceeds, and Issuer Purchases of Equity Securities

None.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

~~None.~~On May 9, 2023, the stockholders of the Company approved an amendment and restatement of the Amneal Pharmaceuticals, Inc. 2018 Incentive Award Plan (the “Stock Plan”), which (1) authorizes an additional 20 million shares of Class A common stock available for issuance under the Stock Plan, resulting in a new Share (as defined in the Stock Plan) reserve under the Stock Plan of 57 million shares, (2) extends the term of the Stock Plan until May 9, 2033, and (3) contains certain other technical modifications to the predecessor plan. The material terms of the Stock Plan are summarized in the Company’s Proxy Statement for the 2023 Annual Meeting of Stockholders of the Company as filed with the Securities and Exchange Commission on March 24, 2023 (the “2023 Proxy Statement”) under the heading “Proposal 4 Approval of Amended and Restated Incentive

4652

Award Plan”. The foregoing description of the Stock Plan is qualified in its entirety by reference to the actual terms of the Stock Plan, as amended, which is filed hereto as Exhibit 10.1.

Item 6. Exhibits


Exhibit No.						Description of Document

10.1						~~Modification No. 2 to Employment Agreement~~Amneal Pharmaceuticals , ~~dated~~ Inc. 2018 Incentive Award Plan, as amended and restated.~~February 21, 2023~~,~~by and among Amneal Pharmaceuticals, Inc. and~~ ~~Anastasios Konidaris~~. ††

10.2						~~Modification~~Amendment No. 1 to ET ~~mployment~~erm Loan Credit Agreement,, dated ~~February 21,~~as of May 30, 2023, entered into by and among ~~Amneal~~A mneal Pharmaceuticals ~~Inc.~~LLC , the Guarantors, and JPM ~~Nikita Shah~~organ Chase Bank , N.A. as administrative agent . †**

10.3						~~Modification No. 2~~Amendment No.1 to ~~Employment~~Revolving Credit and Term Loan Agreement, dated ~~February~~ ~~21,~~as of April 20, 2023,by and among ~~Amneal Pharmaceuticals, Inc.~~Rondo Holdings, LLC, Rondo Intermediate Holdings, LLC, the Subsidiary Loan Parties party hereto, the Lenders party hereto and ~~Andrew Boyer~~. †Truist Bank as Administrative Agent.

31.1						Certification of the President and Co - Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*

31.2						Certification of the Co - Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*

31.3						Certification of the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*

32.1						Certification of the President and Co - Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.**

32.2						Certification of the Co - Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.**

32.3						Certification of the Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.**



101						The following materials from the Company’s Quarterly Report on Form 10-Q for the quarter ended ~~March 31,~~June 30, 2023 formatted in Inline XBRL (eXtensible Business Reporting Language): (i) Consolidated Statements of Operations for each of the three and six months ended ~~March 31,~~June 30, 2023 and 2022, (ii) Consolidated Statements of Comprehensive Income (Loss) ~~Income~~ for each of the three and six months ended ~~March 31,~~June 30, 2023 and 2022, (iii) Consolidated Balance Sheets as of ~~March 31,~~June 30, 2023 and December 31, 2022, (iv) Consolidated Statements of Cash Flows for the ~~three~~six months ended ~~March 31,~~June 30, 2023 and 2022, (v) Consolidated Statements of Changes in Stockholders' Equity for each of the three and six months ended ~~March 31,~~June 30, 2023 and 2022 and (vi) Notes to Consolidated Financial Statements.*

104						Cover Page Interactive Data File – The cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended ~~March 31,~~June 30, 2023 is formatted in Inline XBRL (included as Exhibit 101).


*			Filed herewith
**			This certificate is being furnished solely to accompany the report pursuant to 18 U.S.C. 1350 and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
†			Denotes management compensatory plan or arrangement.

4754

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


Date: ~~May 9,~~August 8, 2023	Amneal Pharmaceuticals, Inc.
		(Registrant)

	By:	/s/ Anastasios Konidaris
		Anastasios Konidaris
		Executive Vice President and Chief Financial Officer (Principal Financial and Accounting Officer)

4855